,Start Date,Start Price,End Date,End Price,Weekly Returns,Bin Label,News,Basics
0,2023-01-08,84.80426788330078,2023-01-15,83.06157684326172,-0.020549567651915623,D3,[],"{""assetTurnoverTTM"": 0.4336, ""bookValue"": 21240, ""cashRatio"": 0.48162320904155914, ""currentRatio"": 1.2853, ""ebitPerShare"": 1.7921, ""eps"": 1.2964, ""ev"": 127495, ""fcfMargin"": 0.3229, ""fcfPerShareTTM"": 6.6913, ""grossMargin"": 0.8111, ""inventoryTurnoverTTM"": 3.6205, ""longtermDebtTotalAsset"": 0.3634, ""longtermDebtTotalCapital"": 0.494, ""longtermDebtTotalEquity"": 1.0808, ""netDebtToTotalCapital"": 0.4265, ""netDebtToTotalEquity"": 0.9331, ""netMargin"": 0.222, ""operatingMargin"": 0.3068, ""payoutRatioTTM"": 0.8077, ""pb"": 5.0695, ""peTTM"": 23.4488, ""pfcfTTM"": 12.9047, ""pretaxMargin"": 0.2749, ""psTTM"": 3.947, ""quickRatio"": 0.9933, ""receivablesTurnoverTTM"": 5.8859, ""roaTTM"": 0.073, ""roeTTM"": 0.2227, ""roicTTM"": 0.0991, ""rotcTTM"": 0.1582, ""salesPerShare"": 5.8411, ""sgaToSale"": 0.1889, ""totalDebtToEquity"": 1.1879, ""totalDebtToTotalAsset"": 0.3994, ""totalDebtToTotalCapital"": 0.5429, ""totalRatio"": 1.5065, ""period"": ""2022-12-31""}"
1,2023-01-15,83.06157684326172,2023-01-22,79.92282104492188,-0.03778830016991752,D4,[],"{""assetTurnoverTTM"": 0.4336, ""bookValue"": 21240, ""cashRatio"": 0.48162320904155914, ""currentRatio"": 1.2853, ""ebitPerShare"": 1.7921, ""eps"": 1.2964, ""ev"": 127495, ""fcfMargin"": 0.3229, ""fcfPerShareTTM"": 6.6913, ""grossMargin"": 0.8111, ""inventoryTurnoverTTM"": 3.6205, ""longtermDebtTotalAsset"": 0.3634, ""longtermDebtTotalCapital"": 0.494, ""longtermDebtTotalEquity"": 1.0808, ""netDebtToTotalCapital"": 0.4265, ""netDebtToTotalEquity"": 0.9331, ""netMargin"": 0.222, ""operatingMargin"": 0.3068, ""payoutRatioTTM"": 0.8077, ""pb"": 5.0695, ""peTTM"": 23.4488, ""pfcfTTM"": 12.9047, ""pretaxMargin"": 0.2749, ""psTTM"": 3.947, ""quickRatio"": 0.9933, ""receivablesTurnoverTTM"": 5.8859, ""roaTTM"": 0.073, ""roeTTM"": 0.2227, ""roicTTM"": 0.0991, ""rotcTTM"": 0.1582, ""salesPerShare"": 5.8411, ""sgaToSale"": 0.1889, ""totalDebtToEquity"": 1.1879, ""totalDebtToTotalAsset"": 0.3994, ""totalDebtToTotalCapital"": 0.5429, ""totalRatio"": 1.5065, ""period"": ""2022-12-31""}"
2,2023-01-22,79.92282104492188,2023-01-29,80.61604309082031,0.00867364335786891,U1,[],{}
3,2023-01-29,80.61604309082031,2023-02-05,81.35740661621094,0.009196228157160036,U1,"[{""date"": ""2023-01-30"", ""headline"": ""Why Gilead (GILD) is Poised to Beat Earnings Estimates Again"", ""summary"": ""Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.""}, {""date"": ""2023-01-30"", ""headline"": ""Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma"", ""summary"": ""SANTA MONICA, Calif. & REDWOOD CITY, Calif., January 30, 2023--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies\u2019 previously announced global strategic collaboration to co-develop and co-commercialize Arcellx\u2019s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, sa""}, {""date"": ""2023-02-01"", ""headline"": ""Gilead Sciences Inc. stock rises Wednesday, still underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.07% higher to $84.00 Wednesday, on what proved to be an all-around positive trading session for the stock market,...""}, {""date"": ""2023-02-01"", ""headline"": ""Drug/Biotech Stocks Q4 Earnings Due on Feb 2: GILD, MRK & Others"", ""summary"": ""Let's look at the four biotech/pharma companies slated to release quarterly results on Feb 2.""}, {""date"": ""2023-02-01"", ""headline"": ""Top 25 Smartest Companies To Buy According To Hedge Funds"", ""summary"": ""In this piece, we will take a look at the top 25 smartest companies to buy according to hedge funds. For more companies, head on over to Top 5 Smartest Companies To Buy According To Hedge Funds. Surviving in the modern day corporate world is not for the faint of heart. Business is a ruthless [\u2026]""}, {""date"": ""2023-02-01"", ""headline"": ""How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings"", ""summary"": ""Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.""}, {""date"": ""2023-02-01"", ""headline"": ""Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer"", ""summary"": ""FOSTER CITY, Calif., February 01, 2023--Gilead awards $7.6 million in grants to 24 U.S.-based organizations through the newly created Toward Health Equity Oncology Grant(TM).""}, {""date"": ""2023-02-02"", ""headline"": ""Gilead Sciences (GILD) Q4 2022 Earnings Call Transcript"", ""summary"": ""Thank you for attending today's fourth quarter and full year 2022 Gilead Sciences earnings conference call.  Just after market closed today, we issued a press release with earnings results for the fourth quarter and full year 2022.  The speakers on today's call will be our chairman and chief executive officer, Daniel O'Day; our chief commercial officer, Johanna Mercier; our chief medical officer, Merdad Parsey; and our chief financial officer, Andrew Dickinson.""}, {""date"": ""2023-02-02"", ""headline"": ""Gilead profit beats Street expectations on COVID and HIV sales"", ""summary"": ""Gilead Sciences Inc on Thursday reported a higher-than-expected fourth-quarter profit driven by strong demand for its HIV and cancer drugs, while COVID-19 antiviral Veklury had sales that were double Wall Street estimates.""}, {""date"": ""2023-02-02"", ""headline"": ""Gilead Sciences (GILD) Tops Q4 Earnings and Revenue Estimates"", ""summary"": ""Gilead (GILD) delivered earnings and revenue surprises of 11.33% and 12.24%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?""}, {""date"": ""2023-02-02"", ""headline"": ""Gilead stock jumps 5% after Q4 beat, dividend increase"", ""summary"": ""Shares of Gilead Sciences Inc.  (GILD)  rose more than 5% in the extended session Thursday after the pharma company reported fourth-quarter earnings and sales above Wall Street expectations, saying higher sales elsewhere took the sting of falling revenue for its COVID-19 drug.  Gilead earned $1.6 billion, or $1.30 a share, compared with $376 million, or 30 cents a share, in the year-ago period in 2021.""}, {""date"": ""2023-02-02"", ""headline"": ""Gilead Sciences, Inc. (GILD) Q4 2022 Earnings Call Transcript"", ""summary"": ""Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Q4 2022 Earnings Conference Call February 2, 2023 4:30 PM ETCompany ParticipantsJacquie Ross - VP, IRDaniel O'Day - Chairman and CEOJohanna...""}, {""date"": ""2023-02-02"", ""headline"": ""Gilead Sciences, Inc. 2022 Q4 - Results - Earnings Call Presentation"", ""summary"": ""The following slide deck was published by Gilead Sciences, Inc.""}, {""date"": ""2023-02-02"", ""headline"": ""Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 Dividend"", ""summary"": ""FOSTER CITY, Calif., February 02, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company\u2019s Board of Directors has declared an increase of 2.7% in the company\u2019s quarterly cash dividend, beginning in the first quarter of 2023. The increase will result in a quarterly dividend of $0.75 per share of common stock. The dividend is payable on March 30, 2023, to stockholders of record at the close of business on March 15, 2023. Future dividends will be subject to Board approval.""}, {""date"": ""2023-02-02"", ""headline"": ""Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results"", ""summary"": ""FOSTER CITY, Calif., February 02, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2022.""}, {""date"": ""2023-02-02"", ""headline"": ""Stocks making the biggest moves after hours: Apple, Amazon, Ford and more"", ""summary"": ""Several major U.S. companies reported disappointing results for their latest quarters, including a decline in sales for Apple. ""}, {""date"": ""2023-02-02"", ""headline"": ""Gilead Sciences Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. shed 3.11% to $81.39 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-02-02"", ""headline"": ""Gilead Sciences 4Q Profit Surges on Oncology, HIV Sales"", ""summary"": ""By Denny Jacob Gilead Sciences Inc. posted a surge in profit in the latest quarter, as sales grew 2% based on higher sales in oncology and HIV coupled with...""}, {""date"": ""2023-02-02"", ""headline"": ""Gilead Sciences: Toward Health Equity for Black People Impacted by TNBC"", ""summary"": ""NORTHAMPTON, MA / ACCESSWIRE / February 2, 2023 / Gilead Sciences Originally Published by Gilead Sciences Racism and the impact of social determinants of health drive disparities in outcomes for Black women impacted by triple-negative breast cancer ...""}, {""date"": ""2023-02-03"", ""headline"": ""Gilead Sciences and 9 More Companies That Boosted Their Dividends This Week"", ""summary"": ""Old Dominion Freight Line, which handles freight shipping logistics, said it will raise its quarterly dividend by 33% to 40 cents from 30 cents.""}, {""date"": ""2023-02-03"", ""headline"": ""Gilead (GILD) Q4 Earnings & Sales Top on Biktarvy & Oncology"", ""summary"": ""Gilead's (GILD) Q4 earnings and sales beat on strong HIV and oncology business. The guidance for 2023 was also ahead of expectations.""}, {""date"": ""2023-02-03"", ""headline"": ""Gilead Snags Another Cancer Win On The Heels Of Its Best Growth In 7 Years"", ""summary"": ""Gilead Sciences followed up a strong quarterly report with a third FDA approval for cancer drug Trodelvy, and GILD stock popped.""}, {""date"": ""2023-02-03"", ""headline"": ""Gilead Sciences, Inc. (NASDAQ:GILD) Q4 2022 Earnings Call Transcript"", ""summary"": ""Gilead Sciences, Inc. (NASDAQ:GILD) Q4 2022 Earnings Call Transcript February 2, 2023 Operator: Good afternoon. Thank you for attending today\u2019s Fourth Quarter and Full Year 2022 Gilead Sciences Earnings Conference Call. My name is Henna, and I will be your moderator for today\u2019s call. I would now like to pass the conference over to our [\u2026]""}, {""date"": ""2023-02-03"", ""headline"": ""Gilead's breast cancer drug gets U.S. FDA approval for third indication"", ""summary"": ""Gilead Sciences said on Friday the U.S. Food and Drug Administration had greenlighted the use of Trodelvy for a third indication, providing another treatment option for patients with the most common type of breast cancer.""}, {""date"": ""2023-02-03"", ""headline"": ""Gilead Sciences' Trovelvy Scores FDA Approval For Advanced/Metastatic Breast Cancer Setting"", ""summary"": ""The FDA has approved Gilead Sciences Inc's (NASDAQ: GILD) Trodelvy (sacituzumab govitecan-hziy) for adult patients with advanced or metastatic breast cancer. The approval covers unresectable locally advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. The approval is based on statistically significant and clinically meani""}, {""date"": ""2023-02-03"", ""headline"": ""Dan O'Day delivers clear Gilead message: stability, sustainability"", ""summary"": ""Through acquisitions and organic research, the HIV and cancer drug developer is in a better position than it was three years ago, its chairman and CEO says.""}, {""date"": ""2023-02-03"", ""headline"": ""15 Best Dividend Leaders to Buy According to Hedge Funds"", ""summary"": ""In this article, we discuss 15 best dividend leaders to buy according to hedge funds. If you want to see more stocks in this selection, check out 5 Best Dividend Leaders to Buy According to Hedge Funds. First Trust Morningstar Dividend Leaders Index Fund (NYSE:FDL) is based on the 100 highest yielding stocks that have [\u2026]""}, {""date"": ""2023-02-03"", ""headline"": ""Gilead Sciences Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. rose 3.82% to $84.50 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-02-03"", ""headline"": ""Gilead's breast cancer drug secures U.S. FDA approval for expanded use"", ""summary"": ""Gilead Sciences Inc said on Friday the U.S. Food and Drug Administration had greenlighted expanded use of Trodelvy to treat the most common type of breast cancer, marking the third approval for the drug.""}, {""date"": ""2023-02-03"", ""headline"": ""UPDATE 3-Gilead's breast cancer drug gets U.S. FDA approval for third indication"", ""summary"": ""Gilead Sciences said on Friday the U.S. Food and Drug Administration had greenlighted the use of Trodelvy for a third indication, providing another treatment option for patients with the most common type of breast cancer.  The drug was approved for an advanced form of breast cancer with a subtype known as HR-positive/HER2-negative in patients, who had stopped responding to a hormone-based therapy and at least two earlier systemic therapies.  Gilead's Trodelvy will likely face competition from AstraZeneca-Daiichi Sankyo's Enhertu, which is approved to treat breast cancer patients with HER2-low type, a subset of HER2-negative breast cancer.""}, {""date"": ""2023-02-03"", ""headline"": ""U.S. FDA approves expanded use of Gilead's breast cancer drug "", ""summary"": ""The U.S. Food and Drug Administration on Friday granted approval for expanded use of Gilead Sciences Inc's cancer drug, Trodelvy, the company said. (Reporting by Raghav Mahobe and Bhanvi Satija in Bengaluru; Editing by Shinjini Ganguli)""}, {""date"": ""2023-02-03"", ""headline"": ""U.S. FDA Approves Trodelvy\u00ae in Pre-treated HR+/HER2- Metastatic Breast Cancer"", ""summary"": ""FOSTER CITY, Calif., February 03, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) has approved Trodelvy\u00ae (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH\u2013) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in""}, {""date"": ""2023-02-03"", ""headline"": ""Is Gilead Sciences Stock a Screaming Buy After Its Strongest Results in 7 Years?"", ""summary"": ""Despite a slower start this year, Gilead appears to be in pretty good shape to resume its momentum.  CEO Dan O'Day stated in the press release announcing the numbers, \""2022 marked Gilead's strongest full-year growth in our base business since HCV sales peaked in 2015.\""  Is Gilead Sciences stock a buy after its strongest results in seven years?""}, {""date"": ""2023-02-03"", ""headline"": ""Gilead (GILD) Reports Q4 Earnings: What Key Metrics Have to Say"", ""summary"": ""Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.""}, {""date"": ""2023-02-03"", ""headline"": ""S&P 500 Futures Fall in Premarket Trading; Bill.com Holdings, Atlassian Lag"", ""summary"": ""With U.S. stock markets set to open in two hours, (BYD) was up 5.8% in pre-market trading, and (FLR) was up 4.5%. (CLX), (GILD), and (BEP) were all posting...""}, {""date"": ""2023-02-04"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of February 5"", ""summary"": ""Dividend Champions list is monthly compilation of companies that consistently increased annual dividend payouts. Check out the full report of the week of February 5.""}]",{}
4,2023-02-05,81.35740661621094,2023-02-12,83.47557830810547,0.02603538854042675,U3,"[{""date"": ""2023-02-04"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of February 5"", ""summary"": ""Dividend Champions list is monthly compilation of companies that consistently increased annual dividend payouts. Check out the full report of the week of February 5.""}, {""date"": ""2023-02-06"", ""headline"": ""Gilead's (GILD) Breast Cancer Drug Trodelvy Gets FDA Nod"", ""summary"": ""Gilead Sciences, Inc. (GILD) announces the FDA approval of their first-in-class, Trop-2 directed antibody-drug conjugate, Trodelvy, for the treatment of metastatic HR+/HER2- breast cancer in adult patients.""}, {""date"": ""2023-02-06"", ""headline"": ""Is Gilead Sciences a Good Stock to Buy Now?"", ""summary"": ""Shares of\u00a0Gilead Sciences (NASDAQ: GILD) marched higher on Thursday, Feb. 2 in response to a fourth-quarter earnings report that exceeded expectations.  A day later, the U.S. Food and Drug Administration (FDA) agreed to dramatically increase the addressable patient population for an important cancer drug called Trodelvy.  Gilead Sciences splashed out with a $21 billion acquisition of Immunomedics in 2020 for access to Trodelvy.""}, {""date"": ""2023-02-07"", ""headline"": ""Gilead Sciences Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. sank 0.36% to $86.05 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""2023-02-07"", ""headline"": ""Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.75"", ""summary"": ""Gilead Sciences, Inc. ( NASDAQ:GILD ) will increase its dividend on the 30th of March to $0.75, which is 2.7% higher...""}, {""date"": ""2023-02-08"", ""headline"": ""Thoughts For Thursday: Risk-Off, Risk-On"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-08"", ""headline"": ""Gilead Sciences Inc. stock outperforms market despite losses on the day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-08"", ""headline"": ""Goodman Financial CORP Buys 2, Sells 3 in 4th Quarter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-08"", ""headline"": ""Gilead Sciences: 4 Questions With See Phan: Discovering New Therapies in Breast Cancer"", ""summary"": ""As a practicing physician and cancer researcher for more than 20 years, See Phan is all too familiar with the need for innovative new treatment options, especially for breast cancer.""}, {""date"": ""2023-02-08"", ""headline"": ""NeurAxis: Should You Buy This IPO?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-08"", ""headline"": ""Oak Asset Management, LLC Buys 2, Sells 3 in 4th Quarter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-08"", ""headline"": ""Top 5 4th Quarter Trades of ICICI Prudential Asset Management Co Ltd"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-08"", ""headline"": ""Top 5 4th Quarter Trades of COZAD ASSET MANAGEMENT INC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-08"", ""headline"": ""Why Gilead Sciences is a Top 25 Dividend Giant (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-09"", ""headline"": ""Gilead Sciences Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-09"", ""headline"": ""Kite's Tecartus CAR T-Cell Therapy Demonstrates Durable Overall Survival Benefit In Leukemia Settings"", ""summary"": ""Kite, a Gilead Sciences Inc (NASDAQ: GILD) company, announced the three-year follow-up results from the pivotal ZUMA-3 study of the CAR T-cell therapy Tecartus (brexucabtagene autoleucel). The analysis showed a median overall survival (OS) of 26 months and demonstrated that responses remained durable in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), with a consistent safety profile observed since the two-year analysis. In the Phase 2 treated patient cohort (n=55""}, {""date"": ""2023-02-09"", ""headline"": ""Biotech Stock Roundup: AMGN, GILD, BMY, REGN's Q4 Results, KPRX Up on Study Update"", ""summary"": ""Earnings results from Amgen (AMGN), Gilead (GILD) and others are the key highlights from the biotech sector during the past week.""}, {""date"": ""2023-02-09"", ""headline"": ""2 Biotech Stocks That Could Make You Richer"", ""summary"": ""The biotech industry is a great place to look for such companies.  Let's look at two biotech stocks that could help make investors richer in the years ahead: Gilead Sciences (NASDAQ: GILD) and CRISPR Therapeutics (NASDAQ: CRSP).  Gilead Sciences is a biotech giant famous for its leadership in the market for HIV drugs.""}, {""date"": ""2023-02-09"", ""headline"": ""Kite\u2019s Tecartus\u00ae CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia"", ""summary"": ""SANTA MONICA, Calif., February 09, 2023--Kite, a Gilead Company (Nasdaq: GILD), today announced the three-year follow-up results from the pivotal ZUMA-3 study of the CAR T-cell therapy Tecartus\u00ae (brexucabtagene autoleucel). Results from the analysis showed a median overall survival (OS) of 26 months and demonstrated that responses remained durable in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) with a consistent safety profile observed since the two-year analys""}, {""date"": ""2023-02-09"", ""headline"": ""IN BRIEF: Gilead Sciences reports positive follow-up for Tecartus"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-09"", ""headline"": ""Gilead`s Tecartus shows long-term overall survival in type of lymphoma"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-09"", ""headline"": ""Moat Stocks Take Early Lead In 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-10"", ""headline"": ""Gilead (GILD) Kite Reports Positive Data on CAR T-Cell Therapy"", ""summary"": ""Gilead (GILD) reports positive long-term results from the phase I/II study on Tecartus (brexucabtagene autoleucel) for acute lymphoblastic leukemia.""}, {""date"": ""2023-02-10"", ""headline"": ""Gilead price target raised to $95 from $90 at Cowen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-10"", ""headline"": ""Medicare mulls rebates in 2025 for drug prices rising faster than inflation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-11"", ""headline"": ""GLOBEFLEX CAPITAL L P Buys 4, Sells 1 in 4th Quarter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-11"", ""headline"": ""Top 5 4th Quarter Trades of KLCM Advisors, Inc."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-11"", ""headline"": ""Galapagos: Crohn's Disease Trial Failure, Still Maintaining A Buy Rating"", ""summary"": ""On February 8th, 2023, Galapagos announced disappointing results of their phase 3 DIVERSITY Crohn's disease study; the company is no longer planning to file an MAA. Read more here.""}, {""date"": ""2023-02-11"", ""headline"": ""Galapagos: Crohn`s Disease Trial Failure, Still Maintaining A Buy Rating"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-12"", ""headline"": ""COVID-19 emergency is ending; What it means for free vaccines and drugs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
5,2023-02-12,83.47557830810547,2023-02-19,81.60774230957031,-0.0223758377766613,D3,"[{""date"": ""2023-02-11"", ""headline"": ""GLOBEFLEX CAPITAL L P Buys 4, Sells 1 in 4th Quarter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-11"", ""headline"": ""Top 5 4th Quarter Trades of KLCM Advisors, Inc."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-12"", ""headline"": ""Large-Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-12"", ""headline"": ""Large Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-12"", ""headline"": ""Guild Esports extends Fortnite contracts with two professional players"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-12"", ""headline"": ""ARK Invest: The 7 Words That Explain Why Wall Street Can`t Stand Cathie Wood"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-12"", ""headline"": ""COVID-19 emergency is ending; What it means for free vaccines and drugs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-13"", ""headline"": ""Gilead Sciences, Inc. (GILD) SVB Securities Global Biopharma Conference (Transcript)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-13"", ""headline"": ""Gilead Sciences Inc. stock rises Monday, still underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.91% higher to $87.49 Monday, on what proved to be an all-around positive trading session for the stock market, with...""}, {""date"": ""2023-02-13"", ""headline"": ""Wainwright initiates Arcellx with a buy on CAR-T pipeline, partnership with Gilead`s Kite"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-13"", ""headline"": ""Mizuho Securities Sticks to Its Buy Rating for Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-14"", ""headline"": ""Top 5 4th Quarter Trades of Avalon Investment & Advisory"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-14"", ""headline"": ""Gilead Sciences Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. shed 2.07% to $85.68 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-02-14"", ""headline"": ""Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023"", ""summary"": ""FOSTER CITY, Calif., February 14, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new clinical and real-world data from the company\u2019s HIV, COVID-19 and viral hepatitis research and development programs at the 30th Conference on Retroviruses and Opportunistic Infections (CROI) from February 19-22. Seventy abstracts, including late-breaking data, demonstrate Gilead\u2019s continued expertise and leadership in virology with a commitment to advance the next wave of""}, {""date"": ""2023-02-14"", ""headline"": ""John Rogers Buys 3, Sells 2 in 4th Quarter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-14"", ""headline"": ""Caxton Associates Buys 4, Sells 1 in 4th Quarter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-14"", ""headline"": ""Gilead price target raised to $101 from $88 at Mizuho"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-15"", ""headline"": ""Top 5 4th Quarter Trades of Nan Shan Life Insurance Co., Ltd."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-15"", ""headline"": ""Gilead Sciences Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Gilead Sciences Inc. slipped 0.74% to $85.05 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P...""}, {""date"": ""2023-02-15"", ""headline"": ""4 Questions With Flavius Martin: Enhancing Innovation by Expanding Gilead\u2019s Research Footprint"", ""summary"": ""Innovation is at the core of Gilead's 35-year history of life-changing medicines. Through bold and transformative science, Gilead has developed therapies that have brought about a cure for hepatitis C, helped to transform the treatment and prevention of HIV and provided breakthrough therapies for people with cancer.""}, {""date"": ""2023-02-15"", ""headline"": ""Medicare mulls limiting per month costs for generic drugs at $2"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-15"", ""headline"": ""4 Questions With Flavius Martin: Enhancing Innovation by Expanding Gilead`s Research Footprint"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-16"", ""headline"": ""Gilead Sciences Inc. stock falls Thursday, underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. shed 1.95% to $83.39 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-02-16"", ""headline"": ""Elliott Wave Technical Analysis: Gilead Inc."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-17"", ""headline"": ""Gilead Sciences Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. advanced 1.64% to $84.76 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...""}, {""date"": ""2023-02-17"", ""headline"": ""Mobile Clinics Expand Access to Cancer Screenings in the U.S. South"", ""summary"": ""Sharneitha Bradford spends her days helping people access cancer diagnostic care, a role she embraces as a nurse navigator.""}, {""date"": ""2023-02-17"", ""headline"": ""Trodelvy\u00ae Demonstrates Positive Efficacy Treating Both Platinum-Ineligible and Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer"", ""summary"": ""FOSTER CITY, Calif., February 17, 2023--Trodelvy Demonstrates Positive Efficacy in Metastatic Urothelial Cancer""}, {""date"": ""2023-02-17"", ""headline"": ""AQR CAPITAL MANAGEMENT LLC Buys 3, Sells 2 in 4th Quarter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-17"", ""headline"": ""Kite CEO Christi Shaw leaving Gilead at end of March"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-17"", ""headline"": ""Gilead updates Phase 2 data for bladder cancer therapy Trodelvy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-17"", ""headline"": ""Gilead announces updated results from three cohorts of TROPHY-U-01 study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-17"", ""headline"": ""VALUEWORKS LLC Buys 1, Sells 4 in 4th Quarter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-17"", ""headline"": ""Top 5 4th Quarter Trades of HealthInvest Partners AB"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
6,2023-02-19,81.60774230957031,2023-02-26,77.66021728515625,-0.04837194257181565,D5,"[{""date"": ""2023-02-20"", ""headline"": ""Gilead reports `positive data` from real-world studies of Veklury"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-20"", ""headline"": ""Gilead says new data from four collaborative HIV studies reported at CROI"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-20"", ""headline"": ""Gilead (GILD) Reports Positive Data From Urothelial Cancer Study"", ""summary"": ""Gilead's (GILD) new and updated positive results from a phase II study show Trodelvy's rapid and durable responses for patients across a range of hard-to-treat types of mUC.""}, {""date"": ""2023-02-20"", ""headline"": ""25 Most Profitable NASDAQ Stocks Today"", ""summary"": ""In this article, we will look at the 25 most profitable NASDAQ stocks today. If you want to explore similar stocks, you can also take a look at 10 Most Profitable NASDAQ Stocks Today. 2022 was one of the worst years for the NASDAQ, primarily because it is dominated by tech, and tech stocks crashed as [\u2026]""}, {""date"": ""2023-02-20"", ""headline"": ""Billionaire Ken Griffin\u2019s Top 10 High Dividend Stock Picks"", ""summary"": ""In this article, we discuss billionaire Ken Griffin\u2019s top 10 high-dividend stock picks. You can skip our detailed analysis of Ken Griffin\u2019s investment strategy, and go directly to read Billionaire Ken Griffin\u2019s Top 5 High Dividend Stock Picks. Ken Griffin\u2019s Citadel Investment Group is one of the 15 Biggest Hedge Funds in the World by [\u2026]""}, {""date"": ""2023-02-21"", ""headline"": ""John Rogers` Firm Enters Carlyle Group Stake, Powers Up Generac Position"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-21"", ""headline"": ""S&P 500 Q4 2022 Earnings Review: Swing And A Miss"", ""summary"": ""As we exit the peak period of earnings season, we review the S&P 500 2022 Q4 earnings season in more detail, providing both aggregate and company level insights.""}, {""date"": ""2023-02-21"", ""headline"": ""Gilead says its COVID-19 drug can help reduce deaths, shorten hospital stays"", ""summary"": ""MARKET PULSE Gilead Sciences Inc. (GILD) said Tuesday that its COVID-19 drug can help reduce deaths and readmission rates among patients hospitalized with COVID-19 and who received the drug, remdesivir, shortly after their hospital admission.""}, {""date"": ""2023-02-21"", ""headline"": ""Veklury\u00ae (Remdesivir) Reduced Risk of Mortality in Hospitalized COVID-19 Patients Across all Variant Time Periods in a Real World Study of More than 500,000 Hospitalized Patients"", ""summary"": ""FOSTER CITY, Calif., February 21, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive data from three retrospective real-world studies which demonstrated that initiation of Veklury\u00ae (remdesivir) within the first two days of hospital admission can help reduce mortality and hospital readmission rates among all patients hospitalized with COVID-19, regardless of disease severity. A reduction in mortality was also observed in vulnerable populations, such as people living with cancer o""}, {""date"": ""2023-02-21"", ""headline"": ""Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and Strategies"", ""summary"": ""FOSTER CITY, Calif., February 21, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from four collaborative studies evaluating novel investigational combinations and strategies with the potential to target the HIV viral reservoir or enhance immune response to maintain virologic control in the absence of antiretroviral therapy (ART). These latest findings represent an ongoing multi-pronged approach in Gilead\u2019s HIV cure research program. The data were presented at the Conference o""}, {""date"": ""2023-02-21"", ""headline"": ""Gilead Sciences Inc. stock outperforms market despite losses on the day"", ""summary"": ""Shares of Gilead Sciences Inc. slipped 0.14% to $84.64 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P...""}, {""date"": ""2023-02-21"", ""headline"": ""Gilead Listed on the 2023 Bloomberg Gender-Equality Index"", ""summary"": ""Gilead's been listed on the 2023 Bloomberg Gender-Equality Index for our support of women's empowerment.""}, {""date"": ""2023-02-21"", ""headline"": ""Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.75"", ""summary"": ""Gilead Sciences, Inc. ( NASDAQ:GILD ) has announced that it will be increasing its dividend from last year's comparable...""}, {""date"": ""2023-02-22"", ""headline"": ""Lightning Round: Stay long Berkshire Hathaway"", ""summary"": ""Mad Money host Jim Cramer takes questions on specific stocks, including Berkshire Hathaway, VF Corp., Tesla, Teva Pharmaceuticals McKesson Corp., Equinix, Gilead Sciences and EQT Corp.""}, {""date"": ""2023-02-22"", ""headline"": ""Gilead Sciences Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. shed 1.35% to $83.50 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P...""}, {""date"": ""2023-02-22"", ""headline"": ""Gilead Sciences Touts Encouraging Data From Real World Studies Of Its Flagship COVID-19 Treatment"", ""summary"": ""Gilead Sciences Inc (NASDAQ: GILD) announced data from three retrospective real-world Veklury (remdesivir) studies for COVID-19 treatment. The studies demonstrated that initiating Veklury within the first two days of hospital admission can help reduce mortality and hospital readmission rates among all patients hospitalized with COVID-19, regardless of disease severity. A reduction in mortality was also observed in vulnerable populations. Related: WHO Recommends Gilead's COVID-19 Therapy For Seve""}, {""date"": ""2023-02-22"", ""headline"": ""Gilead Presents Positive Proof-of-Concept Data for Investigational Combination Regimen of Lenacapavir with Broadly Neutralizing Antibodies as a Potential Twice-Yearly Approach for the Treatment of HIV"", ""summary"": ""FOSTER CITY, Calif., February 22, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced data evaluating lenacapavir in combination with broadly neutralizing antibodies (bNAbs) teropavimab and zinlirvimab as a potential long-acting treatment regimen with twice-yearly dosing. Results from the Phase 1b clinical trial demonstrated the investigational combination was generally well tolerated with high efficacy in select virologically suppressed participants living with HIV. These data were prese""}, {""date"": ""2023-02-22"", ""headline"": ""IN BRIEF: Gilead hails results of study for Covid-19 drug Veklury"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-22"", ""headline"": ""GSK's ViiV says study shows its long-acting HIV shot as effective as Gilead's daily pill"", ""summary"": ""British drugmaker GSK's HIV treatment division, ViiV Healthcare, published data on Wednesday showing its long-acting HIV injection is as effective as the market-leading daily pill made by Gilead Sciences Inc.""}, {""date"": ""2023-02-22"", ""headline"": ""Kite Completes Acquisition of Tmunity"", ""summary"": ""SANTA MONICA, Calif., February 22, 2023--Kite, a Gilead Company (NASDAQ: GILD), today announced the completion of the previously announced transaction to acquire Tmunity Therapeutics (Tmunity), a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies.""}, {""date"": ""2023-02-22"", ""headline"": ""Gilead posts Phase 1 data to support twice yearly potential of HIV therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-22"", ""headline"": ""GSK`s long-acting HIV med Cabenuva equals Gilead`s daily Biktarvy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-22"", ""headline"": ""Gilead presents PoC data for investigational combination of lenacapavir, bNAbs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-22"", ""headline"": ""Mizuho Securities Sticks to Its Buy Rating for Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-23"", ""headline"": ""Cambridge biotech Jounce to cut staff, merge with U.K. drug developer"", ""summary"": ""A Cambridge-based cancer company and longtime partner of pharma giant Gilead Sciences Inc. is merging with another firm, one day after announcing it would lay off most of its staff.""}, {""date"": ""2023-02-23"", ""headline"": ""Gilead Sciences Inc. stock falls Thursday, underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. slid 1.15% to $82.54 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""2023-02-23"", ""headline"": ""Gilead Sciences: Black HIV/AIDS Awareness Day"", ""summary"": ""NORTHAMPTON, MA / ACCESSWIRE / February 23, 2023 / Gilead Sciences: This Black HIV/AIDS Awareness Day, we recognize the major strides made to combat the disproportionate impact of HIV on Black communities - but there is more work to do. Learn ...""}, {""date"": ""2023-02-24"", ""headline"": ""Gilead Sciences Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. slipped 2.28% to $80.66 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-02-24"", ""headline"": ""WHO panel is reviewing whether COVID vaccines need updating, as agency monitors 7 omicron subvariants"", ""summary"": ""Most of the week's COVID news is focused on vaccines, including the big slide in Moderna's revenue caused by falling demand.""}, {""date"": ""2023-02-24"", ""headline"": ""WHO panel is reviewing whether COVID vaccines need to be updated "", ""summary"": ""Most of the week's COVID news is focused on vaccines, including the big slide in Moderna's revenue caused by falling demand.""}, {""date"": ""2023-02-24"", ""headline"": ""UK shareholder meetings calendar - next 7 days"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-25"", ""headline"": ""3 Stocks to Buy Right Now That Are Cash Cows"", ""summary"": ""With this in mind, three Motley Fool contributors were asked to pick stocks to buy right now that are cash cows.  Here's why they chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Vertex Pharmaceuticals (NASDAQ: VRTX).  Prosper Junior Bakiny (AbbVie): There are many ways in which a company can be deemed a \""cash cow.\""""}, {""date"": ""2023-02-25"", ""headline"": ""Regeneron: Innovation And Disruption Done Right"", ""summary"": ""Regeneron Pharmaceuticals' collaborative energy is strong and the medium-term looks good. Check out why we rate REGN stock a Hold for now.""}, {""date"": ""2023-02-26"", ""headline"": ""7 Cash-Rich Companies to Invest in During Economic Uncertainty"", ""summary"": ""While it\u2019s generally good to be optimistic, in the market, it also pays to be realistic, thus incentivizing consideration for cash-rich stocks to buy. Here, we\u2019re not necessarily talking about the most exciting ventures available. Rather, we\u2019re targeting enterprises that have plenty of green-colored paper in the bank. This way, these cash-imbued entities can weather whatever storms might break out. At the same time, it doesn\u2019t make too much sense to have plenty of cash if you\u2019re also waist-deep""}, {""date"": ""2023-02-26"", ""headline"": ""Here's What David Siegel's Two Sigma Hedge Fund Loaded Up On to Close Out 2022"", ""summary"": """"}, {""date"": ""2023-02-26"", ""headline"": ""The one-year decline in earnings for Gilead Sciences NASDAQ:GILD) isn't encouraging, but shareholders are still up 38% over that period"", ""summary"": ""Passive investing in index funds can generate returns that roughly match the overall market. But if you pick the right...""}]",{}
7,2023-02-26,77.66021728515625,2023-03-05,78.05496978759766,0.005083072340525963,U1,"[{""date"": ""2023-02-26"", ""headline"": ""7 Cash-Rich Companies to Invest in During Economic Uncertainty"", ""summary"": ""While it\u2019s generally good to be optimistic, in the market, it also pays to be realistic, thus incentivizing consideration for cash-rich stocks to buy. Here, we\u2019re not necessarily talking about the most exciting ventures available. Rather, we\u2019re targeting enterprises that have plenty of green-colored paper in the bank. This way, these cash-imbued entities can weather whatever storms might break out. At the same time, it doesn\u2019t make too much sense to have plenty of cash if you\u2019re also waist-deep""}, {""date"": ""2023-02-26"", ""headline"": ""Here's What David Siegel's Two Sigma Hedge Fund Loaded Up On to Close Out 2022"", ""summary"": """"}, {""date"": ""2023-02-26"", ""headline"": ""The one-year decline in earnings for Gilead Sciences NASDAQ:GILD) isn't encouraging, but shareholders are still up 38% over that period"", ""summary"": ""Passive investing in index funds can generate returns that roughly match the overall market. But if you pick the right...""}, {""date"": ""2023-02-27"", ""headline"": ""Moderna\u2019s Covid Boom Is Ending. Why the Outlook Isn\u2019t All Grim."", ""summary"": ""Troubles that were put off during the biotech\u2019s pandemic-era boom, notably various intellectual property wrinkles, are now coming home to roost.""}, {""date"": ""2023-02-27"", ""headline"": ""Top 10 Drug Companies in USA and Their China Reliance"", ""summary"": ""In this article, we will be taking a look at the top 10 drug companies in USA and their China reliance. To skip our detailed analysis of the pharmaceutical sector, you can go directly to see the Top 5 Drug Companies in USA and Their China Reliance. The US has long been reliant on China [\u2026]""}, {""date"": ""2023-02-27"", ""headline"": ""Gilead Sciences Inc. stock rises Monday, still underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.29% higher to $80.89 Monday, on what proved to be an all-around favorable trading session for the stock market, with...""}, {""date"": ""2023-02-28"", ""headline"": ""Gilead Sciences Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Gilead Sciences Inc. slid 0.45% to $80.53 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-02-28"", ""headline"": ""Honoring the History and Impact of the Aids Memorial Quilt"", ""summary"": ""The San Francisco-based AIDS Memorial Quilt is the world's largest living memorial project.""}, {""date"": ""2023-03-01"", ""headline"": ""Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. shed 1.17% to $79.59 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...""}, {""date"": ""2023-03-01"", ""headline"": ""Gilead: Good 3.7%+ Yield But More Growth Required"", ""summary"": ""Gilead punches above its weight with its very attractive 3.7%+ dividend yield. Read to know if GILD stock can get back to its dividend growth rate.""}, {""date"": ""2023-03-02"", ""headline"": ""Gilead Sciences Inc. stock rises Thursday, still underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.04% higher to $79.62 Thursday, on what proved to be an all-around great trading session for the stock market, with...""}, {""date"": ""2023-03-02"", ""headline"": ""Gilead Foundation Donating $1 Million for Relief Efforts in T\u00fcrkiye and Syria"", ""summary"": ""As a way to support those impacted by Monday's devastating earthquake in T\u00fcrkiye and Syria, the Gilead Foundation is donating $1 million for on-the-ground relief efforts.""}, {""date"": ""2023-03-02"", ""headline"": ""How Did Gilead Sciences, Inc.'s (NASDAQ:GILD) 22% ROE Fare Against The Industry?"", ""summary"": ""Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...""}, {""date"": ""2023-03-02"", ""headline"": ""UK shareholder meetings calendar - next 7 days"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-02"", ""headline"": ""Interesting GILD Put And Call Options For April 14th"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-02"", ""headline"": ""Gilead Foundation Donating $1 Million for Relief Efforts in T\ufffd\ufffdrkiye and Syria"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-03"", ""headline"": ""Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know"", ""summary"": ""Gilead Sciences (GILD) closed the most recent trading day at $81.07, moving +1.82% from the previous trading session.""}, {""date"": ""2023-03-03"", ""headline"": ""Gilead Sciences Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. rose 1.82% to $81.07 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...""}, {""date"": ""2023-03-03"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), Veru (VERU) and Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
8,2023-03-05,78.05496978759766,2023-03-12,76.5433578491211,-0.01936599223073099,D2,"[{""date"": ""2023-03-05"", ""headline"": ""What To Expect From Pfizer In The Post-COVID-19 Era"", ""summary"": ""In Q4 2022, the company's revenue was $24.29 billion, up 1.9% from the last three months of 2021, despite a significant decrease in people's desire to vaccinate against COVID-19.""}, {""date"": ""2023-03-06"", ""headline"": ""Gilead Sciences Inc. stock rises Monday, still underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.05% higher to $81.11 Monday, on what proved to be an all-around favorable trading session for the stock market, with...""}, {""date"": ""2023-03-06"", ""headline"": ""Healthcare Is Lagging But Biotech Offers Good Potential For Value And Trading"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-06"", ""headline"": ""What Contributed to Gilead Sciences (GILD)\u2019s Outperformance in Q4?"", ""summary"": ""ClearBridge Investments, an investment management company, released its \u201cClearBridge Sustainability Leaders Strategy\u201d fourth 2022 investor letter. A copy of the same can be downloaded here. The strategy underperformed its benchmark, the Russell 3000 Index, in the fourth quarter. In the quarter, the strategy gained in eight of the ten sectors it invested in on an absolute [\u2026]""}, {""date"": ""2023-03-06"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Addus Homecare (ADUS), Gilead Sciences (GILD) and Surgery Partners (SGRY)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-07"", ""headline"": ""U.S. Wide-Moat Stocks On Sale - The March 2023 Heat Map"", ""summary"": ""We are only interested in those targets that are attractively valued in historical comparison. Click here for our 3-step process that focuses on wide-moat stocks.""}, {""date"": ""2023-03-07"", ""headline"": ""Gilead Sciences Inc. stock falls Tuesday, still outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. slipped 1.02% to $80.28 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P...""}, {""date"": ""2023-03-07"", ""headline"": ""2 Healthcare Stocks That Could Help Set You Up for Life"", ""summary"": ""Let's look at two stocks that can help you grow your wealth for decades: Gilead Sciences (NASDAQ: GILD) and Medtronic (NYSE: MDT).  Gilead Sciences is a major biotech company whose primary therapeutic area of focus is HIV.  The company has become a leader in this field thanks to products such as Biktarvy and Descovy, which are among the most-prescribed medicines in the HIV and HIV pre-exposure prophylaxis (PrEP) markets, respectively.""}, {""date"": ""2023-03-07"", ""headline"": ""Gilead Sciences, Inc. (GILD) Presents at Cowen 43rd Annual Healthcare Conference (Transcript)"", ""summary"": ""Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Cowen 43rd Annual Healthcare Conference March 7, 2023 11:10 AM ETCompany ParticipantsAndy Dickinson - Chief Financial OfficerConference Call...""}, {""date"": ""2023-03-07"", ""headline"": ""My Dividend Stock Portfolio: New February Record - 99 Holdings With 32 Buys And 4 Sales"", ""summary"": ""Inflation and (expected) actions by the Federal Reserve continue to dominate market movements. Click here to read more about the dividend stocks.""}, {""date"": ""2023-03-07"", ""headline"": ""Blue Star Capital swings to loss after fair valuation movements, costs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-07"", ""headline"": ""Biden to announce plan to keep Medicare solvent beyond 2050"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-08"", ""headline"": ""Gilead Sciences Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Gilead Sciences Inc. shed 0.10% to $80.20 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P...""}, {""date"": ""2023-03-08"", ""headline"": ""Gilead Sciences: Global Community Accountability Groups Pave Way Forward for Inclusive Clinical Trials"", ""summary"": ""Gilead Sciences (left to right) Bridget Ndagaano Jjuuko, Executive Director, ACTS 101 Uganda and Yvette Raphael, Executive Director, Advocacy for the Prevention of HIV/AIDS in South Africa.""}, {""date"": ""2023-03-08"", ""headline"": ""Is Gilead Sciences, Inc. (NASDAQ:GILD) Trading At A 50% Discount?"", ""summary"": ""Key Insights The projected fair value for Gilead Sciences is US$159 based on 2 Stage Free Cash Flow to Equity Gilead...""}, {""date"": ""2023-03-09"", ""headline"": ""Gilead Sciences (GILD) Stock Moves -1.55%: What You Should Know"", ""summary"": ""In the latest trading session, Gilead Sciences (GILD) closed at $78.96, marking a -1.55% move from the previous day.""}, {""date"": ""2023-03-09"", ""headline"": ""Gilead Sciences Inc. stock outperforms market despite losses on the day"", ""summary"": ""Shares of Gilead Sciences Inc. shed 1.56% to $78.95 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-03-09"", ""headline"": ""37 Upcoming Dividend Increases, Including 2 Dividend Kings"", ""summary"": ""All these stocks have at least 5 fiscal years of dividend growth history and come from the U.S. Dividend Champions List. Click here to see our exclusive list.""}, {""date"": ""2023-03-09"", ""headline"": ""Gilead Sciences: Underlying Growth Obscured By Veklury Swings"", ""summary"": ""Gilead Sciences, Inc. got very lucky with its Veklury anti-viral, as it proved very valuable in combatting Covid-19. Click here for more on GILD stock prospects.""}, {""date"": ""2023-03-10"", ""headline"": ""Gilead Sciences Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.70% higher to $79.50 Friday, on what proved to be an all-around grim trading session for the stock market, with the...""}, {""date"": ""2023-03-10"", ""headline"": ""Ex-Dividend Reminder: Gilead Sciences, Atrion and CONMED"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-10"", ""headline"": ""Assuming No-Growth, Gilead Is The Safest Choice Among The Large Biotechs"", ""summary"": ""Gilead has a strong credit profile and a low cost of equity. Find out why for an investor seeking relative safety, GILD stock is worth a look.""}, {""date"": ""2023-03-11"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of March 12"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.""}, {""date"": ""2023-03-12"", ""headline"": ""Gilead Sciences, Inc. (NASDAQ:GILD) is a favorite amongst institutional investors who own 84%"", ""summary"": ""Key Insights Given the large stake in the stock by institutions, Gilead Sciences' stock price might be vulnerable to...""}]",{}
9,2023-03-12,76.5433578491211,2023-03-19,75.14362335205078,-0.018286818561440765,D2,"[{""date"": ""2023-03-12"", ""headline"": ""Arcellx initiated with a Buy at Stifel"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-12"", ""headline"": ""Gilead Sciences, Inc. (NASDAQ:GILD) is a favorite amongst institutional investors who own 84%"", ""summary"": ""Key Insights Given the large stake in the stock by institutions, Gilead Sciences' stock price might be vulnerable to...""}, {""date"": ""2023-03-13"", ""headline"": ""Gilead Sciences Inc. stock underperforms Monday when compared to competitors despite daily gains"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.01% higher to $79.51 Monday, on what proved to be an all-around grim trading session for the stock market, with the...""}, {""date"": ""2023-03-14"", ""headline"": ""Gilead Sciences Inc. stock rises Tuesday, still underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. rallied 1.28% to $79.77 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P...""}, {""date"": ""2023-03-15"", ""headline"": ""Medicare identifies drug makers that will owe penalties for raising prices on 27 drugs faster than rate of inflation"", ""summary"": ""The Biden administration is making good on promises to help lower drug costs, though the impact is largely for Medicare patients.""}, {""date"": ""2023-03-15"", ""headline"": ""Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. slid 0.15% to $79.65 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-03-15"", ""headline"": ""First Drugs Facing Medicare Price Penalty Are Named"", ""summary"": ""U.S. health officials listed 27 medications whose prices rose faster than inflation, triggering rebates under a new federal law.""}, {""date"": ""2023-03-15"", ""headline"": ""Gilead Sciences, Inc. (GILD) Presents at Barclays 2023 Global Healthcare Conference (Transcript)"", ""summary"": ""Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Barclays 2023 Global Healthcare Conference March 15, 2023 10:00 AM ETCompany ParticipantsMerdad Parsey - Chief Medical OfficerConference Call...""}, {""date"": ""2023-03-15"", ""headline"": ""Stacey Bledsoe's Resolve To Make Clinical Trials Available to Everyone"", ""summary"": ""NORTHAMPTON, MA / ACCESSWIRE / March 15, 2023 / Gilead Sciences Stacey Bledsoe's life took a personal and professional turn in 2015, when her father was diagnosed with lung cancer. A nurse by training, Stacey asked his oncologist whether she could ...""}, {""date"": ""2023-03-15"", ""headline"": ""The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-15"", ""headline"": ""Stacey Bledsoe`s Resolve To Make Clinical Trials Available to Everyone"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-15"", ""headline"": ""AbbVie, Gilead, Seagen among firms fined for raising prices faster than inflation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-16"", ""headline"": ""Gilead Sciences (GILD) Gains But Lags Market: What You Should Know"", ""summary"": ""Gilead Sciences (GILD) closed at $79.85 in the latest trading session, marking a +0.25% move from the prior day.""}, {""date"": ""2023-03-16"", ""headline"": ""Gilead Sciences Inc. stock rises Thursday, still underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.25% higher to $79.85 Thursday, on what proved to be an all-around great trading session for the stock market, with...""}, {""date"": ""2023-03-16"", ""headline"": ""Gilead (GILD) Gains 34% in 12 Months: Will the Trend Sustain?"", ""summary"": ""Gilead (GILD) gains 34% in the past 12 months as its HIV business and rapidly growing oncology business maintain momentum despite volatility.""}, {""date"": ""2023-03-16"", ""headline"": ""IN BRIEF: Guild Esports enters AI-driven technology partnership"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-16"", ""headline"": ""Here\u2019s Why Gilead Sciences (GILD) Outperformed in Q4"", ""summary"": ""Ariel Investments, an investment management company, released its \u201cAriel Global Strategy\u201d fourth-quarter investor letter. A copy of the same can be downloaded here. In the fourth quarter, the Ariel Global Composite delivered a 10.72% gross of fees compared to a +9.76% return for the primary MSCI ACWI Index and a +14.21% gain for the MSCI ACWI [\u2026]""}, {""date"": ""2023-03-16"", ""headline"": ""Gilead Sciences (NASDAQ:GILD) Seems To Use Debt Quite Sensibly"", ""summary"": ""Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...""}, {""date"": ""2023-03-16"", ""headline"": ""JPMorgan biotech/pharma analysts to hold KOL analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-16"", ""headline"": ""PBE: Healthcare Dashboard For March"", ""summary"": ""Healthcare equipment is the less attractive subsector regarding both valuation and quality. Click here to find out why PBE is a Hold.""}, {""date"": ""2023-03-17"", ""headline"": ""Gilead Sciences Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. slid 3.18% to $77.31 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-03-19"", ""headline"": ""Nurix: Promising Early Data From This Protein Degrader Company"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
10,2023-03-19,75.14362335205078,2023-03-26,77.75824737548828,0.03479502194335082,U4,"[{""date"": ""2023-03-19"", ""headline"": ""Nurix: Promising Early Data From This Protein Degrader Company"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-20"", ""headline"": ""Gilead Sciences Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. rallied 2.78% to $79.46 Monday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-03-20"", ""headline"": ""Gilead Exercises First License Option Under Agreement With Nurix Therapeutics"", ""summary"": ""Gilead Sciences Inc (NASDAQ: GILD) has exercised its option to license Nurix Therapeutics Inc's (NASDAQ: NRIX) investigational targeted protein degrader molecule NX-0479 exclusively. This bivalent degrader, GS-6791, is the first development candidate from the previously announced Nurix-Gilead collaboration. GS-6791 is a potent, selective, oral IRAK4 degrader with potential applications in rheumatoid arthritis (RA) and other inflammatory diseases. Under the terms of the Collaboration, Nurix will""}, {""date"": ""2023-03-20"", ""headline"": ""Nurix\u2019s stock rallies on Gilead\u2019s option"", ""summary"": ""MARKET PULSE Shares of Nurix Therapeutics Inc. (NRIX) gained about 6% in premarket trading on Monday after Gilead Sciences Inc. (GILD) said it exercised the option to exclusively license Nurix\u2019s targeted protein degrader molecule, which is being considered as a tool to treat inflammatory conditions like rheumatoid arthritis.""}, {""date"": ""2023-03-20"", ""headline"": ""Oppenheimer reiterates Outperform on Nurix Therapeutics following Gilead news"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-20"", ""headline"": ""Gilead Exercises Option to License Nurix\u2019s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479"", ""summary"": ""FOSTER CITY, Calif. & SAN FRANCISCO, March 20, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation therapies, today announced that Gilead has exercised its option to exclusively license Nurix\u2019s investigational targeted protein degrader molecule NX\u20110479. This bivalent degrader, designated GS-6791, is the first development candidate resulting from the previously announced Nurix-Gil""}, {""date"": ""2023-03-20"", ""headline"": ""First Republic Bank`s stock plummets and Peloton`s stock falls while New York Community Bank shares soar, and other stocks on the move"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-20"", ""headline"": ""Gilead licenses protein degrader from Nurix Therapeutics"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-20"", ""headline"": ""First Republic Bank's stock plummets and Peloton's stock falls while New York Community Bank shares soar, and other stocks on the move"", ""summary"": ""NYCB stock benefits from news it is snapping up some assets of failed Signature Bank.""}, {""date"": ""2023-03-20"", ""headline"": ""Nurix`s stock rallies on Gilead`s option"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-20"", ""headline"": ""Gilead exercises option to license Nurix`s NX-0479"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-20"", ""headline"": ""Gilead exercises option to exclusively license NX-0479 from Nurix Therapeutics"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-21"", ""headline"": ""Oppenheimer emerging biotech analyst to hold analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-21"", ""headline"": ""Gilead's Flagship CAR T-cell Therapy Shows Improved Overall Survival In Pretreated Lymphoma Patients"", ""summary"": ""Kite, a Gilead Science Inc (NASDAQ: GILD) company, announced the primary overall survival (OS) analysis results of the Phase 3 ZUMA-7 study. The results showed a statistically significant improvement for Yescarta in OS versus historical treatment, which was the standard of care (SOC) in a curative setting for nearly 30 years, for initial treatment of adult patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) within 12 months of completion of first-line therapy. Historical SOC is a""}, {""date"": ""2023-03-21"", ""headline"": ""Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. dropped 0.40% to $79.14 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-03-21"", ""headline"": ""Nurix's (NRIX) Stock Up Due to License Option Exercise by Gilead"", ""summary"": ""Nurix Therapeutics (NRIX) to earn an option fee of $20 million as partner Gilead exercised its option to exclusively license Nurix's investigational targeted protein degrader molecule NX 0479.""}, {""date"": ""2023-03-21"", ""headline"": ""Kite\u2019s Yescarta\u00ae CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma"", ""summary"": ""SANTA MONICA, Calif., March 21, 2023--Kite, a Gilead Company (Nasdaq: GILD), today announced the primary overall survival (OS) analysis results of the Phase 3 ZUMA-7 study. The results showed a statistically significant improvement for Yescarta in OS versus historical treatment, which was the standard of care (SOC) in a curative setting for nearly 30 years, for initial treatment of adult patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) within 12 months of completion of first-li""}, {""date"": ""2023-03-21"", ""headline"": ""Gilead`s Kite unit touts survival benefit of Yescarta in large B-cell lymphoma"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-21"", ""headline"": ""Kite announces primary OS analysis results of Phase 3 ZUMA-7 study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-22"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Akero Therapeutics (AKRO)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-22"", ""headline"": ""Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know"", ""summary"": ""Gilead Sciences (GILD) closed at $77.81 in the latest trading session, marking a -1.68% move from the prior day.""}, {""date"": ""2023-03-22"", ""headline"": ""Gilead (GILD) Announces OS Data on Yescarta From ZUMA-7 Study"", ""summary"": ""Gileads Yescarta shows statistically significant improvement in overall survival for initial treatment of R/R LBCL patients versus historical standard of care in curative setting.""}, {""date"": ""2023-03-22"", ""headline"": ""Gilead Sciences Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Gilead Sciences Inc. shed 1.68% to $77.81 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-03-22"", ""headline"": ""Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities"", ""summary"": ""FOSTER CITY, Calif., March 22, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is providing a total of $3 million in grant funding to eight organizations to provide services to communities disproportionately impacted by HIV in rural areas in the United States. My Brother\u2019s Keeper, based in Ridgeland, Mississippi, will provide technical assistance and capacity building to the organizations funded through this initiative. These grants are part of Gilead\u2019s ongoing Zeroing In\u2122 program""}, {""date"": ""2023-03-22"", ""headline"": ""Groups Around the World Work to Eliminate Hepatitis C by Meeting People Where They Are"", ""summary"": ""NORTHAMPTON, MA / ACCESSWIRE / March 22, 2023 / Gilead Sciences Every Friday for more than two years, a community church in North Wales, U.K., would transform into a one-stop shop of social services for people experiencing homelessness. Everything ...""}, {""date"": ""2023-03-22"", ""headline"": ""Vectoring In On Vir Biotechnology"", ""summary"": ""Vir Biotechnology is a San Francisco-based commercial-stage immunological concern focused on the development of treatments for infectious diseases. Read more about VIR here.""}, {""date"": ""2023-03-23"", ""headline"": ""Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval"", ""summary"": ""Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.""}, {""date"": ""2023-03-23"", ""headline"": ""Gilead Sciences Inc. stock rises Thursday, outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. rose 1.22% to $78.76 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""2023-03-23"", ""headline"": ""Pionyr Immunotherapeutics and Gilead Change Exclusive Option Agreement"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-23"", ""headline"": ""Gilead waives rights to acquire immune-oncology biotech Pionyr"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-23"", ""headline"": ""Gilead, Pionyr Immunotherapeutics change 2020 exclusive option agreements"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-24"", ""headline"": ""Gilead Sciences Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. rose 1.57% to $80.00 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""2023-03-24"", ""headline"": ""Final Trades: Bunge, Hershey, Gilead & more"", ""summary"": ""The \""Halftime Report\"" traders give their top picks to watch for the second half.""}, {""date"": ""2023-03-25"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of March 26"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the companies with upcoming ex-dividend dates.""}, {""date"": ""2023-03-25"", ""headline"": ""The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-25"", ""headline"": ""MCN: Strong Performance, But Premium Persists"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
11,2023-03-26,77.75824737548828,2023-04-02,80.64501953125,0.03712496427320078,U4,"[{""date"": ""2023-03-26"", ""headline"": ""NuCana Craters after EU Patent Problems"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-27"", ""headline"": ""Gilead Sciences Inc. stock falls Monday, underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. slumped 0.53% to $79.58 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""2023-03-27"", ""headline"": ""Gilead Sciences Could Retreat Further From Here"", ""summary"": ""Biopharmaceutical company Gilead Sciences  makes and distributes many drugs but today I am more interested in the position of the charts and indicators.  Bottom-line strategy: GILD is a volatile stock that can move up or down quickly depending on the results of any given drug or treatment.""}, {""date"": ""2023-03-27"", ""headline"": ""Oppenheimer emerging biotech analyst to hold analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-27"", ""headline"": ""NuCana falls 36% after setback for patent dispute in EU for Gilead`s antiviral"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-27"", ""headline"": ""Model N stock rises as Morgan Stanley starts coverage with overweight rating"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-28"", ""headline"": ""Gilead Sciences (GILD) Gains As Market Dips: What You Should Know"", ""summary"": ""Gilead Sciences (GILD) closed at $80.99 in the latest trading session, marking a +1.77% move from the prior day.""}, {""date"": ""2023-03-28"", ""headline"": ""Gilead Sciences Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. advanced 1.75% to $80.97 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P...""}, {""date"": ""2023-03-29"", ""headline"": ""Is It Time to Buy These Ultra-Cheap Dividend Stocks?"", ""summary"": ""High-quality dividend stocks can be a great way to tilt the odds in your favor as an investor.  The core reason is that top-shelf dividend stocks generally have a long-standing shareholder base due to the reliability of their payouts.""}, {""date"": ""2023-03-29"", ""headline"": ""Gilead Sciences Inc. stock rises Wednesday, still underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.40% higher to $81.29 Wednesday, on what proved to be an all-around positive trading session for the stock market,...""}, {""date"": ""2023-03-29"", ""headline"": ""Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities"", ""summary"": ""Gilead Sciences, Inc. (Nasdaq:GILD) today announced it is providing a total of $3 million in grant funding to eight organizations to provide services to communities disproportionately impacted by HIV in rural areas in the United States. My Brother's Keeper, based in Ridgeland, Mississippi, will provide technical assistance and capacity building to the organizations funded through this initiative.""}, {""date"": ""2023-03-29"", ""headline"": ""Investors more bullish on Gilead Sciences (NASDAQ:GILD) this week as stock climbs 4.1%, despite earnings trending downwards over past year"", ""summary"": ""The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you...""}, {""date"": ""2023-03-30"", ""headline"": ""Gilead Sciences Inc. stock rises Thursday, still underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.20% higher to $81.45 Thursday, on what proved to be an all-around favorable trading session for the stock market,...""}, {""date"": ""2023-03-30"", ""headline"": ""Texas judge blocks Obamacare for free HIV drugs, cancer screenings"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-30"", ""headline"": ""Gilead Sciences: Don't Be Scared Post Run-Up"", ""summary"": ""There's no denying that Gilead has made poor acquisition choices. However, the cost is gone and the GILD cash flow should come. Click for more on GILD stock.""}, {""date"": ""2023-03-30"", ""headline"": ""Texas judge blocks Obamacare for HIV drugs, cancer screenings"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-30"", ""headline"": ""Gilead Sciences: Don`t Be Scared Post Run-Up"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-30"", ""headline"": ""Arcellx price target raised to $39 from $35 at SVB Securities"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-31"", ""headline"": ""Gilead Sciences Inc. stock rises Friday, outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. rallied 1.87% to $82.97 Friday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-03-31"", ""headline"": ""My Top 10 High Dividend Yield Stocks To Invest In April 2023"", ""summary"": ""In today\u00e2\u0080\u0099s article, I will present you with my top 10 high Dividend Yield stocks to invest in for April 2023. Read more here.""}, {""date"": ""2023-04-02"", ""headline"": ""Is Gilead Sciences, Inc.'s (NASDAQ:GILD) 22% ROE Strong Compared To Its Industry?"", ""summary"": ""One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...""}]","{""assetTurnoverTTM"": 0.4319, ""bookValue"": 20997, ""cashRatio"": 0.4688449848024316, ""currentRatio"": 1.2781, ""ebitPerShare"": 1.3521, ""eps"": 0.801, ""ev"": 123849.56, ""fcfMargin"": 0.2572, ""fcfPerShareTTM"": 6.7188, ""grossMargin"": 0.7794, ""inventoryTurnoverTTM"": 3.6848, ""longtermDebtTotalAsset"": 0.371, ""longtermDebtTotalCapital"": 0.4965, ""longtermDebtTotalEquity"": 1.0933, ""netDebtToTotalCapital"": 0.4391, ""netDebtToTotalEquity"": 0.9669, ""netMargin"": 0.159, ""operatingMargin"": 0.2684, ""payoutRatioTTM"": 0.6686, ""pb"": 4.9315, ""peTTM"": 18.5468, ""pfcfTTM"": 12.349, ""pretaxMargin"": 0.2047, ""psTTM"": 3.829, ""quickRatio"": 0.9531, ""receivablesTurnoverTTM"": 6.8041, ""roaTTM"": 0.0892, ""roeTTM"": 0.2673, ""roicTTM"": 0.1204, ""rotcTTM"": 0.1906, ""salesPerShare"": 5.0373, ""sgaToSale"": 0.2206, ""totalDebtToEquity"": 1.202, ""totalDebtToTotalAsset"": 0.4079, ""totalDebtToTotalCapital"": 0.5459, ""totalRatio"": 1.5136, ""period"": ""2023-03-31""}"
12,2023-04-02,80.64501953125,2023-04-09,81.0338134765625,0.004821053396382835,U1,"[{""date"": ""2023-04-02"", ""headline"": ""Is Gilead Sciences, Inc.'s (NASDAQ:GILD) 22% ROE Strong Compared To Its Industry?"", ""summary"": ""One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...""}, {""date"": ""2023-04-03"", ""headline"": ""Gilead Sciences (GILD) Gains But Lags Market: What You Should Know"", ""summary"": ""In the latest trading session, Gilead Sciences (GILD) closed at $83.24, marking a +0.33% move from the previous day.""}, {""date"": ""2023-04-03"", ""headline"": ""Gilead Sciences Inc. stock rises Monday, still underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.33% higher to $83.24 Monday, on what proved to be an all-around great trading session for the stock market, with the...""}, {""date"": ""2023-04-03"", ""headline"": ""Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-03"", ""headline"": ""CMS shortens list of drugs subject to new Medicare rebates in 2025"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-04"", ""headline"": ""U.S. Wide-Moat Stocks On Sale - The April 2023 Heat Map"", ""summary"": ""We believe that the most widely used valuation multiples are terribly flawed. Click here for a complete analysis.""}, {""date"": ""2023-04-04"", ""headline"": ""Gilead details promising early COVID antiviral data, setting up larger studies"", ""summary"": ""Gilead Sciences Inc on Tuesday unveiled data from the first human study of its experimental oral COVID-19 antiviral, saying the results in healthy volunteers cleared the way for two large Phase III trials of the drug that have begun enrolling patients.  The drug, obeldesivir and previously known as GS-5245, is designed to keep the coronavirus that causes COVID from replicating in the body and overwhelming a patient's immune system.  Once metabolized, it works in the same way as Gilead's older intravenous COVID treatment Veklury (remdesivir), which targets virus replication through inhibition of the viral RNA polymerase.""}, {""date"": ""2023-04-04"", ""headline"": ""Gilead Sciences Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. shed 1.35% to $82.12 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-04-05"", ""headline"": ""WHO chief expects COVID emergency to end this year"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-05"", ""headline"": ""Gilead Sciences Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. advanced 1.86% to $83.65 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the...""}, {""date"": ""2023-04-05"", ""headline"": ""Gilead Sciences: Overcoming COVID-19 in Early 2020: Keith\u2019s Story"", ""summary"": ""Early in 2020, Keith Prowell was making the most of his retirement in New York and staying active with swimming and tai chi.""}, {""date"": ""2023-04-05"", ""headline"": ""InflaRx upgraded to Buy at Guggenheim after Gohibic gets COVID EUA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-05"", ""headline"": ""Gilead said to be in late-stage trials for oral COVID therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-05"", ""headline"": ""Gilead Sciences: Overcoming COVID-19 in Early 2020: Keith`s Story"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-05"", ""headline"": ""GILD - Chart Of The Week"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-06"", ""headline"": ""Gilead Sciences Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. slumped 0.33% to $83.37 Thursday, on what proved to be an all-around positive trading session for the stock market, with the...""}, {""date"": ""2023-04-06"", ""headline"": ""6 Reasons to Buy Gilead Sciences Stock"", ""summary"": ""Gilead Sciences\u00a0(NASDAQ: GILD) is a top healthcare company with a market capitalization north of $100 billion.  Whether you're a dividend investor or interested in growth, this is the type of investment that has something for everyone, and that can be a good fit for any portfolio.  What I like a lot about Gilead is that the company has a strong, sound HIV business at its core.""}, {""date"": ""2023-04-06"", ""headline"": ""FDA forces pre-term birth drug off the market after 12 years"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-07"", ""headline"": ""Magic Formula Dividend Portfolio For April"", ""summary"": ""The following is a dividend portfolio strategy for large caps that score the highest amongst Joel Greenblatt's Magic Formula screener. Read more about the list here.""}, {""date"": ""2023-04-07"", ""headline"": ""RBC Capital Sticks to Its Hold Rating for Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-09"", ""headline"": ""Is Gilead Sciences, Inc. (NASDAQ:GILD) Trading At A 49% Discount?"", ""summary"": ""Key Insights Gilead Sciences' estimated fair value is US$163 based on 2 Stage Free Cash Flow to Equity Gilead Sciences...""}, {""date"": ""2023-04-09"", ""headline"": ""3 Dividend Stocks Billionaires Seem to Love"", ""summary"": ""There is no shortage of corporations that pay dividends, but they aren't all created equal.  Let's look at three dividend stocks that got the investing attention of some billionaires: Gilead Sciences (NASDAQ: GILD), Microsoft (NASDAQ: MSFT), and Apple (NASDAQ: AAPL).  Gilead Sciences is a leading biotech company with a particular focus on the HIV drug market.""}]","{""assetTurnoverTTM"": 0.4319, ""bookValue"": 20997, ""cashRatio"": 0.4688449848024316, ""currentRatio"": 1.2781, ""ebitPerShare"": 1.3521, ""eps"": 0.801, ""ev"": 123849.56, ""fcfMargin"": 0.2572, ""fcfPerShareTTM"": 6.7188, ""grossMargin"": 0.7794, ""inventoryTurnoverTTM"": 3.6848, ""longtermDebtTotalAsset"": 0.371, ""longtermDebtTotalCapital"": 0.4965, ""longtermDebtTotalEquity"": 1.0933, ""netDebtToTotalCapital"": 0.4391, ""netDebtToTotalEquity"": 0.9669, ""netMargin"": 0.159, ""operatingMargin"": 0.2684, ""payoutRatioTTM"": 0.6686, ""pb"": 4.9315, ""peTTM"": 18.5468, ""pfcfTTM"": 12.349, ""pretaxMargin"": 0.2047, ""psTTM"": 3.829, ""quickRatio"": 0.9531, ""receivablesTurnoverTTM"": 6.8041, ""roaTTM"": 0.0892, ""roeTTM"": 0.2673, ""roicTTM"": 0.1204, ""rotcTTM"": 0.1906, ""salesPerShare"": 5.0373, ""sgaToSale"": 0.2206, ""totalDebtToEquity"": 1.202, ""totalDebtToTotalAsset"": 0.4079, ""totalDebtToTotalCapital"": 0.5459, ""totalRatio"": 1.5136, ""period"": ""2023-03-31""}"
13,2023-04-09,81.0338134765625,2023-04-16,80.6741714477539,-0.004438172330524903,D1,"[{""date"": ""2023-04-09"", ""headline"": ""Is Gilead Sciences, Inc. (NASDAQ:GILD) Trading At A 49% Discount?"", ""summary"": ""Key Insights Gilead Sciences' estimated fair value is US$163 based on 2 Stage Free Cash Flow to Equity Gilead Sciences...""}, {""date"": ""2023-04-09"", ""headline"": ""3 Dividend Stocks Billionaires Seem to Love"", ""summary"": ""There is no shortage of corporations that pay dividends, but they aren't all created equal.  Let's look at three dividend stocks that got the investing attention of some billionaires: Gilead Sciences (NASDAQ: GILD), Microsoft (NASDAQ: MSFT), and Apple (NASDAQ: AAPL).  Gilead Sciences is a leading biotech company with a particular focus on the HIV drug market.""}, {""date"": ""2023-04-10"", ""headline"": ""Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-10"", ""headline"": ""Gilead Sciences: Patience"", ""summary"": ""Gilead Sciences ended 2022 on a solid note. The 2023 guidance (ex-Covid-19 contribution), though, feels a touch light. Click here for my take on GILD stock.""}, {""date"": ""2023-04-10"", ""headline"": ""Gilead Sciences Inc. stock falls Monday, underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. slipped 0.92% to $82.60 Monday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-04-10"", ""headline"": ""If You Invested $10,000 in Gilead Sciences in 2013, This Is How Much You Would Have Today"", ""summary"": ""Gilead Sciences\u00a0(NASDAQ: GILD) is a top HIV treatment company that has a bright future ahead.  In 2022, Gilead's top line was flat as a drop in COVID-related sales offset gains the company achieved in other areas of its business.  In 2017, for instance, Gilead's revenue declined by 14% to $26.1 billion as the company saw double-digit declines in revenue for multiple products.""}, {""date"": ""2023-04-10"", ""headline"": ""GSK Vs. Bristol-Myers Squibb: Who's More Underrated By Mr. Market"", ""summary"": ""GSK's dividend yield is 3.58%, slightly higher than Bristol-Myers Squibb's 3.22%. BMY's EBITDA margin was 43.7% for 2022, 11.4% more than GSK. Read more here.""}, {""date"": ""2023-04-10"", ""headline"": ""GSK Vs. Bristol-Myers Squibb: Who`s More Underrated By Mr. Market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-11"", ""headline"": ""Why Healthcare Stocks Are A Prescription For Investors In Q2 2023"", ""summary"": ""The recent drop in biopharma stocks presents a buying opportunity for investors. Find out why XLV seems like the best fit.""}, {""date"": ""2023-04-11"", ""headline"": ""DivHut Portfolio Update: March 2023"", ""summary"": ""The system is clearly broken, and has been for a while; however, I could find comfort in one thing, my dividends. Four figures in a month is a win in my book.""}, {""date"": ""2023-04-11"", ""headline"": ""12 Best Covid Treatment Stocks to Buy Today"", ""summary"": ""In this piece, we will take a look at the 12 best covid treatment stocks to buy today. For more stocks, head on over to 5 Best Covid Treatment Stocks to Buy Today. If there\u2019s one thing that can be said for sure, it\u2019s that the coronavirus pandemic has changed the world. The deadly disease, [\u2026]""}, {""date"": ""2023-04-12"", ""headline"": ""Morgan Stanley Maintains Gilead Sciences (GILD) Equal-Weight Recommendation"", ""summary"": """"}, {""date"": ""2023-04-12"", ""headline"": ""Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know"", ""summary"": ""Gilead Sciences (GILD) closed at $82.16 in the latest trading session, marking a -0.46% move from the prior day.""}, {""date"": ""2023-04-12"", ""headline"": ""Gilead Sciences Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. shed 0.46% to $82.16 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-04-12"", ""headline"": ""Gilead Sciences: 4 Questions: Global Experts Convene To Identify Key Measures to Long-Term Success in HIV"", ""summary"": ""NORTHAMPTON, MA / ACCESSWIRE / April 12, 2023 / Gilead Sciences: Originally published by Gilead Sciences Dr. Jeffrey Lazarus was studying at New York University in the late 1980s when he saw first-hand the devastation of the HIV epidemic. ...""}, {""date"": ""2023-04-12"", ""headline"": ""My Dividend Stock Portfolio: New All-Time Dividend Record - 99 Holdings With 25 Buys"", ""summary"": ""My dividend income in March amounted to a record $950. This represents growth of 61% Y/Y and 40% sequentially. Click here for a detailed analysis.""}, {""date"": ""2023-04-12"", ""headline"": ""Could Gilead Sciences Stock Help You Become a Millionaire?"", ""summary"": ""Gilead Sciences (NASDAQ: GILD) stock has been a standout among biotech companies over the past year, with its shares up more than 36%.  Fourth-quarter sales rose 2% year over year to $7.4 billion, led by increased sales of oncology, HIV, and hepatitis C virus therapies.  This year, Gilead expects revenue to slide to between $26 billion and $26.5 billion, with Veklury sales hard to gauge.""}, {""date"": ""2023-04-12"", ""headline"": ""Gilead Sciences Now Barely A Hold, Market Looks Uninspired (Rating Downgrade)"", ""summary"": ""Gilead Sciences has lagged the broad market since previous coverage. Guidance is lackluster. Despite that GILD is a hold now, explore more here.""}, {""date"": ""2023-04-12"", ""headline"": ""Gilead price target raised to $85 from $81 at Morgan Stanley"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-12"", ""headline"": ""Dividend Income Update March 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-13"", ""headline"": ""Gilead Sciences Inc. stock falls Friday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-13"", ""headline"": ""Gilead Sciences to Release First Quarter 2023 Financial Results on Thursday, April 27, 2023"", ""summary"": ""FOSTER CITY, Calif., April 13, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2023 financial results will be released on Thursday, April 27, 2023 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead\u2019s management will host a webcast to discuss the company\u2019s first quarter 2023 financial results and provide a business update.""}, {""date"": ""2023-04-13"", ""headline"": ""Gilead Sciences Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. rallied 1.35% to $83.27 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-04-13"", ""headline"": ""Gilead Sciences, Inc. (NASDAQ:GILD) is a favorite amongst institutional investors who own 84%"", ""summary"": ""Key Insights Institutions' substantial holdings in Gilead Sciences implies that they have significant influence over...""}, {""date"": ""2023-04-14"", ""headline"": ""Nurix Therapeutics Shares Rise 21% on 1Q Performance"", ""summary"": ""By Denny Jacob Nurix Therapeutics Inc. shares rose 21% to $12.21 after narrowing its loss and posting higher revenue in the latest quarter. The clinical...""}, {""date"": ""2023-04-15"", ""headline"": ""3 Dividend Stocks to Buy and Hold for the Next Decade"", ""summary"": ""The best ones even pay you to hold them for years via generous dividends.  Three Motley Fool contributors identified their picks for dividend stocks to buy and hold for the next decade.  Here's why they chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ).""}, {""date"": ""2023-04-16"", ""headline"": ""Veklury\u00ae (Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations"", ""summary"": ""FOSTER CITY, Calif., April 16, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive results from several COVID-19 clinical and real-world evidence studies being presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). A Phase 3 clinical study demonstrated that Veklury\u00ae (remdesivir) was generally well tolerated in people with moderate to severe renal impairment. Additional data includes a retrospective real-world study which demonstrated that""}, {""date"": ""2023-04-16"", ""headline"": ""Gilead announces results from several COVID-19 clinical, real-world studies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]","{""assetTurnoverTTM"": 0.4319, ""bookValue"": 20997, ""cashRatio"": 0.4688449848024316, ""currentRatio"": 1.2781, ""ebitPerShare"": 1.3521, ""eps"": 0.801, ""ev"": 123849.56, ""fcfMargin"": 0.2572, ""fcfPerShareTTM"": 6.7188, ""grossMargin"": 0.7794, ""inventoryTurnoverTTM"": 3.6848, ""longtermDebtTotalAsset"": 0.371, ""longtermDebtTotalCapital"": 0.4965, ""longtermDebtTotalEquity"": 1.0933, ""netDebtToTotalCapital"": 0.4391, ""netDebtToTotalEquity"": 0.9669, ""netMargin"": 0.159, ""operatingMargin"": 0.2684, ""payoutRatioTTM"": 0.6686, ""pb"": 4.9315, ""peTTM"": 18.5468, ""pfcfTTM"": 12.349, ""pretaxMargin"": 0.2047, ""psTTM"": 3.829, ""quickRatio"": 0.9531, ""receivablesTurnoverTTM"": 6.8041, ""roaTTM"": 0.0892, ""roeTTM"": 0.2673, ""roicTTM"": 0.1204, ""rotcTTM"": 0.1906, ""salesPerShare"": 5.0373, ""sgaToSale"": 0.2206, ""totalDebtToEquity"": 1.202, ""totalDebtToTotalAsset"": 0.4079, ""totalDebtToTotalCapital"": 0.5459, ""totalRatio"": 1.5136, ""period"": ""2023-03-31""}"
14,2023-04-16,80.6741714477539,2023-04-23,84.14413452148438,0.043012069556582766,U5,"[{""date"": ""2023-04-16"", ""headline"": ""Veklury\u00ae (Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations"", ""summary"": ""FOSTER CITY, Calif., April 16, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive results from several COVID-19 clinical and real-world evidence studies being presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). A Phase 3 clinical study demonstrated that Veklury\u00ae (remdesivir) was generally well tolerated in people with moderate to severe renal impairment. Additional data includes a retrospective real-world study which demonstrated that""}, {""date"": ""2023-04-16"", ""headline"": ""Gilead announces results from several COVID-19 clinical, real-world studies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""Gilead Sciences Inc. stock rises Tuesday, outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""Johnson & Johnson: 4 Key Areas Of Focus Ahead Of Q1 Earnings"", ""summary"": """"}, {""date"": ""2023-04-18"", ""headline"": ""Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know"", ""summary"": ""In the latest trading session, Gilead Sciences (GILD) closed at $83.78, marking a +0.18% move from the previous day.""}, {""date"": ""2023-04-18"", ""headline"": ""Hookipa Pharma: A Speculative Biotech Worthy Of A Spot On My Watch List"", ""summary"": """"}, {""date"": ""2023-04-18"", ""headline"": ""Jounce Acquisition: Exploring Whether It Is Worth It To Pay Up For CVR Value"", ""summary"": """"}, {""date"": ""2023-04-18"", ""headline"": ""Gilead Sciences (NASDAQ:GILD) Has A Pretty Healthy Balance Sheet"", ""summary"": ""Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...""}, {""date"": ""2023-04-18"", ""headline"": ""COWZ ETF: A Cash Cow for Your Portfolio"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-19"", ""headline"": ""Strong Quant Screens Say These 7 Growth Stocks Are a Buy"", ""summary"": ""Strong quantitative screens will show investors a variety of growth stocks to buy. For example, StockRover is a screening service that scores stocks on three key metrics. One, growth scores are based on five year historical growth, compared to forward EBITDA estimates. Two, quality scores depend on profitability and a healthy balance sheet. Three, value scores are based on the usual price-to-earnings multiple and earnings per share predictability. Quant scores offer investors a numerical charact""}, {""date"": ""2023-04-19"", ""headline"": ""Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors despite daily gains"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.39% higher to $84.11 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with...""}, {""date"": ""2023-04-19"", ""headline"": ""Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?"", ""summary"": ""Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.""}, {""date"": ""2023-04-19"", ""headline"": ""Gilead Sciences: Breaking Down Barriers To Access in HIV and Beyond: A Perspective"", ""summary"": ""NORTHAMPTON, MA / ACCESSWIRE / April 19, 2023 / Gilead Sciences When I came to Gilead in 2019, I did so in part because of the revolutionary way this company thinks about bringing therapies to those who could benefit. Health equity and access ...""}, {""date"": ""2023-04-20"", ""headline"": ""Gilead Sciences Now #76 Largest Company, Surpassing Elevance Health"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-20"", ""headline"": ""Notable Friday Option Activity: GILD, SAVA, SONO"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-20"", ""headline"": ""Gilead Sciences Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.69% higher to $84.69 Thursday, on what proved to be an all-around dismal trading session for the stock market, with...""}, {""date"": ""2023-04-20"", ""headline"": ""Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release"", ""summary"": ""Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.""}, {""date"": ""2023-04-20"", ""headline"": ""Get Income On Gilead Stock, Or Buy It At A Discount With This Option Trade"", ""summary"": ""Gilead Sciences is showing high volatility due to the upcoming earnings announcement next Thursday.  The goal is to either have the put expire worthless and keep the premium, or to be assigned and acquire the stock below the current price.  It's important that anyone selling puts understands that they may be assigned 100 shares at the strike price, if the stock is below the strike price at expiration.""}, {""date"": ""2023-04-20"", ""headline"": ""Final Trades: Gilead, Vertex, Wynn & more"", ""summary"": ""The \""Halftime Report\"" traders give their top picks to watch for the second half.""}, {""date"": ""2023-04-21"", ""headline"": ""Unusual Call Option Trade in Gilead Sciences (GILD)  Worth $140.52K"", ""summary"": """"}, {""date"": ""2023-04-21"", ""headline"": ""Gilead Sciences Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. rallied 2.22% to $86.57 Friday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-04-21"", ""headline"": ""Will HIV and Oncology Propel Gilead's (GILD) Q1 Earnings?"", ""summary"": ""Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its first-quarter 2023 results.""}, {""date"": ""2023-04-21"", ""headline"": ""12 Best Pharma Dividend Stocks To Buy in 2023"", ""summary"": ""In this article, we discuss 12 best pharma dividend stocks to buy in 2023. You can skip our detailed analysis of the pharmaceutical sector and its outlook this year, and go directly to read 5 Best Pharma Dividend Stocks To Buy in 2023. The pharmaceutical industry in the US is one of the largest in [\u2026]""}, {""date"": ""2023-04-21"", ""headline"": ""Earnings Week Ahead: Amazon, Meta Platforms, Alphabet, Coca-Cola, Boeing, and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-21"", ""headline"": ""OmniAb a new buy at Benchmark on technology to develop monoclonal antibodies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
15,2023-04-23,84.14413452148438,2023-04-30,79.90630340576172,-0.05036395156742168,D5+,"[{""date"": ""2023-04-24"", ""headline"": ""COWG ETF: Investing in Stocks with High Free Cash Flow Margins"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-24"", ""headline"": ""Gilead Sciences Releases Inaugural ESG Impact Report"", ""summary"": ""Gilead Sciences recently released its inaugural Environmental, Social and Governance (ESG) Impact Report.""}, {""date"": ""2023-04-24"", ""headline"": ""Gilead Sciences Inc. stock underperforms Monday when compared to competitors despite daily gains"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.15% higher to $86.70 Monday, on what proved to be an all-around great trading session for the stock market, with the...""}, {""date"": ""2023-04-24"", ""headline"": ""SDOG: ETF With A Simple And Sensible Strategy, But Average Result"", ""summary"": """"}, {""date"": ""2023-04-24"", ""headline"": ""Second Quarter Outlook For Biotech Stocks"", ""summary"": """"}, {""date"": ""2023-04-25"", ""headline"": ""RBC Capital Reiterates Gilead Sciences (GILD) Sector Perform Recommendation"", ""summary"": """"}, {""date"": ""2023-04-25"", ""headline"": ""3 Biotech Stocks To Watch Today"", ""summary"": ""Biotech stocks for your late-April 2023 watchlist.""}, {""date"": ""2023-04-25"", ""headline"": ""Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. shed 1.28% to $85.59 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-04-25"", ""headline"": ""Incyte (INCY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release"", ""summary"": ""Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.""}, {""date"": ""2023-04-25"", ""headline"": ""3 Cash-Rich Biotech Stocks to Bet on for the Long Haul"", ""summary"": ""The Federal Reserve\u2019s recent interest rate hikes mean banks charge much higher interest rates for loans. The interest on loans can be considered the price of borrowing more money. And since acquiring cash now costs more money, it\u2019s becoming much more complicated for companies to invest. For biotech stocks, the pain is clearly borne by investors, who choose to dive into these capital-intensive businesses. For a cash-strapped company, the rising cost of money can be a death sentence. But cash-rich""}, {""date"": ""2023-04-25"", ""headline"": ""Robert W. Baird Reaffirms Their Hold Rating on Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-25"", ""headline"": ""2 Excellent Dividend Stocks to Buy for Less Than $100"", ""summary"": ""With that in mind, let's look at two dividend-paying companies whose shares are trading for less than $100 right now: Gilead Sciences (NASDAQ: GILD) and Pfizer (NYSE: PFE).  The past three years have been an up-and-down battle for Gilead Sciences.  Filgotinib was supposed to be Gilead Sciences' next blockbuster, so this was a blow for the company.""}, {""date"": ""2023-04-25"", ""headline"": ""Analysts Conflicted on These Healthcare Names: Gilead Sciences (GILD), Legend Biotech (LEGN) and GE Healthcare Technologies Inc (GEHC)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-25"", ""headline"": ""Gilead Sciences Q1 2023 Earnings Preview - Keeping The Faith"", ""summary"": ""Gilead's Q1 2023 earnings will be announced on Thursday, April 27th. Check out my long-term and post earnings price targets for GILD stock.""}, {""date"": ""2023-04-26"", ""headline"": ""Gilead Sciences (GILD) Gets a Buy from Mizuho Securities"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""Gilead slips after cutting 2023 earnings guidance"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""Gilead Sciences beats revenue estimates but misses profit consensus"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""Gilead backs FY23 adjusted EPS view $6.60-$7.00, consensus $6.84"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""Gilead reports Q1 Biktarvy sales up 24% y/y"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""Gilead Sciences reports Q1 adjusted EPS $1.37, consensus $1.54"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""Gilead options imply 3.8% move in share price post-earnings"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""Notable companies reporting after market close"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""GLOBAL BRIEFING: Samsung posts weakest profit in 14 years in Q1"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. slipped 2.16% to $83.74 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P...""}, {""date"": ""2023-04-26"", ""headline"": ""Drug/Biotech Stocks' Q1 Earnings Due Apr 27: LLY, ABBV & More"", ""summary"": ""Let's look at the five biotech/pharma companies slated to release quarterly results on Apr 27.""}, {""date"": ""2023-04-26"", ""headline"": ""Gilead set to continue revenue beat streak with Q1 results"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""EU publishes proposed reforms for pharma industry"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-27"", ""headline"": ""Analysts Conflicted on These Healthcare Names: Edwards Lifesciences (EW), Gilead Sciences (GILD) and Revance Therapeutics (RVNC)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-27"", ""headline"": ""Gilead Sciences (GILD) Q1 Earnings and Revenues Lag Estimates"", ""summary"": ""Gilead (GILD) delivered earnings and revenue surprises of -15.95% and 0.52%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?""}, {""date"": ""2023-04-27"", ""headline"": ""Gilead Sciences, Inc. (GILD) Q1 2023 Earnings Call Transcript"", ""summary"": ""Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Q1 2023 Earnings Conference Call April 27, 2023 4:30 AM ETCompany ParticipantsJacquie Ross - VP, IRDaniel O'Day - Chairman and CEOJohanna Mercier...""}, {""date"": ""2023-04-27"", ""headline"": ""Gilead Stock Dives As Light Profit Hamstrings Strong Cancer Drug Sales"", ""summary"": ""Biotech giants Gilead Sciences and Amgen posted mixed quarters on Thursday \u2014 leading GILD stock and Amgen stock to topple.""}, {""date"": ""2023-04-27"", ""headline"": ""Gilead profit misses Wall Street expectations as COVID drug sales decline"", ""summary"": ""Gilead Sciences Inc on Thursday reported a lower-than-expected first-quarter profit as sales from COVID-19 antiviral Veklury declined more than anticipated, and its shares fell more than 2%.""}, {""date"": ""2023-04-27"", ""headline"": ""UPDATE 1-Gilead profit misses Wall Street expectations as COVID drug sales decline"", ""summary"": ""Gilead Sciences Inc on Thursday reported a lower-than-expected first-quarter profit as sales from COVID-19 antiviral Veklury declined more than anticipated, and its shares fell more than 2%.""}, {""date"": ""2023-04-27"", ""headline"": ""Gilead Sciences Announces First Quarter 2023 Financial Results"", ""summary"": ""FOSTER CITY, Calif., April 27, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter of 2023.""}, {""date"": ""2023-04-27"", ""headline"": ""Stocks making the biggest moves after hours: Amazon, Intel, Snap, Pinterest and more"", ""summary"": ""These are the stocks posting the largest moves in extended trading.""}, {""date"": ""2023-04-27"", ""headline"": ""Gilead reduces earnings guidance as first quarter sales fall 2%"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-27"", ""headline"": ""Gilead Sciences, Inc. 2023 Q1 - Results - Earnings Call Presentation"", ""summary"": ""The following slide deck was published by Gilead Sciences, Inc.""}, {""date"": ""2023-04-27"", ""headline"": ""Gilead: Q1 Earnings Snapshot"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-27"", ""headline"": ""Gilead shares fall after mixed results, as weaker COVID-19 drug remand weighs"", ""summary"": ""Gilead Sciences Inc. on Thursday cut one of its profit forecasts and reported first-quarter profit that missed expectations.""}, {""date"": ""2023-04-27"", ""headline"": ""Gilead Sciences 1Q Adjusted Earnings Decline on Lower Revenue, Higher Expenses"", ""summary"": ""By Bob Henderson Gilead Sciences Inc. on Thursday reported a first-quarter adjusted earnings decline of 65% that it attributed to lower revenue and higher...""}, {""date"": ""2023-04-27"", ""headline"": ""Gilead Earnings Fall Short, Stock Tumbles"", ""summary"": ""Aales of its cancer and HIV drugs rose, while sales of its Covid-19 antiviral fell.""}, {""date"": ""2023-04-27"", ""headline"": ""Merck Q1 Earnings: Delivering Strong Results"", ""summary"": ""Merck reported Q1 results and beat estimates on both lines. Read why I believe that MRK is a good long-term holding, but not a great buy any longer.""}, {""date"": ""2023-04-27"", ""headline"": ""Better Buy: Pfizer vs. Gilead"", ""summary"": ""Two great examples are Pfizer (NYSE: PFE) and Gilead Sciences (NASDAQ: GILD).  Pfizer is facing two challenges right now.  First, demand for its coronavirus vaccine and treatment is falling as we move toward a post-pandemic situation.""}, {""date"": ""2023-04-28"", ""headline"": ""RBC Capital Maintains Gilead Sciences (GILD) Sector Perform Recommendation"", ""summary"": """"}, {""date"": ""2023-04-28"", ""headline"": ""Gilead Sciences (GILD) Q1 2023 Earnings Call Transcript"", ""summary"": ""Jacquie, please go ahead.  The speakers on today's call will be our chairman and chief executive officer, Daniel O'Day; our chief commercial officer, Johanna Mercier; our chief medical officer, Merdad Parsey; and our chief financial officer, Andrew Dickinson.""}, {""date"": ""2023-04-28"", ""headline"": ""Gilead's (GILD) Q1 Earnings Miss, Veklury Sales Plunge"", ""summary"": ""Gilead's (GILD) Q1 earnings and sales miss estimates due to lower Veklury sales.""}, {""date"": ""2023-04-28"", ""headline"": ""Gilead Sciences Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. slipped 1.60% to $82.21 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""2023-04-28"", ""headline"": ""Why Gilead Sciences Stock Is Falling Today"", ""summary"": ""Gilead Sciences Inc (NASDAQ: GILD) reported Q1 FY23 sales decreased 4% Y/Y to $6.35 billion, slightly above the consensus of $6.33 billion, due to lower Veklury (remdesivir) sales, partially offset by increased sales in HIV and Oncology. \""Biktarvy outperformed once again, and Oncology revenue increased 59% year-over-year, driven by Trodelvy and Cell Therapy,\"" said Daniel O'Day, Gilead's Chairman & CEO. Product sales decreased by 3% to $6.3 billion; excluding Veklury, product sales increased 15%""}, {""date"": ""2023-04-28"", ""headline"": ""Gilead`s hepatitis B therapy Vemlidy gets EMA nod for use in kids above 6"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-28"", ""headline"": ""Video: Nasdaq 100 Movers: GILD, INTC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-28"", ""headline"": ""Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-28"", ""headline"": ""Jefferies Sticks to Their Buy Rating for Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-28"", ""headline"": ""Gilead assumed with an Overweight at Piper Sandler"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-28"", ""headline"": ""Analysts` Opinions Are Mixed on These Healthcare Stocks: Gilead Sciences (GILD), Encompass Health (EHC) and PROCEPT BioRobotics (PRCT)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-29"", ""headline"": ""27 Largest Biotech Companies in the US"", ""summary"": ""In this article, we take a look at 27 largest biotech companies in the US. You can skip our detailed analysis of the biotech industry and go directly to the 5 Largest Biotech Companies in the US. The largest biotech companies in the US have a total market cap of $88 trillion. Latest Developments in [\u2026]""}, {""date"": ""2023-04-29"", ""headline"": ""Gilead Sciences (NASDAQ:GILD) sheds 5.0% this week, as yearly returns fall more in line with earnings growth"", ""summary"": ""If you want to compound wealth in the stock market, you can do so by buying an index fund. But you can significantly...""}]",{}
16,2023-04-30,79.90630340576172,2023-05-07,77.51525115966797,-0.029923199349518925,D3,"[{""date"": ""2023-04-29"", ""headline"": ""27 Largest Biotech Companies in the US"", ""summary"": ""In this article, we take a look at 27 largest biotech companies in the US. You can skip our detailed analysis of the biotech industry and go directly to the 5 Largest Biotech Companies in the US. The largest biotech companies in the US have a total market cap of $88 trillion. Latest Developments in [\u2026]""}, {""date"": ""2023-04-30"", ""headline"": ""Gilead Sciences (GILD) Declares $0.75 Dividend"", ""summary"": """"}, {""date"": ""2023-05-01"", ""headline"": ""Gilead Sciences to Present at Upcoming Investor Conferences"", ""summary"": ""FOSTER CITY, Calif., May 01, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:""}, {""date"": ""2023-05-01"", ""headline"": ""Morgan Stanley Maintains Gilead Sciences (GILD) Equal-Weight Recommendation"", ""summary"": """"}, {""date"": ""2023-05-01"", ""headline"": ""Gilead Sciences Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. shed 0.96% to $81.42 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-05-01"", ""headline"": ""SVB Securities Remains a Hold on Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-01"", ""headline"": ""Gilead Sciences: A Mixed First Quarter"", ""summary"": ""Gilead Sciences saw strong sales growth in the first quarter. Click here to find out why GILD stock is a Buy.""}, {""date"": ""2023-05-02"", ""headline"": ""You Can Have Dividends and Growth. Here\u2019s How. "", ""summary"": ""Gilead Sciences and Merck offer attractive dividends and the potential for growth in a sluggish economy.""}, {""date"": ""2023-05-02"", ""headline"": ""Gilead call volume above normal and directionally bullish"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-02"", ""headline"": ""GLOBAL BRIEFING: European stocks called up ahead of Fed rate decision"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-02"", ""headline"": ""Gilead vs. CDC: The $1B Showdown Over HIV Drug Profits"", ""summary"": ""Gilead Sciences Inc (NASDAQ: GILD) is reportedly looking to fight claims that it owes the U.S. government a share of over $1 billion in profits from its HIV-treatment drug Truvada that could help prevent the disease. It generated sales of $147 million in 2022 compared to $371 million a year ago. The FDA approved Gilead's Truvada for HIV prevention in 2012 and its related drug Descovy for the same purpose in 2019. Descovy sales came in at 1.87 billion versus $1.7 billion in 2021. The government i""}, {""date"": ""2023-05-02"", ""headline"": ""Gilead Sciences Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. slid 1.20% to $80.44 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-05-02"", ""headline"": ""Gilead Sciences battles U.S. government in court over HIV prevention patent"", ""summary"": ""The U.S. claims Gilead's drugs Truvada and Descovy infringe on CDC patents. ""}, {""date"": ""2023-05-02"", ""headline"": ""Gilead Sciences' (NASDAQ:GILD) Shareholders Will Receive A Bigger Dividend Than Last Year"", ""summary"": ""Gilead Sciences, Inc. ( NASDAQ:GILD ) will increase its dividend from last year's comparable payment on the 29th of...""}, {""date"": ""2023-05-02"", ""headline"": ""Gilead, US square off in billion-dollar HIV drug patent trial"", ""summary"": ""Gilead Sciences Inc is headed to trial in Delaware federal court this week to fight claims that it owes the U.S. government a share of multibillion-dollar profits from its HIV-prevention drug regimen.""}, {""date"": ""2023-05-02"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Lineage Therap (LCTX) and Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-03"", ""headline"": ""WHO meeting is set to decide whether to end COVID emergency"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-03"", ""headline"": ""GILD June 23rd Options Begin Trading"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-03"", ""headline"": ""Gilead Sciences Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Gilead Sciences Inc. slid 1.23% to $79.45 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-05-03"", ""headline"": ""Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts"", ""summary"": ""The recent national conversation on hepatitis C (HCV) is an encouraging step towards viral hepatitis elimination in the U.S. With its long history of leadership in viral hepatitis, Gilead continues to support efforts that focus on HCV elimination. Gilead is proud that its medicines have treated over four million individuals living with HCV globally.""}, {""date"": ""2023-05-03"", ""headline"": ""Gilead Versus AbbVie: The Better Bet After Q1, 2023 Earnings"", ""summary"": """"}, {""date"": ""2023-05-03"", ""headline"": ""Big Pharma Stocks Offer Income and Growth Potential. The Case for Gilead Sciences and Merck."", ""summary"": ""Gilead Sciences and Merck offer attractive dividends and the potential for growth in a sluggish economy.""}, {""date"": ""2023-05-04"", ""headline"": ""Gilead Sciences Inc. stock falls Thursday, underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. shed 1.17% to $78.52 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-05-04"", ""headline"": ""Gilead Sciences Stock Has Only Done This in 1 of the Past 7 Years"", ""summary"": ""Gilead Sciences\u00a0(NASDAQ: GILD) has a bright future ahead with HIV treatment Sunlenca obtaining approval from the Food and Drug Administration last year and cancer drug Trodelvy continuing to show strong growth.  Why has Gilead Sciences stock struggled?  The simple reason for Gilead's woes is that the business has had trouble generating growth.""}, {""date"": ""2023-05-04"", ""headline"": ""CHMP Adopts Positive Opinion Recommending Hepcludex\u00ae (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV)"", ""summary"": ""FOSTER CITY, Calif., May 04, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Hepcludex\u00ae (bulevirtide) for the treatment of adults with chronic HDV and compensated liver disease, and recommended granting full Marketing Authorisation (MA) that is no longer subject to specific obligations. Bulevirtide was initially granted conditional marketing authoris""}, {""date"": ""2023-05-04"", ""headline"": ""Gilead wins EU nod for full approval of hepatitis delta virus therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-05"", ""headline"": ""Gilead Sciences Inc. stock rises Friday, still underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. rose 1.57% to $79.75 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""2023-05-05"", ""headline"": ""Final Trades: Chevron, American Express & Gilead"", ""summary"": ""The \""Halftime Report\"" traders give their top picks to watch for the second half.""}, {""date"": ""2023-05-05"", ""headline"": ""2 Magnificent Dividend Stocks to Buy Before the Next Recession"", ""summary"": ""Let's look at two great dividend stocks to consider buying before the economy worsens: Gilead Sciences (NASDAQ: GILD) and Amgen (NASDAQ: AMGN).  Gilead Sciences is a biotech company with a particular focus on developing HIV medicines.  It has helped Gilead Sciences' revenue stay afloat as the company failed to earn approval for important candidates.""}, {""date"": ""2023-05-05"", ""headline"": ""10 Best Stocks To Buy For A Stock Market Game"", ""summary"": ""In this article, we will be taking a look at the 10 best stocks to buy for a stock market game. To see more of these stocks, you can go directly to see the 5 Best Stocks To Buy For A Stock Market Game. Investing in Penny Stocks In a time when the markets are [\u2026]""}, {""date"": ""2023-05-07"", ""headline"": ""Gilead Sciences, Inc. (NASDAQ:GILD) Delivered A Better ROE Than Its Industry"", ""summary"": ""While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...""}, {""date"": ""2023-05-07"", ""headline"": ""InvestingPro exclusive: 5 biotech beasts to get your hands on"", ""summary"": ""Here is your VIP list of Pro Picks for the week, offered exclusively to InvestingPro subscribers: a hand-picked selection of S&P 500 stocks that InvestingPro awarded a high financial health score of at least 2.75 out of 5.00.""}]",{}
17,2023-05-07,77.51525115966797,2023-05-14,75.9795150756836,-0.01981205067401548,D2,"[{""date"": ""2023-05-07"", ""headline"": ""Gilead Sciences, Inc. (NASDAQ:GILD) Delivered A Better ROE Than Its Industry"", ""summary"": ""While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...""}, {""date"": ""2023-05-07"", ""headline"": ""InvestingPro exclusive: 5 biotech beasts to get your hands on"", ""summary"": ""Here is your VIP list of Pro Picks for the week, offered exclusively to InvestingPro subscribers: a hand-picked selection of S&P 500 stocks that InvestingPro awarded a high financial health score of at least 2.75 out of 5.00.""}, {""date"": ""2023-05-08"", ""headline"": ""Gilead Sciences Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. shed 1.45% to $78.59 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-05-08"", ""headline"": ""You Can Have Dividends and Growth. Here\u2019s How."", ""summary"": ""Gilead Sciences and Merck offer attractive dividends and the potential for growth in a sluggish economy.""}, {""date"": ""2023-05-08"", ""headline"": ""Rates Have Risen. Here Are 5 Stocks With Little Debt"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-09"", ""headline"": ""15 Biggest Immunotherapy Companies in the World"", ""summary"": ""In this article, we will take a look at the 15 biggest immunotherapy companies in the world. If you want to see more companies in this selection, go to the 5 Biggest Immunotherapy Companies in the World. The immunotherapy industry is a rapidly growing field that is focused on developing treatments that harness the power [\u2026]""}, {""date"": ""2023-05-09"", ""headline"": ""Gilead Sciences prevails in US government lawsuit over HIV drug patents"", ""summary"": ""A federal jury on Tuesday found that Gilead Sciences Inc did not infringe U.S. patents with its HIV-prevention regimens using the drugs Truvada and Descovy, handing the government a defeat in its billion-dollar lawsuit.""}, {""date"": ""2023-05-09"", ""headline"": ""UPDATE 1-Gilead Sciences prevails in US government lawsuit over HIV drug patents"", ""summary"": ""A federal jury on Tuesday found that Gilead Sciences Inc did not infringe U.S. patents with its HIV-prevention regimens using the drugs Truvada and Descovy, handing the government a defeat in its billion-dollar lawsuit.  The Delaware jury found the government's patents were invalid and not infringed following a five-day trial and a morning of deliberations.  The federal government had argued that Gilead failed to compensate the U.S. Centers for Disease Control and Prevention (CDC) for discovering that its drug Truvada, which was first approved to treat HIV, could also help prevent infection by the virus.""}, {""date"": ""2023-05-09"", ""headline"": ""Gilead Sciences Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.27% higher to $78.80 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with...""}, {""date"": ""2023-05-09"", ""headline"": ""Gilead Sciences defeats U.S. government lawsuit alleging HIV drug patent violations"", ""summary"": ""The U.S. government had accused Gilead Science of violating patents for drugs used in the HIV prevention regimen PrEP.""}, {""date"": ""2023-05-09"", ""headline"": ""Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera"", ""summary"": ""FOSTER CITY, Calif., May 09, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the acquisition of all outstanding shares of XinThera, a privately held biotech company in San Diego. The acquisition complements Gilead\u2019s existing clinical development priorities by adding additional pipeline assets for well-validated targets in oncology and inflammation.""}, {""date"": ""2023-05-09"", ""headline"": ""Gilead wins jury verdict in patent battle with U.S. govt. over HIV therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-09"", ""headline"": ""Gilead adds to oncology, inflammation portfolio with XinThera acquisition"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-09"", ""headline"": ""Gilead Sciences to Buy Private Biotech XinThera >GILD"", ""summary"": ""By Colin Kellaher Gilead Sciences on Tuesday said it is bolstering its early pipeline in oncology and inflammation through the acquisition of privately held...""}, {""date"": ""2023-05-09"", ""headline"": ""Gilead acquires XinThera, terms undisclosed"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-09"", ""headline"": ""Hookipa Pharma announces first patient dosed in Phase 1a/b trial of HB-400"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-10"", ""headline"": ""Gilead management to meet virtually with Oppenheimer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-10"", ""headline"": ""Gilead Sciences Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. slid 0.88% to $78.11 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P...""}, {""date"": ""2023-05-10"", ""headline"": ""Gilead Emphasizes Unique Ways To Hire Top Talent"", ""summary"": ""When Jamari Brooks was looking for a new job last fall, he knew he wanted his future employer to have a few key qualities.""}, {""date"": ""2023-05-10"", ""headline"": ""First Week of July 21st Options Trading For Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-10"", ""headline"": ""Guild Esports expects revenue growth on strong first half trading"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-10"", ""headline"": ""G1 Therapeutics trilaciclib cuts adverse events linked to Trodelvy in breast cancer patients"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-11"", ""headline"": ""Gilead Sciences Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.76% higher to $78.70 Thursday, on what proved to be an all-around dismal trading session for the stock market, with...""}, {""date"": ""2023-05-11"", ""headline"": ""Here's Why We Think Gilead Sciences (NASDAQ:GILD) Might Deserve Your Attention Today"", ""summary"": ""Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...""}, {""date"": ""2023-05-12"", ""headline"": ""Gilead Sciences Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. shed 0.67% to $78.17 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-05-12"", ""headline"": ""Gilead Sciences Stock: Bear vs. Bull"", ""summary"": ""You may know of Gilead Sciences (NASDAQ: GILD) because of its blockbuster coronavirus treatment Veklury.  In fact, the S&P 500 has outperformed Gilead over the past five years.  Gilead has struggled to consistently deliver annual revenue growth ever since its hepatitis C portfolio's revenue reached a peak back in 2015.""}, {""date"": ""2023-05-13"", ""headline"": ""Gilead Sciences, Inc. (GILD) Presents at BofA Securities 2023 Health Care Conference (Transcript)"", ""summary"": ""Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) BofA Securities 2023 Health Care Conference May 9, 2023 2:20 PM ETCompany ParticipantsAndy Dickinson - CFOConference Call ParticipantsGeoff...""}]",{}
18,2023-05-14,75.9795150756836,2023-05-21,76.64046478271484,0.00869905140053695,U1,"[{""date"": ""2023-05-14"", ""headline"": ""Gilead Sciences Strikes New Deal with Arcus Biosciences"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-15"", ""headline"": ""Gilead upgraded to Outperform from Market Perform at BMO Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-15"", ""headline"": ""Positive Report for Gilead Sciences (GILD) from BMO Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-15"", ""headline"": ""Gilead Sciences Inc. stock rises Monday, still underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.27% higher to $78.38 Monday, on what proved to be an all-around favorable trading session for the stock market, with...""}, {""date"": ""2023-05-15"", ""headline"": ""Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation"", ""summary"": ""FOSTER CITY, Calif., & HAYWARD, Calif., May 15, 2023--Gilead Sciences, Inc. (Nasdaq:GILD) and Arcus Biosciences, Inc. (NYSE:RCUS) today announced that the companies have expanded the previously announced research collaboration focused on oncology to include therapies for the treatment of inflammatory diseases. The expanded collaboration builds upon Gilead\u2019s growing presence in inflammatory disease and serves as a step towards broadening Arcus\u2019 capabilities and portfolio beyond oncology and into""}, {""date"": ""2023-05-15"", ""headline"": ""Gilead expands research with Arcus to include inflammatory disease"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-15"", ""headline"": ""Gilead projects earnings impact after expanding research deal with Arcus"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-15"", ""headline"": ""Arcus Biosciences jumps 2% amid expanded inflammation pact with Gilead"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-15"", ""headline"": ""Gilead: Arcus deal may reduce Gilead`s FY23 GAAP and non-GAAP EPS by 2c"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-15"", ""headline"": ""Expanded Gilead- Arcus pact may result in up to $1B in payments to Arcus"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-15"", ""headline"": ""Arcus to receive upfront payment of $35M from Gilead in expanded research pact"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-16"", ""headline"": ""Gilead Appoints Cindy Perettie Executive Vice President of Kite"", ""summary"": ""FOSTER CITY, Calif., May 16, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Cindy Perettie will join the company as Executive Vice President of Kite, a Gilead Company, overseeing the cell therapy business, and will become a member of Gilead\u2019s senior leadership team, effective May 30.""}, {""date"": ""2023-05-16"", ""headline"": ""Gilead Sciences Inc. stock outperforms market despite losses on the day"", ""summary"": ""Shares of Gilead Sciences Inc. dropped 0.08% to $78.32 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P...""}, {""date"": ""2023-05-16"", ""headline"": ""BMO Capital Upgrades Gilead Sciences (GILD)"", ""summary"": """"}, {""date"": ""2023-05-16"", ""headline"": ""Arcus (RCUS) & Gilead Re-Collaborate for Inflammatory Diseases"", ""summary"": ""Arcus (RCUS) surges as it expands its previous research collaboration with partner Gilead, to focus on developing therapies for inflammatory diseases.""}, {""date"": ""2023-05-16"", ""headline"": ""Gilead Sciences, Inc. (GILD) Presents at RBC Capital Markets Global Healthcare Conference (Transcript)"", ""summary"": ""Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) RBC Capital Markets Global Healthcare Conference May 16, 2023 11:00 AM ETCompany ParticipantsMerdad Parsey - Chief Medical OfficerConference Call...""}, {""date"": ""2023-05-16"", ""headline"": ""What To Expect From GSK In 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-16"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-16"", ""headline"": ""Abortion pill case heads back to federal appeals court: What`s at stake"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-16"", ""headline"": ""GDC Stock Alert: Why Is GD Culture Group Up 106% Today?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-16"", ""headline"": ""Gilead Sciences (NASDAQ:GILD) Is Paying Out A Larger Dividend Than Last Year"", ""summary"": ""The board of Gilead Sciences, Inc. ( NASDAQ:GILD ) has announced that it will be paying its dividend of $0.75 on the...""}, {""date"": ""2023-05-16"", ""headline"": ""Why Is Guardforce AI (GFAI) Stock Up Today?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-16"", ""headline"": ""GILD Stock Price Predictions: Is Gilead Sciences Really Worth $100?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-16"", ""headline"": ""Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-16"", ""headline"": ""Ensoma Closes Series B Extension, Bringing Total Round to $135 Million"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-16"", ""headline"": ""What You Missed On Wall Street On Tuesday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-17"", ""headline"": ""Former Immunomedics CFO pleads guilty to insider trading"", ""summary"": ""The former chief financial officer of a New Jersey biotechnology company pleaded guilty on Wednesday to insider trading, after prosecutors said he had given nonpublic information about a new breast cancer drug to his girlfriend at the time.""}, {""date"": ""2023-05-17"", ""headline"": ""3 Analyst Upgrades That Smart Investors Won\u2019t Ignore"", ""summary"": ""Even the most experienced investors have only so many hours in the day to perform their due diligence. That\u2019s where analyst ratings can be helpful. Analyst upgrades and downgrades frequently move stocks. Analysts spend a great deal of time covering a particular stock or an entire sector. This gives them access to information and company insiders that retail investors don\u2019t have. One of an analyst\u2019s key responsibilities is to issue a rating and/or price target for the stocks that they cover. Many""}, {""date"": ""2023-05-17"", ""headline"": ""Gilead Sciences Inc. stock rises Wednesday, still underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.63% higher to $78.81 Wednesday, on what proved to be an all-around great trading session for the stock market, with...""}, {""date"": ""2023-05-17"", ""headline"": ""3 Analyst Upgrades That Smart Investors Won`t Ignore"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-17"", ""headline"": ""Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023"", ""summary"": ""FOSTER CITY, Calif. & SANTA MONICA, Calif., May 17, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 30 abstracts during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. These data reinforce the strength of Gilead and Kite Oncology\u2019s transformative science in hard-to-treat cancers.""}, {""date"": ""2023-05-17"", ""headline"": ""Gilead taps former Roche exec to lead Kite unit"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-17"", ""headline"": ""GILD Makes Notable Cross Below Critical Moving Average"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-17"", ""headline"": ""Gilead to present advances across its oncology pipeline at ASCO Annual Meeting"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-18"", ""headline"": ""Catalyst watch: Eyes on Ford event, Virgin Galactic launch, Nvidia earnings and Microsoft conference"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-18"", ""headline"": ""5 High Yield Stocks With Steady Dividend Growth And An Attractive Valuation"", ""summary"": ""I consider companies that combine a relatively high Dividend Yield and Dividend Growth Rate to be particularly attractive for dividend income investors. Read more here.""}, {""date"": ""2023-05-18"", ""headline"": ""Gilead Sciences Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. slipped 0.76% to $78.21 Thursday, on what proved to be an all-around positive trading session for the stock market, with the...""}, {""date"": ""2023-05-18"", ""headline"": ""Arcellx a buy at Truist on unique cancer cell therapies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-19"", ""headline"": ""Gilead Sciences Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.81% higher to $78.85 Friday, on what proved to be an all-around dismal trading session for the stock market, with the...""}, {""date"": ""2023-05-20"", ""headline"": ""3 Relatively Safe Stocks to Buy if a Recession Is on the Way"", ""summary"": ""Here's why three Motley Fool contributors think that AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ) are relatively safe stocks to buy if a recession is declared this year.  Prosper Junior Bakiny (AbbVie): It may be hard to believe that AbbVie is a safe stock right now.""}, {""date"": ""2023-05-21"", ""headline"": ""Gilead Sciences, Inc. (NASDAQ:GILD) is favoured by institutional owners who hold 85% of the company"", ""summary"": ""Key Insights Given the large stake in the stock by institutions, Gilead Sciences' stock price might be vulnerable to...""}, {""date"": ""2023-05-21"", ""headline"": ""Billions of dollars at stake as FDA shortcut allows half-proven drugs - report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
19,2023-05-21,76.64046478271484,2023-05-28,74.92977905273438,-0.022320920610678363,D3,"[{""date"": ""2023-05-21"", ""headline"": ""Gilead Sciences, Inc. (NASDAQ:GILD) is favoured by institutional owners who hold 85% of the company"", ""summary"": ""Key Insights Given the large stake in the stock by institutions, Gilead Sciences' stock price might be vulnerable to...""}, {""date"": ""2023-05-21"", ""headline"": ""Billions of dollars at stake as FDA shortcut allows half-proven drugs - report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-22"", ""headline"": ""Gilead Sciences Inc. stock falls Monday, underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. sank 0.29% to $78.62 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-05-22"", ""headline"": ""Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-23"", ""headline"": ""Gilead Sciences Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-23"", ""headline"": ""Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. slid 0.05% to $78.58 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-05-23"", ""headline"": ""My Dividend Stock Portfolio: New April Dividend Record - 99 Holdings With 21 Buys"", ""summary"": ""Markets are racing higher as earnings season turned out much better than expected. Click here to read more.""}, {""date"": ""2023-05-24"", ""headline"": ""Gilead Sciences Inc. stock falls Thursday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-24"", ""headline"": ""Lightning Round: Cloudflare has had a couple bad quarters but should be able to 'get it together'"", ""summary"": ""Mad Money' host Jim Cramer weighs in on stocks including: RB Global, Cloudflare, Bank of Hawaii, Mosaic Co., Gilead Sciences, and Lendingtree.""}, {""date"": ""2023-05-24"", ""headline"": ""Cramer's Lightning Round: Stay away from Gilead Sciences"", ""summary"": ""\""Mad Money\"" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.""}, {""date"": ""2023-05-24"", ""headline"": ""14 Best Healthcare Dividend Stocks to Buy"", ""summary"": ""In this article, we will take a look at 14 best healthcare dividend stocks to buy. You can skip our detailed analysis of the healthcare sector and dividend stocks, and go directly to read 5 Best Healthcare Dividend Stocks to Buy. The healthcare sector in the US encompasses a wide range of providers, facilities, and [\u2026]""}, {""date"": ""2023-05-25"", ""headline"": ""Gilead Sciences to Present at Upcoming Investor Conference"", ""summary"": ""FOSTER CITY, Calif., May 25, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference:""}, {""date"": ""2023-05-25"", ""headline"": ""Gilead Sciences Stock Reaches 80-Plus Relative Strength Rating Benchmark"", ""summary"": ""Gilead Sciences shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.""}, {""date"": ""2023-05-25"", ""headline"": ""How Gilead\u2019s Supportive Culture Helps Working Parents: LJ\u2019s Story"", ""summary"": ""NORTHAMPTON, MA / ACCESSWIRE / May 25, 2023 / Gilead Sciences When LJ Mizzi joined Gilead in 2013, she already had a personal connection to the company. \""A Gilead medicine saved the life of a loved one, so I was excited to begin a career here ...""}, {""date"": ""2023-05-25"", ""headline"": ""Here's Why Gilead Sciences (NASDAQ:GILD) Can Manage Its Debt Responsibly"", ""summary"": ""The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...""}, {""date"": ""2023-05-25"", ""headline"": ""Gilead call volume above normal and directionally bullish"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-25"", ""headline"": ""14 Best Biotech Stocks To Buy According To Hedge Funds"", ""summary"": ""In this piece, we will take a look at 14 best biotechnology stocks to buy according to hedge funds. For more stocks, head on over to 5 Best Biotech Stocks To Buy According To Hedge Funds. Biotechnology is one of the hottest sectors these days. A handful of industries, such as space exploration, artificial intelligence, [\u2026]""}, {""date"": ""2023-05-26"", ""headline"": ""Gilead Sciences Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. shed 0.72% to $77.09 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""2023-05-26"", ""headline"": ""Gilead's Veklury gets positive opinion from EU's CHMP for Covid"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-26"", ""headline"": ""Gilead's (GILD) Veklury Gets Positive CHMP View for Extended Use"", ""summary"": ""Gilead (GILD) obtains positive opinion for the use of Veklury in COVID-19 patients with severe renal impairment, including those on dialysis, from the European Medicines Agency's CHMP.""}, {""date"": ""2023-05-26"", ""headline"": ""10 Health Care Stocks Whale Activity In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-26"", ""headline"": ""Drugmakers Released a Ton of New Cancer Treatment Data. The Biggest Developments."", ""summary"": ""Ahead of the American Society of Clinical Oncology meeting, Pfizer, Merck, and other companies released scientific abstracts of papers that they'll present...""}, {""date"": ""2023-05-26"", ""headline"": ""TD Cowen pharma/biotech analysts hold an analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-26"", ""headline"": ""Gilead's COVID drug Veklury gets EMA greenlight for expanded use"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-26"", ""headline"": ""CHMP Adopts Positive Opinion to Extend the Use of Veklury\u00ae (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis"", ""summary"": ""FOSTER CITY, Calif., May 26, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted a positive opinion for the use of Veklury\u00ae (remdesivir) in COVID-19 patients with severe renal impairment, including those on dialysis. The European Commission (EC) will review the CHMP recommendation and, if adopted, Veklury will become the first and only authorized antiviral COVID-19 treatment that""}, {""date"": ""2023-05-26"", ""headline"": ""Gilead announces CHMP reccomendation for the use of Veklury"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-27"", ""headline"": ""Stocks Going Ex-Dividend In June 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
20,2023-05-28,74.92977905273438,2023-06-04,75.70736694335938,0.010377554831407565,U2,"[{""date"": ""2023-05-28"", ""headline"": ""Drug pricing watchdog raises alarm over upcoming liver disease meds"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-30"", ""headline"": ""Gilead Sciences Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. dropped 0.99% to $76.33 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P...""}, {""date"": ""2023-05-30"", ""headline"": ""Gilead Sciences (NASDAQ:GILD) Is Paying Out A Larger Dividend Than Last Year"", ""summary"": ""Gilead Sciences, Inc.'s ( NASDAQ:GILD ) dividend will be increasing from last year's payment of the same period to...""}, {""date"": ""2023-05-31"", ""headline"": ""2 Large Cap Biotech Stocks To Watch Right Now"", ""summary"": ""Large-cap biotech stocks to check out in the stock market today.""}, {""date"": ""2023-05-31"", ""headline"": ""Gilead: Pharma Play Worth Watching On Multitude Of ASCO Data Readouts"", ""summary"": ""Gilead Sciences, Inc. is expected to offer 30 Abstract Presentations at the ASCO 2023 meeting to be held between June 2 - 6 of 2023. Click here for more on GILD stock.""}, {""date"": ""2023-05-31"", ""headline"": ""Bilal Piperdi on How Gilead Is Striving To Create New Possibilities for People With Lung Cancer"", ""summary"": ""After finishing medical school in the late 1990s, Bilal Piperdi wanted to follow his mentor into the field of thoracic oncology, the specialized area that focuses on lung cancer.""}, {""date"": ""2023-05-31"", ""headline"": ""Gain Therapeutics: Undervalued Based On Drug Development Platform And Lead Parkinson's Asset"", ""summary"": ""Gain Therapeutics is furthering drug development in unique way and SEE-Tx platform may be useful for a larger pharma company. See why I rate GANX a strong buy.""}, {""date"": ""2023-06-01"", ""headline"": ""Cantor Fitzgerald biotech analyst to hold analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-01"", ""headline"": ""Catalyst Watch: Apple's WWDC event, OPEC fallout and REITs on display"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-01"", ""headline"": ""Gilead Sciences Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. slumped 0.95% to $76.21 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-06-01"", ""headline"": ""15 Best Healthcare Stocks To Buy Now"", ""summary"": ""In this article, we will take a look at the 15 best healthcare stocks to buy now. For more stocks, head on over to 5 Best Healthcare Stocks To Buy Now. In the midst of uncertain economic conditions globally, the healthcare sector has displayed a notable degree of resilience. Historically, the demand for healthcare products [\u2026]""}, {""date"": ""2023-06-01"", ""headline"": ""Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA"", ""summary"": ""FOSTER CITY, Calif. & SANTA MONICA, Calif., June 01, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 17 abstracts from its industry-leading cell therapy portfolio and growing blood cancer pipeline at the upcoming 2023 European Hematology Association (EHA) Annual Congress being held in Frankfurt, Germany, June 8-11, and virtually June 14-15.""}, {""date"": ""2023-06-01"", ""headline"": ""July 14th Options Now Available For Gilead Sciences"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-02"", ""headline"": ""Gilead, Arcus announce updated results from interim analysis of ARC-7 study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-02"", ""headline"": ""Gilead Sciences Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. rose 2.20% to $77.89 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""2023-06-02"", ""headline"": ""3 Undervalued Biotech Stocks to Buy Before They Blast Off"", ""summary"": ""When investors hear the words \u201cundervalued biotech stocks to buy,\u201d they frequently think of companies in the clinical trial stage. That\u2019s understandable. If you can buy a company\u2019s stock before it releases a game-changing drug or therapeutic into the market, you can make a fortune. That line of thinking was displayed in 2020 when many biotech companies raced to produce a Covid-19 vaccine. But every investor also knows that many of those moonshots never pan out. That\u2019s not the kind of uncertainty""}, {""date"": ""2023-06-02"", ""headline"": ""Gilead continues to make regulatory progress, says Argus"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-02"", ""headline"": ""Oppenheimer biotech analyst to hold a reception"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-03"", ""headline"": ""Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study"", ""summary"": ""FOSTER CITY, Calif., & HAYWARD, Calif., June 03, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced updated results from an interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) \u226550% without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations. ARC-7 is the first Phase 2, randomized, open-label study evaluating the comb""}, {""date"": ""2023-06-03"", ""headline"": ""3 Dividend Stocks You Can Buy Without Any Hesitation"", ""summary"": ""Three Motley Fool contributors identified dividend stocks that should be easy buy decisions for investors.  Here's why they think Bristol Myers Squibb (NYSE: BMY), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE) are investments you can make in June without any hesitation.  David Jagielski\u00a0(Bristol Myers Squibb):\u00a0 Bristol Myers Squibb has been paying dividends for more than 90 consecutive years.""}, {""date"": ""2023-06-04"", ""headline"": ""Those who invested in Gilead Sciences (NASDAQ:GILD) a year ago are up 28%"", ""summary"": ""Passive investing in index funds can generate returns that roughly match the overall market. But investors can boost...""}, {""date"": ""2023-06-04"", ""headline"": ""Mizuho Securities Keeps Their Buy Rating on Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-04"", ""headline"": ""Wall Street Breakfast: The Week Ahead"", ""summary"": ""Investors head into next week with the debt ceiling crisis resolved for the near term.""}]",{}
21,2023-06-04,75.70736694335938,2023-06-11,75.9309310913086,0.0029530038749925325,U1,"[{""date"": ""2023-06-04"", ""headline"": ""Gilead says new lung cancer antibody still improving survival rates"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-04"", ""headline"": ""Biotech stocks could soon get a M&A boost. Here are 3 likely takeover plays."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-04"", ""headline"": ""Those who invested in Gilead Sciences (NASDAQ:GILD) a year ago are up 28%"", ""summary"": ""Passive investing in index funds can generate returns that roughly match the overall market. But investors can boost...""}, {""date"": ""2023-06-04"", ""headline"": ""Mizuho Securities Keeps Their Buy Rating on Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-04"", ""headline"": ""Wall Street Breakfast: The Week Ahead"", ""summary"": ""Investors head into next week with the debt ceiling crisis resolved for the near term.""}, {""date"": ""2023-06-05"", ""headline"": ""Barclays Reaffirms Their Hold Rating on Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-05"", ""headline"": ""Gilead (GILD), Arcus Announce Results From Mid-Stage NSCLC Study"", ""summary"": ""Gilead (GILD) and Arcus announce data from the interim analysis of the mid-stage ARC-7 study on domvanalimab in the NSCLC study.""}, {""date"": ""2023-06-05"", ""headline"": ""Gilead Sciences Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. dropped 0.22% to $77.72 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...""}, {""date"": ""2023-06-05"", ""headline"": ""Trodelvy\u00ae Continues to Show Durable Overall Survival Advantage in Pre-Treated HR+/HER2- Metastatic Breast Cancer"", ""summary"": ""FOSTER CITY, Calif., June 05, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced longer-term overall survival (OS) results from the Phase 3 TROPiCS-02 study evaluating Trodelvy\u00ae (sacituzumab govitecan-hziy) versus comparator chemotherapy (physicians\u2019 choice of chemotherapy, TPC) in patients with HR+/HER2- (IHC0, IHC1+, IHC2+/ISH-) metastatic breast cancer who received endocrine-based therapies and at least two chemotherapies. In this exploratory analysis, Trodelvy demonstrated a clinical""}, {""date"": ""2023-06-05"", ""headline"": ""Kite\u2019s Yescarta\u00ae CAR T-cell Therapy Demonstrates Significantly Longer Overall Survival Versus Standard of Care as Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma"", ""summary"": ""SANTA MONICA, Calif., June 05, 2023--Kite, a Gilead Company (Nasdaq: GILD), today announces detailed results from the overall survival (OS) analysis of the landmark Phase 3 ZUMA-7 study of Yescarta\u00ae (axicabtagene ciloleucel [axi-cel]) CAR T-cell therapy compared with historical standard of care (SOC) as initial treatment in the curative setting for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL). Yescarta is the first treatment in nearly 30 years to demonstrate a significan""}, {""date"": ""2023-06-05"", ""headline"": ""IN BRIEF: Gilead says Trodelvy shows survival advantage in study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-05"", ""headline"": ""Gilead: Trodelvy delivered meaningful improvement in median OS in study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-05"", ""headline"": ""Kite's Yescarta CAR T-cell therapy shows longer OS vs. SOC in study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-05"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), IGM Biosciences (IGMS) and GT Biopharma (GTBP)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-05"", ""headline"": ""Gilead Sciences (GILD) Receives a Buy from BMO Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-06"", ""headline"": ""IN BRIEF: Gilead reports Tecartus study shows good response rates"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-06"", ""headline"": ""Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. slid 1.96% to $76.20 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...""}, {""date"": ""2023-06-06"", ""headline"": ""Kite\u2019s Tecartus\u00ae CAR T-cell Therapy Demonstrates 78% Complete Response Rate and 90% Overall Response Rate in Largest Real-World Evidence Analysis for Relapsed/Refractory Mantle Cell Lymphoma"", ""summary"": ""SANTA MONICA, Calif., June 06, 2023--Kite, a Gilead Company (Nasdaq: GILD), today announces findings from the largest real-world analysis to date of Tecartus\u00ae (brexucabtagene autoleucel) in patients with relapsed or refractory mantle cell lymphoma (R/R MCL), which show that outcomes of Tecartus therapy had consistent high complete response (CR) and overall response rates (ORR), regardless of type of prior treatment, including: Bruton's tyrosine kinase inhibitor (BTKi), bendamustine or autologous""}, {""date"": ""2023-06-06"", ""headline"": ""U.S. Wide-Moat Stocks On Sale - The June 2023 Heat Map"", ""summary"": ""Our 3-step process focuses on wide-moat stocks (as per Morningstar\u00e2\u0080\u0099s rating). Click here to see the heat map of the most investable candidates for June 2023.""}, {""date"": ""2023-06-06"", ""headline"": ""Gilead says Tecartus demonstrates 78% CR rate in real-world evidence analysis"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-06"", ""headline"": ""Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-06"", ""headline"": ""Why Gilead Sciences is a Top Socially Responsible Dividend Stock (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-07"", ""headline"": ""Gilead Sciences (GILD) Shares Cross Above 200 DMA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-07"", ""headline"": ""Gilead Sciences (GILD) Stock Moves -0.16%: What You Should Know"", ""summary"": ""Gilead Sciences (GILD) closed the most recent trading day at $76.08, moving -0.16% from the previous trading session.""}, {""date"": ""2023-06-07"", ""headline"": ""Gilead Sciences Inc. stock falls Wednesday, still outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. sank 0.16% to $76.08 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...""}, {""date"": ""2023-06-07"", ""headline"": ""Gilead Sciences, Inc. (GILD) Jefferies Global Healthcare Conference Transcript"", ""summary"": ""Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Jefferies Global Healthcare Conference June 7, 2023 11:00 AM ETCompany ParticipantsJohanna Mercier - Chief Commercial OfficerConference Call...""}, {""date"": ""2023-06-07"", ""headline"": ""Gilead Sciences: Living with a Rare Blood Cancer: Marion\u2019s Story"", ""summary"": ""Marion grew up very healthy, never even getting colds or the flu - but that changed as she got older.""}, {""date"": ""2023-06-07"", ""headline"": ""3 Biotech Stocks That Could Skyrocket in the Next 12 Months"", ""summary"": ""Navigating the turbulent waters in the biotech space is no mean feat. With the sector\u2019s inherent volatility due to testing clinical trials and regulatory hurdles, the road toward market approval can be incredibly challenging. However, for the savvy investor, promising biotech stocks to buy can translate into significant returns. According to Grand View Research, the global biotech market reached an impressive $1.37 trillion valuation last year. Additionally, analysts anticipate a compound annual""}, {""date"": ""2023-06-07"", ""headline"": ""Gilead Sciences Enters Oversold Territory"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-07"", ""headline"": ""AbTherx Announces License Agreement with Gilead"", ""summary"": ""AbTherx, Inc., a privately held biotech company focused on accelerating the discovery and development of antibody therapeutics, today announced a license agreement with Gilead Sciences, Inc. (NASDAQ:GILD). The license agreement will provide AbTherx rights to Gilead's recently acquired novel transgenic mouse technologies, which were developed by three of the AbTherx founders.""}, {""date"": ""2023-06-08"", ""headline"": ""Pfizer Or Gilead Sciences? Let's Ask Peter Lynch"", ""summary"": ""This article employs Lynch's approach to evaluate Pfizer and Gilead Sciences. Read on to see which of the two is a better dividend stock according to Peter Lynch.""}, {""date"": ""2023-06-08"", ""headline"": ""Gilead Sciences Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. rose 3.05% to $78.40 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""2023-06-08"", ""headline"": ""Interesting GILD Put And Call Options For July 28th"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-08"", ""headline"": ""Bank of America Securities Sticks to Their Hold Rating for Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-09"", ""headline"": ""Gilead Sciences Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. shed 0.36% to $78.12 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...""}, {""date"": ""2023-06-09"", ""headline"": ""2 Top Biotech Stocks to Buy in June"", ""summary"": ""Biotech stocks have taken investors on an unpredictable ride so far in 2023.  Two of the better biotech stocks I see this month are Gilead Sciences (NASDAQ: GILD) and Vertex Pharmaceuticals (NASDAQ: VRTX).  While Gilead's shares are down more than 11% so far this year, Vertex's shares are up more than 14%.""}, {""date"": ""2023-06-09"", ""headline"": ""10 Health Care Stocks With Whale Alerts In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-09"", ""headline"": ""Gilead Sciences, Inc. (NASDAQ:GILD) Will Pay A US$0.75 Dividend In Four Days"", ""summary"": ""It looks like Gilead Sciences, Inc. ( NASDAQ:GILD ) is about to go ex-dividend in the next 4 days. The ex-dividend date...""}, {""date"": ""2023-06-09"", ""headline"": ""Cantor Fitzgerald biotech analyst to hold analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-11"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of June 11"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the full weekly update.""}]",{}
22,2023-06-11,75.9309310913086,2023-06-18,77.39005279541016,0.01921643371325099,U2,"[{""date"": ""2023-06-11"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of June 11"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the full weekly update.""}, {""date"": ""2023-06-12"", ""headline"": ""Gilead Sciences Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. slumped 0.33% to $77.86 Monday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-06-12"", ""headline"": ""Gilead Sciences, Inc. (GILD) Goldman Sachs 44th Annual Global Healthcare Conference (Transcript)"", ""summary"": ""Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Goldman Sachs 44th Annual Global Healthcare Conference June 12, 2023 1:40 PM ETCompany ParticipantsDaniel O\u00e2\u0080\u0099Day - Chairman & CEOMerdad Parsey...""}, {""date"": ""2023-06-12"", ""headline"": ""5 Stocks to Buy With Explosive 500% Potential"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-12"", ""headline"": ""IN BRIEF: Guild Esports signs deal to build 'sim racing' facility"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-13"", ""headline"": ""Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know"", ""summary"": ""Gilead Sciences (GILD) closed the most recent trading day at $78.45, moving +0.76% from the previous trading session.""}, {""date"": ""2023-06-13"", ""headline"": ""Gilead Sciences Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.76% higher to $78.45 Tuesday, on what proved to be an all-around positive trading session for the stock market, with...""}, {""date"": ""2023-06-13"", ""headline"": ""Gilead Sciences goes ex dividend tomorrow"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-13"", ""headline"": ""Top 20 Most Profitable Pharmaceutical Companies In The World"", ""summary"": ""In this article, we will be covering the top 20 most profitable pharmaceutical companies in the world. If you wish to see the top ones, head straight to the Top 5 Most Profitable Pharmaceutical Companies In The World. Undoubtedly, the pharmaceutical industry stands as one of the most financially rewarding and essential sectors worldwide, leading [\u2026]""}, {""date"": ""2023-06-13"", ""headline"": ""Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.75"", ""summary"": ""Gilead Sciences, Inc. ( NASDAQ:GILD ) has announced that it will be increasing its dividend from last year's comparable...""}, {""date"": ""2023-06-14"", ""headline"": ""Galapagos appoints Thad Huston as CFO and COO as of July 1"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-14"", ""headline"": ""Gilead Sciences Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.32% higher to $77.95 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with...""}, {""date"": ""2023-06-14"", ""headline"": ""Asian American Women Engineers Find Community and Purpose at Gilead"", ""summary"": ""NORTHAMPTON, MA / ACCESSWIRE / June 14, 2023 / Gilead Sciences When Vicky Choi began her career as an engineer, she noticed that women and Asian people overall were well represented in the field - but that Asian women weren't reflected in upper ...""}, {""date"": ""2023-06-14"", ""headline"": ""My Dividend Stock Portfolio: New All-Time Dividend Record - 99 Holdings With 25 Buys"", ""summary"": ""US stocks ended May with solid gains and extended their strong performance into June, boosted by positive labor market data and the debt ceiling bill's progress.""}, {""date"": ""2023-06-14"", ""headline"": ""Gilead to Present Latest Liver Disease Research at the European Association for the Study of the Liver (EASL) Congress 2023"", ""summary"": ""FOSTER CITY, Calif., June 14, 2023--Gilead Sciences, Inc. (Nasdaq:GILD) today announced new data to be presented at the European Association for the Study of the Liver (EASL) Congress 2023, June 21-24, 2023. Key findings from more than 70 presentations will include Week 96 data from the pivotal Phase 3 study of Hepcludex\u00ae (bulevirtide) evaluating the efficacy and safety for the treatment of hepatitis delta virus (HDV) and late-breaking data on the impact of continued treatment with bulevirtide.""}, {""date"": ""2023-06-15"", ""headline"": ""Gilead Sciences Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. rose 1.35% to $79.00 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""2023-06-15"", ""headline"": ""Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-16"", ""headline"": ""Gilead Sciences Inc. stock falls Friday, still outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. slumped 0.18% to $78.86 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...""}, {""date"": ""2023-06-18"", ""headline"": ""How to Retire Rich: Biotech Stocks Edition"", ""summary"": ""Among the most difficult endeavors when it comes to deciphering the best retirement planning stocks is to identify companies that will remain relevant for years, if not decades to come. While no guarantees exist for anything, those who focus on investing in biotech own a clear advantage. Almost surely, the underlying sector \u2013 which falls under the broad healthcare industry \u2013 is permanently relevant. Further, I submitted a query on ChatGPT to extract key reasons why biotech stocks for retirement""}]",{}
23,2023-06-18,77.39005279541016,2023-06-25,76.02596282958984,-0.01762616662669103,D2,"[{""date"": ""2023-06-18"", ""headline"": ""How to Retire Rich: Biotech Stocks Edition"", ""summary"": ""Among the most difficult endeavors when it comes to deciphering the best retirement planning stocks is to identify companies that will remain relevant for years, if not decades to come. While no guarantees exist for anything, those who focus on investing in biotech own a clear advantage. Almost surely, the underlying sector \u2013 which falls under the broad healthcare industry \u2013 is permanently relevant. Further, I submitted a query on ChatGPT to extract key reasons why biotech stocks for retirement""}, {""date"": ""2023-06-19"", ""headline"": ""PBE: Healthcare Dashboard For June"", ""summary"": ""Pharma/biotechnology and healthcare providers are slightly undervalued relative to 11-year averages. Click here for the June edition of the Healthcare Dashboard.""}, {""date"": ""2023-06-20"", ""headline"": ""Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know"", ""summary"": ""Gilead Sciences (GILD) closed the most recent trading day at $77.71, moving -1.46% from the previous trading session.""}, {""date"": ""2023-06-20"", ""headline"": ""Gilead Sciences Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. slid 1.46% to $77.71 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-06-20"", ""headline"": ""Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death"", ""summary"": ""The FDA placed a study of Arcellx's multiple myeloma drug on hold after a patient died, leading ACLX stock to crumble Tuesday.""}, {""date"": ""2023-06-20"", ""headline"": ""IN BRIEF: Guild Esports completes fundraise for working capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-21"", ""headline"": ""Gilead Sciences Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Gilead Sciences Inc. sank 0.13% to $77.61 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-06-21"", ""headline"": ""2 Biotech Stocks You Can Buy and Hold for the Next Decade"", ""summary"": ""Biotech companies use living organisms to develop their therapies, and much like some living things, biotech stocks can be notoriously volatile.  Part of that is due to the complexities of making biotech therapies.  The success rate for biotech start-ups is low, but Gilead Sciences (NASDAQ: GILD), founded 36 years ago and Regeneron Pharmaceuticals (NASDAQ: REGN), founded 35 years ago, have already stood the test of time.""}, {""date"": ""2023-06-21"", ""headline"": ""Gilead Sciences Supports the LGBTQ+ Community in Oakland: Love Is the Answer"", ""summary"": ""NORTHAMPTON, MA / ACCESSWIRE / June 21, 2023 / Gilead Sciences: As a young gay man growing up in Detroit, Joe Hawkins witnessed the stigma and discrimination against the LGBTQ+ community. And when he entered the military in the 1980s, during the ...""}, {""date"": ""2023-06-21"", ""headline"": ""Arcellx's CAR-T Hold: Turmoil, Triumphs, And Trading Tips"", ""summary"": ""Arcellx's CART-ddBCMA program faces a clinical hold due to a patient's death. Find out why I advise investors to hold ACLX stock.""}, {""date"": ""2023-06-22"", ""headline"": ""Gilead Sciences Inc. stock rises Thursday, outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.64% higher to $78.11 Thursday, on what proved to be an all-around mixed trading session for the stock market, with...""}, {""date"": ""2023-06-22"", ""headline"": ""Gilead notes transfer of Yescarta marketing authorisation from Daiichi"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-22"", ""headline"": ""Kite Announces Completion of Marketing Authorization Transfer for Yescarta\u00ae CAR T-cell Therapy in Japan"", ""summary"": ""SANTA MONICA, Calif., June 22, 2023--Kite Pharma, Inc., a Gilead Company (Nasdaq: GILD), today announced that the Marketing Authorization in Japan for Yescarta\u00ae (axicabtagene ciloleucel), a chimeric antigen receptor (CAR) T-cell therapy, has been transferred from Daiichi Sankyo Co., Ltd. to Gilead Sciences K.K., the Japan subsidiary of Gilead Sciences, Inc.""}, {""date"": ""2023-06-22"", ""headline"": ""Gilead announces completion of marketing authorization in Japan for Yescarta"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-23"", ""headline"": ""Gilead Sciences (GILD) Announces Positive HDV Treatment Data"", ""summary"": ""Gilead Sciences, Inc. (GILD) announces data on Hepcludex that reinforces the potential of bulevirtide as an effective and well-tolerated treatment for chronic HDV after 96 weeks.""}, {""date"": ""2023-06-23"", ""headline"": ""Gilead Sciences Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. slipped 0.82% to $77.47 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-06-23"", ""headline"": ""Gilead's Chronic Hepatitis Delta Infection Treatment Shows Sustained Efficacy, Safety Profile At Two Years"", ""summary"": ""Gilead Sciences Inc (NASDAQ: GILD) announced Week 96 results from the MYR301 Phase 3 clinical trial evaluating bulevirtide for chronic hepatitis delta (HDV) infection. Bulevirtide is the only approved treatment for HDV in Europe and is not approved in the U.S. The Week 96 findings demonstrated improved combined response compared to Week 48, with no signs of treatment resistance and sustained virologic response with continued bulevirtide monotherapy. Prolonged bulevirtide treatment showed clinica""}, {""date"": ""2023-06-23"", ""headline"": ""IN BRIEF: Gilead Sciences says test results show Hepcludex effective"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-23"", ""headline"": ""Gilead Receives CHMP Positive Opinion for Trodelvy\u00ae in Pre-Treated HR+/HER2- Metastatic Breast Cancer"", ""summary"": ""FOSTER CITY, Calif., June 23, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Trodelvy\u00ae (sacituzumab govitecan) as monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the adva""}, {""date"": ""2023-06-23"", ""headline"": ""Analysts Conflicted on These Healthcare Names: Gilead Sciences (GILD), Sarepta Therapeutics (SRPT) and Intra-Cellular Therapies (ITCI)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-23"", ""headline"": ""Gilead Gets Positive European Opinion for Additional Indication for Trodelvy"", ""summary"": ""By Robb M. Stewart Gilead Sciences has received a positive response from the European Medicines Agency's Committee for Medicinal Products for Human Use on an...""}, {""date"": ""2023-06-23"", ""headline"": ""Gilead's Trodelvy for breast cancer endorsed by EMA panel"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-23"", ""headline"": ""Gilead announces CHMP recommendation for the use of Trodelvy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-23"", ""headline"": ""Hepcludex\u00ae (Bulevirtide) Demonstrates Sustained Efficacy and Safety Profile in People With Chronic Hepatitis Delta Virus at 96 Weeks"", ""summary"": ""FOSTER CITY, Calif., June 23, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced Week 96 results from the pivotal MYR301 Phase 3 clinical trial evaluating the first-in-class entry inhibitor Hepcludex\u00ae (bulevirtide) for the treatment of adults with chronic hepatitis delta (HDV) infection. These new data presented at the European Association for the Study of the Liver (EASL) Congress 2023 reinforce the role of bulevirtide as an efficacious and well-tolerated treatment for the management of""}, {""date"": ""2023-06-23"", ""headline"": ""IN BRIEF: Guild Esports inks one-year deal with Secretlab for chairs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-23"", ""headline"": ""Gilead announces Week 96 results from MYR301 clinical trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-25"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of June 25"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the June 25th weekly update.""}]",{}
24,2023-06-25,76.02596282958984,2023-07-02,75.63341522216797,-0.005163336218467318,D1,"[{""date"": ""2023-06-25"", ""headline"": ""GILD Crosses Above 4% Yield Territory"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-25"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of June 25"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the June 25th weekly update.""}, {""date"": ""2023-06-26"", ""headline"": ""Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know"", ""summary"": ""Gilead Sciences (GILD) closed the most recent trading day at $76.56, moving -1.17% from the previous trading session.""}, {""date"": ""2023-06-26"", ""headline"": ""Gilead (GILD) Breast Cancer Drug Gets Positive CHMP Opinion"", ""summary"": ""Gilead's breast cancer drug Trodelvy gets positive CHMP opinion for a second indication in Europe.""}, {""date"": ""2023-06-26"", ""headline"": ""Gilead Sciences Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. slipped 1.17% to $76.56 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-06-27"", ""headline"": ""10 Martin Shkreli Stock Picks and Their Performance"", ""summary"": ""In this article, we will take a look at the 10 Martin Shkreli stock picks and their performance. To see more such companies, go directly to 5 Martin Shkreli Stock Picks and Their Performance. Martin Shkreli a.k.a. \u201cPharma Bro\u201d is known for a variety of reasons, many of which are tinged with notoriety. He cofounded [\u2026]""}, {""date"": ""2023-06-27"", ""headline"": ""Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. slipped 0.72% to $76.01 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-06-28"", ""headline"": ""Looking Into Gilead Sciences's Recent Short Interest"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-28"", ""headline"": ""Gilead Sciences' Debt Overview"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-28"", ""headline"": ""Gilead Sciences Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.22% higher to $76.18 Wednesday, on what proved to be an all-around grim trading session for the stock market, with...""}, {""date"": ""2023-06-28"", ""headline"": ""Gilead Sciences adds $10.99M to AlloVir stake"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-29"", ""headline"": ""Gilead Sciences Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. slumped 0.22% to $76.01 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P...""}, {""date"": ""2023-06-29"", ""headline"": ""Hepatitis C cure is not reaching overwhelming majority of patients due to financial barriers"", ""summary"": ""Hepatitis C is often referred to as the silent killer because the initial infection has few to no symptoms. ""}, {""date"": ""2023-06-29"", ""headline"": ""With 85% ownership, Gilead Sciences, Inc. (NASDAQ:GILD) boasts of strong institutional backing"", ""summary"": ""Key Insights Institutions' substantial holdings in Gilead Sciences implies that they have significant influence over...""}, {""date"": ""2023-06-29"", ""headline"": ""GILD August 11th Options Begin Trading"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-29"", ""headline"": ""A Drug for Itchy Dogs Costs $1,200. Why Is the Human Equivalent $43,000?"", ""summary"": ""If your eczema is making you itchy, your doctor might prescribe Dupixent, a Sanofi monoclonal antibody therapy with a U.S. list price of around $43,000 a year.  On a biological level, there\u2019s little difference between them: Dupixent targets proteins\u00a0in the human immune system called interleukin-4 and interleukin- 13, while Cytopoint targets a protein in the dog immune system called interleukin-31.  While Cytopoint was licensed by the U.S. Department of Agriculture, Zoetis\u2019 (ticker: ZTS) other two monoclonal antibodies were approved by the Food and Drug Administration.""}, {""date"": ""2023-06-30"", ""headline"": ""AlloVir: Several Late-Stage Programs Make This Worth A Look"", ""summary"": ""A good thing about AlloVir is that it is already having its drug posoleucel being explored in several phase 3 studies. Read more about ALVR here.""}, {""date"": ""2023-06-30"", ""headline"": ""Gilead Sciences : Prevails in HIV Antitrust Trial"", ""summary"": ""Foster City, Calif., June 30, 2023 - Gilead Sciences, Inc.  announced today that a jury in the U.S. District Court for the Northern District of California returned a verdict in favor...""}, {""date"": ""2023-06-30"", ""headline"": ""Gilead Sciences Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. advanced 1.39% to $77.07 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P...""}, {""date"": ""2023-06-30"", ""headline"": ""10 Health Care Stocks With Whale Alerts In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-30"", ""headline"": ""Medicare revises guidance on drug price negotiations amid lawsuits"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-30"", ""headline"": ""This Is What Whales Are Betting On Gilead Sciences"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-30"", ""headline"": ""Amgen Inc. Dividend Stock Analysis"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-01"", ""headline"": ""Gilead, Teva acquitted in pay for delay generic HIV drugs case"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]","{""assetTurnoverTTM"": 0.4382, ""bookValue"": 21158, ""cashRatio"": 0.40847894586078487, ""currentRatio"": 1.0231, ""ebitPerShare"": 1.3235, ""eps"": 0.8307, ""ev"": 115648.29, ""fcfMargin"": 0.3334, ""fcfPerShareTTM"": 7.158, ""grossMargin"": 0.7815, ""inventoryTurnoverTTM"": 3.6035, ""longtermDebtTotalAsset"": 0.3402, ""longtermDebtTotalCapital"": 0.4571, ""longtermDebtTotalEquity"": 1.0024, ""netDebtToTotalCapital"": 0.4211, ""netDebtToTotalEquity"": 0.9236, ""netMargin"": 0.1584, ""operatingMargin"": 0.2523, ""payoutRatioTTM"": 0.6851, ""pb"": 4.5423, ""peTTM"": 17.5249, ""pfcfTTM"": 10.767, ""pretaxMargin"": 0.2406, ""psTTM"": 3.5098, ""quickRatio"": 0.7804, ""receivablesTurnoverTTM"": 6.5609, ""roaTTM"": 0.0878, ""roeTTM"": 0.2597, ""roicTTM"": 0.1183, ""rotcTTM"": 0.1828, ""salesPerShare"": 5.2456, ""sgaToSale"": 0.2185, ""totalDebtToEquity"": 1.1932, ""totalDebtToTotalAsset"": 0.405, ""totalDebtToTotalCapital"": 0.544, ""totalRatio"": 1.5138, ""period"": ""2023-06-30""}"
25,2023-07-02,75.63341522216797,2023-07-09,73.0328140258789,-0.034384288857642775,D4,"[{""date"": ""2023-07-03"", ""headline"": ""Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know"", ""summary"": ""Gilead Sciences (GILD) closed at $76.72 in the latest trading session, marking a -0.46% move from the prior day.""}, {""date"": ""2023-07-03"", ""headline"": ""HQH: Deep Discount Presents An Opportunity"", ""summary"": ""Tekla Healthcare Investors focuses on biotech subsector of healthcare, leading to potential volatility and potential for high returns. Read my analysis of HQH.""}, {""date"": ""2023-07-03"", ""headline"": ""Gilead receives positive verdict from US court in HIV antitrust trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-04"", ""headline"": ""Gilead Sciences: An Evolving Biopharma Navigating Through Challenges And Opportunities"", ""summary"": ""Gilead's Q1 2023 revenues fell to $6.4bn, offset by positive developments in their promising oncology drug, Trodelvy. See why GILD stock is a Hold.""}, {""date"": ""2023-07-04"", ""headline"": ""Guild Esports sees shares rise on first British F4 Esports entry"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-05"", ""headline"": ""The 3 Best Biotech Stocks to Buy In July"", ""summary"": ""Although it\u2019s been a difficult year for biotechnology stocks, there are still plenty of reasons for investors to be bullish on the sector. Many of the biggest innovations in medicine are occurring at small and midsized biotech companies in the U.S. These are the incubators for medical advancements and where important scientific breakthroughs are happening. New products and treatments are boosting sales and earnings at biotech companies, making them great long-term investments. Although the S&P B""}, {""date"": ""2023-07-05"", ""headline"": ""Gilead Sciences Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.68% higher to $77.24 Wednesday, on what proved to be an all-around poor trading session for the stock market, with...""}, {""date"": ""2023-07-05"", ""headline"": ""Those who invested in Gilead Sciences (NASDAQ:GILD) a year ago are up 27%"", ""summary"": ""The simplest way to invest in stocks is to buy exchange traded funds. But you can significantly boost your returns by...""}, {""date"": ""2023-07-05"", ""headline"": ""Gilead Sciences (GILD) Gets a Buy from Jefferies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-05"", ""headline"": ""NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-05"", ""headline"": ""Why the 5 Highest-Yielding Nasdaq Stocks Could Rip Higher With the Red-Hot Summer Rally"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-05"", ""headline"": ""Analysts\u2019 Opinions Are Mixed on These Healthcare Stocks: Amneal Pharmaceuticals (AMRX), Replimune Group (REPL) and Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-06"", ""headline"": ""Gilead Sciences Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. shed 1.29% to $76.24 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-07-06"", ""headline"": ""4 Big Pharma Stocks On Sale Right Now "", ""summary"": ""The key is to buy a basket of the cheap ones, so that gains in a few of them can offset disappointing performance in others.""}, {""date"": ""2023-07-06"", ""headline"": ""U.S. Wide-Moat Stocks On Sale - The July 2023 Heat Map"", ""summary"": ""Our 3-step process focuses on wide-moat stocks. We're only interested in targets attractively valued in historical comparison. Read what investors need to know.""}, {""date"": ""2023-07-06"", ""headline"": ""Gilead raises stake in Arcus Biosciences to 35%"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-06"", ""headline"": ""DBS Keeps Their Buy Rating on Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-07"", ""headline"": ""Gilead Sciences Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. shed 2.39% to $74.42 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-07-07"", ""headline"": ""14 Best NASDAQ Dividend Stocks To Buy"", ""summary"": ""In this article, we discuss 14 best NASDAQ dividend stocks to buy. You can skip our detailed analysis of dividend stocks and their returns over the years, and go directly to read 5 Best NASDAQ Dividend Stocks To Buy. NASDAQ is commonly associated with technology and growth-oriented companies that usually don\u2019t pay dividends but there [\u2026]""}, {""date"": ""2023-07-07"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Biogen (BIIB) and Crinetics Pharmaceuticals (CRNX)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-09"", ""headline"": ""Goldman Sachs sees rays of hope in underperforming health sector"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-09"", ""headline"": ""Pfizer among big pharma stocks on sale right now, Barron's says"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-09"", ""headline"": ""Fly Intel: Top five weekend stock stories"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-09"", ""headline"": ""Acumen, BridgeBio, Arcus among BTIG's top healthcare picks for 2H 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]","{""assetTurnoverTTM"": 0.4382, ""bookValue"": 21158, ""cashRatio"": 0.40847894586078487, ""currentRatio"": 1.0231, ""ebitPerShare"": 1.3235, ""eps"": 0.8307, ""ev"": 115648.29, ""fcfMargin"": 0.3334, ""fcfPerShareTTM"": 7.158, ""grossMargin"": 0.7815, ""inventoryTurnoverTTM"": 3.6035, ""longtermDebtTotalAsset"": 0.3402, ""longtermDebtTotalCapital"": 0.4571, ""longtermDebtTotalEquity"": 1.0024, ""netDebtToTotalCapital"": 0.4211, ""netDebtToTotalEquity"": 0.9236, ""netMargin"": 0.1584, ""operatingMargin"": 0.2523, ""payoutRatioTTM"": 0.6851, ""pb"": 4.5423, ""peTTM"": 17.5249, ""pfcfTTM"": 10.767, ""pretaxMargin"": 0.2406, ""psTTM"": 3.5098, ""quickRatio"": 0.7804, ""receivablesTurnoverTTM"": 6.5609, ""roaTTM"": 0.0878, ""roeTTM"": 0.2597, ""roicTTM"": 0.1183, ""rotcTTM"": 0.1828, ""salesPerShare"": 5.2456, ""sgaToSale"": 0.2185, ""totalDebtToEquity"": 1.1932, ""totalDebtToTotalAsset"": 0.405, ""totalDebtToTotalCapital"": 0.544, ""totalRatio"": 1.5138, ""period"": ""2023-06-30""}"
26,2023-07-09,73.0328140258789,2023-07-16,75.75118255615234,0.03722119387745604,U4,"[{""date"": ""2023-07-09"", ""headline"": ""Gilead call volume above normal and directionally bullish"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-09"", ""headline"": ""Goldman Sachs sees rays of hope in underperforming health sector"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-09"", ""headline"": ""Pfizer among big pharma stocks on sale right now, Barron's says"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-09"", ""headline"": ""Fly Intel: Top five weekend stock stories"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-09"", ""headline"": ""Acumen, BridgeBio, Arcus among BTIG's top healthcare picks for 2H 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-10"", ""headline"": ""AlloVir: 'Takes One To Know One'"", ""summary"": ""Allovir's lead product, posoleucel, is in Phase III clinical trials and targets six viral pathogens in immunocompromised individuals. Find out why ALVR stock is a Strong Buy.""}, {""date"": ""2023-07-10"", ""headline"": ""Gilead Sciences Inc. stock rises Monday, outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. advanced 1.71% to $75.69 Monday, on what proved to be an all-around positive trading session for the stock market, with the...""}, {""date"": ""2023-07-10"", ""headline"": ""We Think Gilead Sciences (NASDAQ:GILD) Can Stay On Top Of Its Debt"", ""summary"": ""David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...""}, {""date"": ""2023-07-10"", ""headline"": ""RBC Capital Keeps Their Hold Rating on Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-10"", ""headline"": ""Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials \u2013 What Other Viruses Could This COVID Treatment Target?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-11"", ""headline"": ""Gilead Just Bought $30 Million More of 2 Biotech Stocks"", ""summary"": ""Gilead recently increased stakes in AlloVir, a developer of drugs to treat or prevent viral diseases, and Arcus Biosciences, a biopharmaceutical firm...""}, {""date"": ""2023-07-11"", ""headline"": ""7 Tech Stocks to Watch on July 14"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-11"", ""headline"": ""Gilead Sciences Inc. stock rises Tuesday, still underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.57% higher to $76.12 Tuesday, on what proved to be an all-around great trading session for the stock market, with the...""}, {""date"": ""2023-07-11"", ""headline"": ""Morgan Stanley Reiterates Gilead Sciences (GILD) Equal-Weight Recommendation"", ""summary"": """"}, {""date"": ""2023-07-11"", ""headline"": ""Barclays Maintains Gilead Sciences (GILD) Equal-Weight Recommendation"", ""summary"": """"}, {""date"": ""2023-07-11"", ""headline"": ""Starbucks and 6 More Stocks That Could Get a Boost From the Nasdaq 100 Rebalance"", ""summary"": ""Starbucks, Mondelez, and Booking are among the possible outperformers from the index\u2019s weighting changes, according to Wells Fargo.""}, {""date"": ""2023-07-11"", ""headline"": ""Wells Fargo highlights Nasdaq 100 rebalance trade opportunities"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-11"", ""headline"": ""Barclays Sticks to Their Hold Rating for Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-11"", ""headline"": ""Gilead price target lowered to $81 from $84 at Barclays"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-12"", ""headline"": ""Half-Time Heroes: Moat Stocks Lead As Second Half Kicks Off"", ""summary"": ""Morningstar\u00e2\u0080\u0099s strategy of focusing on quality companies at attractive prices has powered its Moat Index to its strongest first-half performance since 2007, putting it ahead of the S&P 500.""}, {""date"": ""2023-07-12"", ""headline"": ""Gilead Sciences Inc. stock rises Wednesday, still underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.34% higher to $76.38 Wednesday, on what proved to be an all-around positive trading session for the stock market,...""}, {""date"": ""2023-07-12"", ""headline"": ""10 Health Care Stocks With Whale Alerts In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-12"", ""headline"": ""ClearBridge All Cap Value Strategy Q2 2023 Portfolio Manager Commentary"", ""summary"": ""The ClearBridge All Cap Value Strategy outperformed its Russell 3000 Value Index during the second quarter of 2023. Click here to read the full fund letter.""}, {""date"": ""2023-07-13"", ""headline"": ""Gilead Sciences (GILD) Gains But Lags Market: What You Should Know"", ""summary"": ""In the latest trading session, Gilead Sciences (GILD) closed at $76.71, marking a +0.43% move from the previous day.""}, {""date"": ""2023-07-13"", ""headline"": ""Gilead Sciences Inc. stock rises Thursday, still underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.43% higher to $76.71 Thursday, on what proved to be an all-around great trading session for the stock market, with...""}, {""date"": ""2023-07-13"", ""headline"": ""Gilead: Assessing How Shares Will Trade Over Upcoming Months (Technical Analysis)"", ""summary"": ""Gilead Sciences' 12-month dividend growth rate of 2.8% is behind the inflation rate, suggesting a negative real return over the next year. Click here to read more.""}, {""date"": ""2023-07-13"", ""headline"": ""Interesting GILD Put And Call Options For September 1st"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-13"", ""headline"": ""Gilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries"", ""summary"": ""FOSTER CITY, Calif., July 13, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) is pleased to announce two public-private partnerships. The first will accelerate the development of an investigational dispersible pediatric formulation containing emtricitabine and tenofovir alafenamide (F/TAF). The second aims to develop investigational pediatric formulations of TAF and sofosbuvir (SOF) designed to eliminate bitterness.""}, {""date"": ""2023-07-13"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-13"", ""headline"": ""With The Massive NASDAQ Rebalance Coming Soon 7 \u2018Strong Buy\u2019 Stocks Could Explode Higher"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-13"", ""headline"": ""Gilead inks deals to improve HIV treatment uptake in children"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-13"", ""headline"": ""Gilead announces two public-private partnerships"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-14"", ""headline"": ""Dividend Income Update June 2023"", ""summary"": ""The beginning of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated. ""}, {""date"": ""2023-07-14"", ""headline"": ""Gilead Sciences to Release Second Quarter 2023 Financial Results on Thursday, August 3, 2023"", ""summary"": ""FOSTER CITY, Calif., July 14, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2023 financial results and guidance will be released on Thursday, August 3, 2023 after the market closes. At 5:00 p.m. Eastern Time that day, Gilead\u2019s management will host a webcast to discuss the company\u2019s second quarter 2023 financial results and provide a business update.""}, {""date"": ""2023-07-14"", ""headline"": ""FDA Approves Gilead's Remdesivir For COVID-19 Treatment Patients With Severe Renal Impairment"", ""summary"": ""The FDA approved Gilead Sciences Inc's (NASDAQ: GILD) supplemental new drug application for using Veklury (remdesivir) in COVID-19 patients with severe renal impairment, including those on dialysis. With this approval, Veklury is now the first and only approved antiviral COVID-19 treatment that can be used across all stages of renal disease. More than 1 in 7 (37 million) people in the U.S. are estimated to have chronic kidney disease (CKD) and are at increased risk of COVID-19-related morbidity""}, {""date"": ""2023-07-14"", ""headline"": ""More Challenges Await AbbVie Following A Disappointing Quarter"", ""summary"": ""AbbVie Inc., one of the leaders in the global immunology market, will release its financial report for the second quarter of 2023. Click here to read more.""}, {""date"": ""2023-07-14"", ""headline"": ""Gilead Sciences Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.63% higher to $77.19 Friday, on what proved to be an all-around mixed trading session for the stock market, with the...""}, {""date"": ""2023-07-14"", ""headline"": ""FDA Approves Veklury\u00ae (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis"", ""summary"": ""FOSTER CITY, Calif., July 14, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) for the use of Veklury\u00ae (remdesivir) in COVID-19 patients with severe renal impairment, including those on dialysis. With this approval, Veklury is now the first and only approved antiviral COVID-19 treatment that can be used across all stages of renal disease. More than 1 in 7 (37 million) people in the U.S.""}, {""date"": ""2023-07-14"", ""headline"": ""Gilead COVID therapy Veklury approved for those with renal impairment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-14"", ""headline"": ""IN BRIEF: Gilead gets FDA approval for Veklury to treat renal disease"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-14"", ""headline"": ""Gilead Covid-19 Drug Remdesivir Cleared by FDA to Treat Renal Disease"", ""summary"": ""By Dean Seal \n\n\n  Gilead Sciences said regulators have approved its antiviral remdesivir, sold under the name brand Veklury, for Covid-19 patients with severe renal impairment, including those on...""}, {""date"": ""2023-07-14"", ""headline"": ""Gilead Sciences says FDA has approved Veklury in COVID patients with severe kidney disease"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-14"", ""headline"": ""Gilead announces FDA approval of Veklury sNDA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-16"", ""headline"": ""Eli Lilly, Merck among top pharma picks in Barclays Q2 preview"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]","{""assetTurnoverTTM"": 0.4382, ""bookValue"": 21158, ""cashRatio"": 0.40847894586078487, ""currentRatio"": 1.0231, ""ebitPerShare"": 1.3235, ""eps"": 0.8307, ""ev"": 115648.29, ""fcfMargin"": 0.3334, ""fcfPerShareTTM"": 7.158, ""grossMargin"": 0.7815, ""inventoryTurnoverTTM"": 3.6035, ""longtermDebtTotalAsset"": 0.3402, ""longtermDebtTotalCapital"": 0.4571, ""longtermDebtTotalEquity"": 1.0024, ""netDebtToTotalCapital"": 0.4211, ""netDebtToTotalEquity"": 0.9236, ""netMargin"": 0.1584, ""operatingMargin"": 0.2523, ""payoutRatioTTM"": 0.6851, ""pb"": 4.5423, ""peTTM"": 17.5249, ""pfcfTTM"": 10.767, ""pretaxMargin"": 0.2406, ""psTTM"": 3.5098, ""quickRatio"": 0.7804, ""receivablesTurnoverTTM"": 6.5609, ""roaTTM"": 0.0878, ""roeTTM"": 0.2597, ""roicTTM"": 0.1183, ""rotcTTM"": 0.1828, ""salesPerShare"": 5.2456, ""sgaToSale"": 0.2185, ""totalDebtToEquity"": 1.1932, ""totalDebtToTotalAsset"": 0.405, ""totalDebtToTotalCapital"": 0.544, ""totalRatio"": 1.5138, ""period"": ""2023-06-30""}"
27,2023-07-16,75.75118255615234,2023-07-23,79.13687133789062,0.04469486373006193,U5,"[{""date"": ""2023-07-16"", ""headline"": ""Price Over Earnings Overview: Gilead Sciences"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-16"", ""headline"": ""Eli Lilly, Merck among top pharma picks in Barclays Q2 preview"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-17"", ""headline"": ""Gilead Sciences Inc. stock rises Monday, still underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.38% higher to $77.48 Monday, on what proved to be an all-around great trading session for the stock market, with the...""}, {""date"": ""2023-07-17"", ""headline"": ""Gilead's (GILD) Veklury Gets FDA Nod for Label Expansion"", ""summary"": ""Gilead's (GILD) antiviral treatment Veklury (remdesivir) has now been approved for the treatment of COVID-19 patients with severe renal impairment, including those on dialysis.""}, {""date"": ""2023-07-17"", ""headline"": ""Buying These 2 Stocks Is a Good Way to Hedge Against a Market Crash"", ""summary"": ""If you're worried about the stock market crashing, then now is a good time to review your portfolio allocation.  Gilead (NASDAQ: GILD) is a biotechnology company with a broad portfolio of drugs focused on the treatment of HIV, viral hepatitis, and several cancers.  Gilead's pipeline also has dozens of candidates at various stages of development and clinical trials.""}, {""date"": ""2023-07-17"", ""headline"": ""Gilead Sciences to Release Second Quarter 2023 Financial Results on Thursday, August 3, 2023"", ""summary"": ""FOSTER CITY - Gilead Sciences, Inc.  announced today that its second quarter 2023 financial results and guidance will be released on Thursday, August 3, 2023 after the market closes.\nAt 5:00 p.m....""}, {""date"": ""2023-07-17"", ""headline"": ""IN BRIEF: Guild Esports signs digital advertising deal with Pixels AI"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-18"", ""headline"": ""Gilead Sciences Inc. stock rises Tuesday, outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.96% higher to $78.22 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with...""}, {""date"": ""2023-07-18"", ""headline"": ""Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-18"", ""headline"": ""My Dividend Stock Portfolio: New June Dividend Record - 99 Holdings With 28 Buys"", ""summary"": ""The broad S&P500 edged up 1.2% in June, while the Dow Jones rose slightly by 0.8% during the month. Click here to see my complete dividend stock portfolio list.""}, {""date"": ""2023-07-18"", ""headline"": ""SARS-CoV-2 Is Not Done Yet \u2014 Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-18"", ""headline"": ""Gilead price target lowered to $95 from $100 at BMO Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-19"", ""headline"": ""Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know"", ""summary"": ""Gilead Sciences (GILD) closed the most recent trading day at $78.96, moving +0.95% from the previous trading session.""}, {""date"": ""2023-07-19"", ""headline"": ""The 7 Most Undervalued Nasdaq Stocks to Buy Now: July 2023"", ""summary"": ""The Nasdaq is known for its high-flying growth stocks, and with good reason. But there\u2019s more to the index than just those aggressive names. In fact, there are even many Nasdaq stocks suitable for people following value investing strategies. The Nasdaq isn\u2019t just a technology index either. There are Nasdaq stocks to buy in industries as diverse as telecom, banks, and financial service companies. The Nasdaq 100 Index has been off to a roaring start in the first half of this year. But fear not; th""}, {""date"": ""2023-07-19"", ""headline"": ""Gilead Sciences: Putting a Spotlight on the Mental Health Needs of LGBTQ+ Youth"", ""summary"": ""Across the country, LGBTQ+ youth face challenges that are negatively affecting their mental health. Some find themselves not feeling accepted by their family or friends, or being verbally harassed at school.""}, {""date"": ""2023-07-19"", ""headline"": ""Gilead Showcases Latest HIV Pipeline Progress and the Impact of Global Collaboration on Health Equity Efforts at IAS 2023"", ""summary"": ""FOSTER CITY, Calif., July 19, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming contributions to the 12th International AIDS Society Conference on HIV Science (IAS 2023), taking place in Brisbane, Australia, and virtually, from July 23-26, 2023. As the leader in HIV innovation, Gilead will provide updates on its signature initiatives and key collaborations while sharing new scientific data from its research and development programs. The breadth of data presented at the meet""}, {""date"": ""2023-07-19"", ""headline"": ""3 Healthcare Stocks to Buy and Hold for the Next 10 Years"", ""summary"": ""The healthcare sector is unlikely to become obsolete anytime soon, but individual companies can very much get left behind if they fail to keep up with the changing dynamics of the industry.  Let's look at three healthcare stocks that are leaders or innovators in their respective niches and could provide excellent returns in the next 10 years: Vertex Pharmaceuticals (NASDAQ: VRTX), Moderna (NASDAQ: MRNA), and Gilead Sciences (NASDAQ: GILD).  Vertex Pharmaceuticals has soundly beaten the market in the past 10 years, and the company is in an excellent position to do so in the next decade.""}, {""date"": ""2023-07-19"", ""headline"": ""Peering Into Gilead Sciences's Recent Short Interest"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-19"", ""headline"": ""Gilead price target lowered to $80 from $85 at Cantor Fitzgerald"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-20"", ""headline"": ""Gilead Sciences Inc. stock outperforms market on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-20"", ""headline"": ""Gilead Sciences Inc. stock underperforms Thursday when compared to competitors despite daily gains"", ""summary"": ""Shares of Gilead Sciences Inc. rose 1.24% to $79.94 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...""}, {""date"": ""2023-07-20"", ""headline"": ""Gilead Announces $8 Million in Grant Funding for Viral Hepatitis Relink Program in the U.S."", ""summary"": ""FOSTER CITY, Calif., July 20, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is providing a total of $8 million in funding through a new grant program in the United States called Gilead Relink, which is focused on bringing diagnosed but untreated people living with hepatitis C virus (HCV) or hepatitis B virus (HBV) back into care. The CDA Foundation (CDAF), based in Lafayette, Colorado, will act as the lead organization for the program and be responsible for implementing and overs""}, {""date"": ""2023-07-20"", ""headline"": ""Center for Disease Analysis Foundation  Announces Receipt of an $8 Million Grant from Gilead Sciences  to Relink Hepatitis B and C Patients to Care in the United States"", ""summary"": ""LAFAYETTE, Colo., July 20, 2023 (GLOBE NEWSWIRE) -- The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead\u2019s Relink grant program. CDA Foundation will disperse the grant to qualifying tax-exempt organizations to contact diagnosed but untreated patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) infection to bring them back into care. Despite the availability of existing tr""}, {""date"": ""2023-07-20"", ""headline"": ""Cantor Fitzgerald Maintains Gilead Sciences (GILD) Neutral Recommendation"", ""summary"": """"}, {""date"": ""2023-07-20"", ""headline"": ""Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant From Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States"", ""summary"": ""The Center for Disease Analysis Foundation  announced today that it received an $8 million grant from Gilead Sciences  as part of Gilead\u2019s Relink grant program. CDA Foundation will disperse the...""}, {""date"": ""2023-07-20"", ""headline"": ""A Note On Gilead Sciences, Inc.'s (NASDAQ:GILD) ROE and Debt To Equity"", ""summary"": ""Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...""}, {""date"": ""2023-07-20"", ""headline"": ""Gilead announces $8M in funding through Gilead Relink program"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-20"", ""headline"": ""Bullish Two Hundred Day Moving Average Cross - GILD"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-21"", ""headline"": ""Pfizer, Gilead, GSK set to dominate infectious diseases market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-21"", ""headline"": ""Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS"", ""summary"": ""FOSTER CITY, Calif., July 21, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes (MDS) has been discontinued due to futility based on a planned analysis. The safety data seen in this study is consistent with the known magrolimab profile and adverse events that are typical in this patient population. Gilead recommends discontinuing treatment with magrolimab in patients with MDS. Magrolimab is a potential first-in-clas""}, {""date"": ""2023-07-21"", ""headline"": ""Gilead Discontinues Study of Immunotherapy to Treat Blood Cancers"", ""summary"": ""By Denny Jacob Gilead Sciences has discontinued its Phase 3 study of magrolimab in higher-risk myelodysplastic syndromes. The biopharmaceutical company said...""}, {""date"": ""2023-07-21"", ""headline"": ""Gilead ends late-stage trial of blood cancer treatment"", ""summary"": ""Shares of Gilead Sciences Inc. dropped nearly 2% in the extended session Friday after the pharma company said it has ended a late-stage trial of a treatment...""}, {""date"": ""2023-07-21"", ""headline"": ""Gilead abandons phase 3 study of magrolimab for myelodysplastic syndromes"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-21"", ""headline"": ""Gilead to discontinue Phase 3 ENHANCE study of magrolimab plus azacitidine"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-22"", ""headline"": ""Gilead Sciences : Statement on New York Times' Story on TDF and TAF Development for HIV"", ""summary"": ""Foster City, Calif., July 22, 2023 -Gilead Sciences provided the following statement pre-publication to the reporters for the New York Times in response to their questions before their...""}, {""date"": ""2023-07-23"", ""headline"": ""New Biktarvy\u00ae Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic"", ""summary"": ""\u2013 Biktarvy Evaluated in a Diverse Range of People With HIV, Including Pregnant Women and Pediatric Populations \u2013\n\n\n\u2013 96-Week Data from ALLIANCE Trial Show Durability of Biktarvy in Adults With...""}, {""date"": ""2023-07-23"", ""headline"": ""Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities"", ""summary"": ""FOSTER CITY, Calif., July 23, 2023--Gilead Sciences Inc. (Nasdaq: GILD) today announced its largest commitment to health equity for Australian and Canadian Indigenous communities. The initiative will support programs addressing societal barriers to care that persistently contribute to the transmission of HIV and viral hepatitis within Indigenous communities.""}, {""date"": ""2023-07-23"", ""headline"": ""Governor DeSantis Says He Would Sue the Drug Company Gilead for Trying to Save Lives"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
28,2023-07-23,79.13687133789062,2023-07-30,75.42733001708984,-0.04687500602547401,D5,"[{""date"": ""2023-07-23"", ""headline"": ""Gilead Sciences Inc. stock falls Monday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-23"", ""headline"": ""Eaton Vance Worldwide Health Sciences Fund Buys Vertex Pharmaceuticals, Exits Dechra Pharmaceuticals"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-23"", ""headline"": ""New Biktarvy\u00ae Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic"", ""summary"": ""FOSTER CITY, Calif., July 24, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from multiple studies reinforcing Biktarvy\u00ae (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) as a treatment option for a broad range of people with HIV. The latest findings include key insights into the treatment of virologically suppressed pregnant women and children two years of age or older (weighing at least 14 kg to less than 25 kg) and positive Week 96 data""}, {""date"": ""2023-07-23"", ""headline"": ""Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities"", ""summary"": ""FOSTER CITY, Calif., July 23, 2023--Gilead Sciences Inc. (Nasdaq: GILD) today announced its largest commitment to health equity for Australian and Canadian Indigenous communities. The initiative will support programs addressing societal barriers to care that persistently contribute to the transmission of HIV and viral hepatitis within Indigenous communities.""}, {""date"": ""2023-07-23"", ""headline"": ""Governor DeSantis Says He Would Sue the Drug Company Gilead for Trying to Save Lives"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-24"", ""headline"": ""Gilead Sciences Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-24"", ""headline"": ""Gilead says twice-yearly lenacapavir has \""sustained impact\"" on HIV"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-24"", ""headline"": ""GLOBAL BRIEFING: Beijing pledges support for faltering economy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-24"", ""headline"": ""Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV"", ""summary"": ""FOSTER CITY, Calif., July 24, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today presented new data reinforcing the efficacy, safety, and tolerability profile of lenacapavir, including patient-reported outcomes (PRO) from the Phase 2/3 CAPELLA trial. These latest findings underscore the role of lenacapavir, the first long-acting injectable HIV treatment medication administered twice-yearly, as a person-centric therapy option and its transformative potential impact on the future of coordinated HIV""}, {""date"": ""2023-07-24"", ""headline"": ""Gilead stops trial of cancer drug that was central to $4.9 billion deal"", ""summary"": ""A Gilead Sciences Inc. drug targeting a protein \u2014 usurped by cancers to send a \""don't eat me signal\"" to the immune system \u2014 failed a late-stage clinical trial three years after the company made it the center of a $4.9 billion acquisition.  Foster City-based Gilead (NASDAQ: GILD) said it recommended stopping the late-stage study of the drug magrolimab, which headlined the company's April 2020 acquisition of Forty Seven Inc., in higher-risk myelodysplastic syndromes.  Studies of the drug are continuing in two ongoing trials in solid tumors and two pivotal studies in acute myeloid leukemia.""}, {""date"": ""2023-07-24"", ""headline"": ""S&P 500 Gains and Losses Today: Oil Industry Stocks Surge as Oil Prices Rise"", ""summary"": ""U.S. equities gained after better-than-expected second quarter earnings reports, with the S&P 500 rising 0.4% on Monday, July 24, 2023.""}, {""date"": ""2023-07-24"", ""headline"": ""Piper Sandler Maintains Gilead Sciences (GILD) Overweight Recommendation"", ""summary"": """"}, {""date"": ""2023-07-24"", ""headline"": ""Cantor Fitzgerald Reiterates Gilead Sciences (GILD) Neutral Recommendation"", ""summary"": """"}, {""date"": ""2023-07-24"", ""headline"": ""Barclays Maintains Gilead Sciences (GILD) Equal-Weight Recommendation"", ""summary"": """"}, {""date"": ""2023-07-24"", ""headline"": ""Gilead Sciences, Inc. Presents New Data Reinforcing the Efficacy, Safety, and Tolerability Profile of Lenacapavir from the Phase 2/3 Capella Trial"", ""summary"": ""Gilead Sciences, Inc. presented new data reinforcing the efficacy, safety, and tolerability profile of lenacapavir, including patient-reported outcomes  from the Phase 2/3 CAPELLA trial. These latest...""}, {""date"": ""2023-07-24"", ""headline"": ""Gilead (GILD) Ends Myelodysplastic Syndromes Study on Magrolimab"", ""summary"": ""Gilead Sciences, Inc. (GILD) discontinues phase III ENHANCE study, evaluating the potential of magrolimab as a treatment for higher-risk myelodysplastic syndromes, due to futility based on a planned analysis.""}, {""date"": ""2023-07-24"", ""headline"": ""Stocks making the biggest moves midday: AMC Entertainment, Mattel, Chevron, Spotify and more"", ""summary"": ""These are the stocks posting the largest moves in midday trading. ""}, {""date"": ""2023-07-24"", ""headline"": ""Cognizant and Gilead Extend Partnership with Five-Year Service Agreement Estimated at $800 Million"", ""summary"": ""Cognizant (NASDAQ: CTSH) today announced an expansion of its relationship with Gilead Sciences (NASDAQ: GILD). Gilead is a leading biopharmaceutical company advancing innovative medicines to prevent and treat life-threatening diseases. Under the agreement, Cognizant will manage Gilead's global IT infrastructure, platforms, applications and advanced analytics, and lead initiatives designed to accelerate its digital transformation. The agreement includes renewal and expansion of Cognizant services""}, {""date"": ""2023-07-24"", ""headline"": ""Cognizant agrees USD800 million IT infrastructure deal with Gilead"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-24"", ""headline"": ""Gilead to Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS"", ""summary"": ""FOSTER CITY - Gilead Sciences, Inc.  today announced that the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes  has been discontinued due to futility based on a planned analysis.\nThe...""}, {""date"": ""2023-07-24"", ""headline"": ""Gilead Sciences, Inc. - New Biktarvy Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic"", ""summary"": ""FOSTER CITY - Gilead Sciences, Inc.  today announced results from multiple studies reinforcing Biktarvy  as a treatment option for a broad range of people with HIV.\nThe latest findings include key...""}, {""date"": ""2023-07-24"", ""headline"": ""Cognizant and Gilead sign a $800M agreement, expands partnership"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-24"", ""headline"": ""Cognizant, Gilead Extend Service Agreement Worth $800 Million"", ""summary"": ""By Ben Glickman \n\n\n   Cognizant Technology Solutions said Monday it would continue to manage Gilead Sciences' global information technology infrastructure for five years in a deal worth up to $800...""}, {""date"": ""2023-07-24"", ""headline"": ""Cognizant, Gilead Extend Service Agreement Worth $800M"", ""summary"": ""By Ben Glickman Cognizant Technology Solutions said Monday it would continue to manage Gilead Sciences' global information technology infrastructure for five...""}, {""date"": ""2023-07-24"", ""headline"": ""Analysts Are Bullish on Top Healthcare Stocks: Gilead Sciences (GILD), Becton Dickinson (BDX)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-24"", ""headline"": ""Gilead price target lowered to $100 from $105 at Piper Sandler"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-24"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Exelixis (EXEL) and Becton Dickinson (BDX)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-24"", ""headline"": ""Bank of America, Bank of New York Mellon And 2 Other Stocks Insiders Are Selling"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-24"", ""headline"": ""Expert Ratings for Gilead Sciences"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-24"", ""headline"": ""Cognizant expands relatonship with Gilead"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-24"", ""headline"": ""Gilead presents new data on lenacapavir"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-24"", ""headline"": ""Gilead price target lowered to $80 from $81 at Barclays"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-24"", ""headline"": ""Bank of America Securities Reaffirms Their Hold Rating on Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-24"", ""headline"": ""Gilead profited by delaying new version of a drug, NY Times reports"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-24"", ""headline"": ""AMC shares surge after judge rejects APE conversion plan, Tesla stock slips on downgrade and other stocks on the move"", ""summary"": ""Here are some of the biggest movers of the day: AMC Entertainment, Tesla and Gilead Sciences.""}, {""date"": ""2023-07-24"", ""headline"": ""Gilead announces results from multiple Biktarvy studies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-24"", ""headline"": ""Gilead lambasts patent lawsuit coverage in mixed week for drug trials"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-25"", ""headline"": ""Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-25"", ""headline"": ""Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know"", ""summary"": ""In the latest trading session, Gilead Sciences (GILD) closed at $77.23, marking a -0.55% move from the previous day.""}, {""date"": ""2023-07-25"", ""headline"": ""GSK, J&J tout Cabenuva preference over Gilead's Biktarvy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-25"", ""headline"": ""Gilead Sciences, Inc. - Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People with HIV"", ""summary"": ""FOSTER CITY - Gilead Sciences, Inc.  today presented new data reinforcing the efficacy, safety, and tolerability profile of lenacapavir, including patient-reported outcomes  from the Phase 2/3...""}, {""date"": ""2023-07-25"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Tonix Pharma (TNXP) and Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-26"", ""headline"": ""Gilead Sciences Inc. stock falls Thursday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-26"", ""headline"": ""Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know"", ""summary"": ""In the latest trading session, Gilead Sciences (GILD) closed at $77.19, marking a -0.05% move from the previous day.""}, {""date"": ""2023-07-26"", ""headline"": ""Truist Financial Reaffirms Their Buy Rating on Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-27"", ""headline"": ""Gilead Sciences Inc. stock rises Friday, still underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-27"", ""headline"": ""Earnings week ahead: Amazon, Apple, Pfizer, Starbucks, Uber and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-27"", ""headline"": ""European Commission Approves Gilead\u2019s Trodelvy\u00ae For Pre-Treated HR+/HER2- Metastatic Breast Cancer"", ""summary"": ""FOSTER CITY, Calif., July 27, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) approved Trodelvy\u00ae (sacituzumab govitecan) as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting.""}, {""date"": ""2023-07-27"", ""headline"": ""European Commission Approves Gilead's Trodelvy\u00ae For Pre-Treated HR+/HER2- Metastatic Breast Cancer"", ""summary"": ""-- Approval Based on Clinically Meaningful Overall Survival Benefit Demonstrated in the TROPiCS-02 Study in Pre-Treated HR+/HER2-  Metastatic Breast Cancer vs. Physician\u2019s Choice of Chemotherapy...""}, {""date"": ""2023-07-27"", ""headline"": ""EC approves Gilead's Trodelvy for pre-treated HR+/HER2- metastatic breast cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-27"", ""headline"": ""20 Countries With Highest Rates Of AIDS"", ""summary"": ""In this article, we will be taking a look at the 20 countries with the highest rate of AIDS. If you are not interested in reading the details, head straight to the 5 Countries With Highest Rates of AIDS. AIDS, or Acquired Immunodeficiency Syndrome, remains a pressing global health concern, and its impact varies significantly [\u2026]""}, {""date"": ""2023-07-28"", ""headline"": ""Gilead (GILD) Gears Up to Report Q2 Earnings: What's in Store?"", ""summary"": ""Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its second-quarter 2023 results.""}, {""date"": ""2023-07-28"", ""headline"": ""Unveiling AbbVie's Hidden Risks: Cautionary Notes For Investors"", ""summary"": ""AbbVie's Q2 2023 financial results exceeded expectations, driven by strong sales of innovative drugs Skyrizi and Rinvoq. Click here to read more.""}, {""date"": ""2023-07-28"", ""headline"": ""Here's Why We Think Gilead Sciences (NASDAQ:GILD) Might Deserve Your Attention Today"", ""summary"": ""It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...""}, {""date"": ""2023-07-28"", ""headline"": ""GILEAD LAUNCHES GLOBAL ALL4LIVER GRANT PROGRAM TO HELP ACHIEVE THE WORLD HEALTH ORGANIZATION'S GOAL OF VIRAL HEPATITIS ELIMINATION BY 2030"", ""summary"": ""Gilead Sciences, Inc. (Nasdaq: GILD) today announced the launch of the 2023 Gilead ALL4LIVER Grant, a grant program with the theme of 'Test. Link. Prioritize', designed to support innovative projects that drive testing, improve linkage to care and/or elevate viral hepatitis on the public health agenda. The ALL4LIVER Grant will support initiatives around the world (excluding the United States) across hepatitis C, hepatitis B or hepatitis D. Eligible organizations can submit funding applications o""}, {""date"": ""2023-07-29"", ""headline"": ""3 Stocks Retirees Should Absolutely Love"", ""summary"": ""Dividend stocks can practically be a retiree's best friend.  Three Motley Fool contributors were asked to identify healthcare dividend stocks they think retirees should absolutely love now.  Here's why they picked AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE).""}]",{}
29,2023-07-30,75.42733001708984,2023-08-06,77.21340942382812,0.023679472763169507,U3,"[{""date"": ""2023-07-30"", ""headline"": ""Gilead Sciences Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-31"", ""headline"": ""Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-31"", ""headline"": ""See Which Of The Latest 13F Filers Holds Gilead Sciences"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-31"", ""headline"": ""Robert W. Baird Remains a Hold on Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-01"", ""headline"": ""Gilead Sciences Inc. stock remains steady Wednesday, still outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-01"", ""headline"": ""Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points"", ""summary"": ""The biotechnology sector is huge and growing. Grand View Research forecasts that the industry will reach $3.88 trillion by 2030, growing at a compound annual growth rate of 14%. Despite the massive amount of revenue being generated, most biotech companies remain small and medium-sized enterprises. Many of the companies operating in the space are start-ups. Yet they are performing cutting-edge research and developing life-saving innovations that are in high demand. This presents an opportunity fo""}, {""date"": ""2023-08-01"", ""headline"": ""With 85% ownership, Gilead Sciences, Inc. (NASDAQ:GILD) boasts of strong institutional backing"", ""summary"": ""Key Insights Given the large stake in the stock by institutions, Gilead Sciences' stock price might be vulnerable to...""}, {""date"": ""2023-08-02"", ""headline"": ""Gilead Sciences Inc. stock outperforms market despite losses on the day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""Gilead\u2019s stock slides 2% after Q2 profit lags consensus and as company lowers guidance"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""Gilead Sciences declares $0.75 dividend"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""Gilead Sciences Non-GAAP EPS of $1.34 misses by $0.30, revenue of $6.59B beats by $140M"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""Gilead cuts FY23 EPS view to $6.45-$6.80 from $6.60-$7.00, consensus $6.73"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""Gilead reports Q2 adjusted EPS $1.34, consensus $1.64"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""Notable companies reporting after market close"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""Stocks Mitigate Losses Ahead Of Apple, Amazon Earnings; Treasury Yields Rocket On Debt Frenzy: Thursday's Market Drivers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""GLOBAL BRIEFING: China's services see strong growth in July"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""Unusually active option classes on open August 2nd"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""Gilead seen reporting higher Q2 earnings, despite drop in COVID-19 drug sales"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""Mizuho Securities Sticks to Their Buy Rating for Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-03"", ""headline"": ""Gilead Sciences Inc. stock rises Friday, outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-03"", ""headline"": ""Barclays Remains a Hold on Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-03"", ""headline"": ""Amazon shares rally 10%, but Apple\u2019s dip, and other stocks on the move"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-03"", ""headline"": ""Gilead (GILD) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates"", ""summary"": ""The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.""}, {""date"": ""2023-08-03"", ""headline"": ""Gilead Sciences (GILD) Q2 Earnings Lag Estimates"", ""summary"": ""Gilead (GILD) delivered earnings and revenue surprises of -16.25% and 2.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?""}, {""date"": ""2023-08-03"", ""headline"": ""Will An Earnings Miss Cloud Gilead's Massive Cancer Treatment Growth?"", ""summary"": ""Two of Gilead's cancer drugs topped second-quarter sales expectations Thursday. GILD stock rose slightly in late action.""}, {""date"": ""2023-08-03"", ""headline"": ""Gilead Sciences, Inc. (GILD) Q2 2023 Earnings Call Transcript"", ""summary"": ""Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ETCompany ParticipantsJacquie Ross - Vice President, Investor RelationsDaniel O'Day -...""}, {""date"": ""2023-08-03"", ""headline"": ""UPDATE 1-Gilead quarterly profit falls on COVID sales drop, legal settlement charge"", ""summary"": ""Gilead Sciences on Thursday reported lower second-quarter profit as costs from a legal settlement and sharply lower sales of its COVID-19 treatment offset another strong performance by HIV drugs.  The drugmaker raised its full-year revenue forecast, even as it trimmed its estimate for COVID antiviral Veklury due to lower pandemic-related hospitalizations.  Gilead reported second-quarter earnings of $1.34 per share excluding items, on total revenue of $6.6 billion, down from $1.58 a share and revenue of $6.26 billion in the year-ago quarter.""}, {""date"": ""2023-08-03"", ""headline"": ""Gilead Sciences Cuts Profit Forecast on Legal Settlement"", ""summary"": ""CEO Daniel O'Day said the biopharma company is \""overperforming significantly, excluding one-time items.\""""}, {""date"": ""2023-08-03"", ""headline"": ""Gilead quarterly profit falls on COVID sales drop, legal settlement charge"", ""summary"": ""(Reuters) -Gilead Sciences on Thursday reported lower second-quarter profit as costs from a legal settlement and sharply lower sales of its COVID-19 treatment offset another strong performance by HIV drugs.  The drugmaker raised its full-year revenue forecast, even as it trimmed its estimate for COVID antiviral Veklury due to lower pandemic-related hospitalizations.  Gilead reported second-quarter earnings of $1.34 per share excluding items, on total revenue of $6.6 billion, down from $1.58 a share and revenue of $6.26 billion in the year-ago quarter.""}, {""date"": ""2023-08-03"", ""headline"": ""Gilead Sciences Announces Second Quarter 2023 Financial Results"", ""summary"": ""FOSTER CITY, Calif., August 03, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter of 2023.""}, {""date"": ""2023-08-03"", ""headline"": ""Gilead Upgrades Product Sales Outlook, Cuts EPS View"", ""summary"": ""By Paul Ziobro \n\n  Gilead Sciences raised the midpoint of its full-year guidance for product sales while reducing the range for its earnings outlook after posting mixed second-quarter results. \n\n ...""}, {""date"": ""2023-08-03"", ""headline"": ""Gilead Sciences 2Q Profit Down On HIV Litigation, Higher Costs"", ""summary"": ""Gilead Sciences 2Q Profit Down On HIV Litigation, Higher Costs \n\n  By Paul Ziobro \n\n  Gilead Sciences posted a drop in second-quarter profit, which was hit by a settlement in HIV antitrust...""}, {""date"": ""2023-08-03"", ""headline"": ""Gilead's profit lags consensus but sales beat, sending stock up after hours"", ""summary"": ""Gilead's quarterly revenue topped estimates and it tweaked guidance.""}, {""date"": ""2023-08-03"", ""headline"": ""Gilead Ups Product Sales Outlook, Cuts EPS View"", ""summary"": ""By Paul Ziobro Gilead Sciences raised the midpoint of its full-year guidance for product sales while reducing the range for its earnings outlook after...""}, {""date"": ""2023-08-03"", ""headline"": ""US Stock Futures Dip As Apple, Amazon Earnings Loom: Analyst Warns Of 'Perfectly Normal' 5% Pullback This Month"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-03"", ""headline"": ""Analysts Are Neutral on Top Healthcare Stocks: Definitive Healthcare Corp (DH), DENTSPLY SIRONA (XRAY)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-03"", ""headline"": ""Gilead boosts 2023 sales projection but cuts EPS outlook"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-03"", ""headline"": ""Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities"", ""summary"": ""- $6 Million USD in Funding Will Help Address Health Disparities Among Indigenous Communities with a Focus on HIV and Viral Hepatitis - Type of Content Press Release Layout Standard Format...""}, {""date"": ""2023-08-03"", ""headline"": ""Gilead\u2019s profit lags consensus but sales beat, sending stock up after hours"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-03"", ""headline"": ""Apple among BofA picks for options opportunity on earnings surprise"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-04"", ""headline"": ""Gilead Plots A Massive Move Into Oncology: A Third Of Sales By 2030"", ""summary"": ""Gilead expects a third of sales to come from its cancer treatments by 2030, and GILD stock jumped Friday despite a mixed earnings report.""}, {""date"": ""2023-08-04"", ""headline"": ""Gilead's (GILD) Q2 Earnings Miss, Revenues Beat on Oncology"", ""summary"": ""Gilead's (GILD) Q2 earnings miss on litigation charges while revenues beat on strong oncology and HIV franchise.""}, {""date"": ""2023-08-04"", ""headline"": ""Is Gilead Sciences (GILD) Fairly Valued? An In-Depth Analysis"", ""summary"": ""With a daily gain of 4.63% and an Earnings Per Share (EPS) of 4.43, Gilead Sciences Inc (NASDAQ:GILD) has been attracting attention in the investment community.  This article aims to answer the pressing question: is Gilead Sciences (NASDAQ:GILD) fairly valued?  Gilead Sciences, a company with a rich portfolio of therapies for life-threatening infectious diseases, has a history of acquisitions that have expanded its focus to pulmonary and cardiovascular diseases and cancer.""}, {""date"": ""2023-08-04"", ""headline"": ""Gilead's Plots A Massive Move Into Oncology: A Third Of Sales By 2030"", ""summary"": ""Gilead expects a third of sales to come from its cancer treatments by 2030, and GILD stock jumped Friday despite a mixed earnings report.""}, {""date"": ""2023-08-04"", ""headline"": ""Amgen Inc: A Strong Contender in the Drug Manufacturers Industry with a GF Score of 85"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-04"", ""headline"": ""Gilead Sciences Q2 Earnings: 'Transitional' Quarter Delivers Mixed Results"", ""summary"": ""Gilead's HIV division contributed $4.6 billion and its oncology division generated $728 million in revenues. Read how one-off costs hit profitability in Gilead's latest earnings.""}, {""date"": ""2023-08-04"", ""headline"": ""Piper Sandler Sticks to Their Buy Rating for Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-04"", ""headline"": ""Gilead Sciences second quarter net profit falls; lowers profit outlook"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-04"", ""headline"": ""BMO Capital Releases a Buy Rating on Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-04"", ""headline"": ""Gilead files for mixed shelf offering"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-04"", ""headline"": ""Gilead files automatic mixed securities shelf"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-04"", ""headline"": ""Gilead Sciences (GILD) Q2 2023 Earnings Call Transcript"", ""summary"": ""Thank you for attending Gilead Sciences second quarter 2023 earnings conference call.  The press release, slides and supplementary data are available on the Investors section of our website at gilead.com.  The speakers on today's call will be our chairman and chief executive officer, Daniel O'Day, our chief commercial officer, Johanna Mercier; our chief medical officer, Merdad Parsey, and our chief financial officer, Andrew Dickinson.""}, {""date"": ""2023-08-05"", ""headline"": ""RBC Capital Maintains Gilead Sciences (GILD) Sector Perform Recommendation"", ""summary"": """"}, {""date"": ""2023-08-05"", ""headline"": ""Morgan Stanley Maintains Gilead Sciences (GILD) Equal-Weight Recommendation"", ""summary"": """"}, {""date"": ""2023-08-05"", ""headline"": ""Is Gilead Sciences (GILD) Stock Fairly Valued? A Comprehensive Analysis"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-06"", ""headline"": ""Gilead Sciences, Inc.'s (NASDAQ:GILD) Intrinsic Value Is Potentially 68% Above Its Share Price"", ""summary"": ""Key Insights Gilead Sciences' estimated fair value is US$132 based on 2 Stage Free Cash Flow to Equity Gilead Sciences...""}, {""date"": ""2023-08-06"", ""headline"": ""Is Gilead Sciences (GILD) Stock Worth Your Investment? A Comprehensive Valuation Analysis"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
30,2023-08-06,77.21340942382812,2023-08-13,78.50880432128906,0.016776812565683308,U2,"[{""date"": ""2023-08-06"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: CVS Health (CVS) and Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-06"", ""headline"": ""Ikena falls on acquisition of Pionyr in all-stock deal"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-06"", ""headline"": ""Gilead Sciences, Inc.'s (NASDAQ:GILD) Intrinsic Value Is Potentially 68% Above Its Share Price"", ""summary"": ""Key Insights Gilead Sciences' estimated fair value is US$132 based on 2 Stage Free Cash Flow to Equity Gilead Sciences...""}, {""date"": ""2023-08-06"", ""headline"": ""Is Gilead Sciences (GILD) Stock Worth Your Investment? A Comprehensive Valuation Analysis"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-07"", ""headline"": ""Gilead Sciences Inc. stock rises Monday, outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. rose 2.53% to $80.67 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...""}, {""date"": ""2023-08-07"", ""headline"": ""Amgen Inc: A Strong Contender in the Drug Manufacturers Industry with a High GF Score"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-07"", ""headline"": ""Monday\u2019s Top Wall Street Analyst Upgrades and Downgrades: Amazon, Apple, Block, Coinbase, Datadog, Fortinet, Gilead Sciences, Moderna, Nvidia, PayPal, Petrobras and More"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-07"", ""headline"": ""Gilead Sciences: Mixed Signals, Again"", ""summary"": ""Gilead Sciences seeks future growth through diversification and pipeline conversion. Click here to see why GILD stock is a Buy.""}, {""date"": ""2023-08-08"", ""headline"": ""Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. slid 0.73% to $80.08 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-08-08"", ""headline"": ""Ligand Reports Second Quarter 2023 Financial Results"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-08"", ""headline"": ""Amgen Inc: A Strong Contender in the Drug Manufacturers Industry with a GF Score of 85"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-08"", ""headline"": ""Wall Street Analysts Are Bullish on Top Healthcare Picks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-08"", ""headline"": ""Gilead Sciences (GILD) Receives a Buy from Truist Financial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-08"", ""headline"": ""2 High-Yield Dividend Stocks to Buy on the Dip"", ""summary"": ""Income-seeking investors tend to be drawn to high dividend yields.  A high yield from the dividend of a great company is highly sought after.  There are plenty of stocks with competitive dividend yields worth serious consideration for investors.""}, {""date"": ""2023-08-08"", ""headline"": ""My Dividend Stock Portfolio: New July Dividend Record - 99 Holdings With 26 Buys"", ""summary"": ""Investment activity remained robust, and dividend income hit a record high. Additionally, passive income equivalent to almost 5 weeks of work was earned in 2023.""}, {""date"": ""2023-08-08"", ""headline"": ""GLOBAL BROKER RATINGS: Deutsche Bank cuts WPP; UBS ups Smith & Nephew"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-08"", ""headline"": ""Robert W. Baird Keeps Their Hold Rating on Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-09"", ""headline"": ""The 3 Best Biotech Stocks to Buy in August"", ""summary"": ""Many healthcare stocks suffer from COVID fatigue as profits fall amid a global decline in the virus\u2019 spread. But medical innovations and technological breakthroughs are rapidly transforming the healthcare landscape, and biotech stocks are garnering unprecedented attention in the investment community. These companies, operating at the intersection of biology and technology, promise groundbreaking treatments, therapies and solutions to some of the world\u2019s most persistent medical challenges. As the""}, {""date"": ""2023-08-09"", ""headline"": ""U.S. Wide-Moat Stocks On Sale - The August 2023 Heat Map"", ""summary"": ""Discover our 3-step process for identifying undervalued wide-moat stocks, including a heat map of top investable candidates. Click here to read our picks.""}, {""date"": ""2023-08-09"", ""headline"": ""Gilead Sciences Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.11% higher to $80.17 Wednesday, on what proved to be an all-around poor trading session for the stock market, with...""}, {""date"": ""2023-08-09"", ""headline"": ""Gilead Sciences: A Cut Above the Rest: Innovative Barbershop Program Educates Indigenous Men About HIV"", ""summary"": ""NORTHAMPTON, MA / ACCESSWIRE / August 9, 2023 / Gilead Sciences: How do you educate people about difficult-to-talk-about, yet incredibly important, health topics? And which settings are ideal for such conversations? Those were the questions plaguing ...""}, {""date"": ""2023-08-09"", ""headline"": ""Gilead Sciences a Top 25 Dividend Giant With 3.75% Yield (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-10"", ""headline"": ""Gilead Sciences Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Gilead Sciences Inc. slid 0.21% to $80.00 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...""}, {""date"": ""2023-08-10"", ""headline"": ""How Is The Market Feeling About Gilead Sciences?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-11"", ""headline"": ""Gilead Sciences Inc. stock remains steady Friday, still outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. were unchanged Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""2023-08-11"", ""headline"": ""$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-11"", ""headline"": ""Gilead Sciences (NASDAQ:GILD) stock performs better than its underlying earnings growth over last year"", ""summary"": ""These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But investors can...""}, {""date"": ""2023-08-11"", ""headline"": ""Gilead call volume above normal and directionally bullish"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-13"", ""headline"": ""13 Best Wide Moat Stocks To Buy According To Hedge Funds"", ""summary"": ""In this piece, we will take a look at the 13 best wide moat stocks to buy according to hedge funds. If you want to skip our primer on wide moat investing, then head on over to 5 Best Wide Moat Stocks To Buy According To Hedge Funds. Among the countless ways in which companies [\u2026]""}]",{}
31,2023-08-13,78.50880432128906,2023-08-20,74.46559143066406,-0.05150012059894038,D5+,"[{""date"": ""2023-08-13"", ""headline"": ""13 Best Wide Moat Stocks To Buy According To Hedge Funds"", ""summary"": ""In this piece, we will take a look at the 13 best wide moat stocks to buy according to hedge funds. If you want to skip our primer on wide moat investing, then head on over to 5 Best Wide Moat Stocks To Buy According To Hedge Funds. Among the countless ways in which companies [\u2026]""}, {""date"": ""2023-08-14"", ""headline"": ""Gilead Sciences Inc. stock falls Tuesday, still outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-14"", ""headline"": ""Piper Sandler Remains a Buy on Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-14"", ""headline"": ""Arcellx up 10% as FDA lifts clinical hold"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-15"", ""headline"": ""Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-15"", ""headline"": ""Mizuho Securities Remains a Buy on Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-15"", ""headline"": ""UPDATE 1-Gilead ties up with Tentarix for cancer, inflammatory disease therapies"", ""summary"": ""Gilead Sciences said on Tuesday it had entered into an agreement with privately held Tentarix Biotherapeutics to develop therapies for cancer and inflammatory diseases.  Tentarix will receive upfront payments and an equity investment totaling $66 million from Gilead, which has the option to buy up to three of the drug developer's units for $80 million each, the companies said.  The deal gives Gilead access to Tentarix's proprietary drug development platform for antibody-based therapies that specifically target immune cells related to the disease without activating other immune cells that may lead to adverse events.""}, {""date"": ""2023-08-15"", ""headline"": ""Gilead and Tentarix to Discover and Develop Novel Therapies to Address Unmet Medical Needs Across Cancer and Inflammation"", ""summary"": ""FOSTER CITY, Calif. & SAN DIEGO, August 15, 2023--Gilead Sciences, Inc. (Nasdaq:GILD) and Tentarix Biotherapeutics today announced that the companies established three multi-year collaborations leveraging Tentarix\u2019s proprietary Tentacles\u2122 platform to discover and develop multi-functional, conditional protein therapeutics for oncology and inflammatory diseases. Designed to enhance both therapeutic benefit and safety, these molecules have the potential to conditionally target immune cells related""}, {""date"": ""2023-08-15"", ""headline"": ""We Think Gilead Sciences (NASDAQ:GILD) Can Stay On Top Of Its Debt"", ""summary"": ""The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...""}, {""date"": ""2023-08-15"", ""headline"": ""Gilead and Tentarix partner to develop protein therapeutics"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-15"", ""headline"": ""Gilead sees transaction with Tentarix to reduce EPS by 3c-4c"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-15"", ""headline"": ""Gilead has option to acquire up to three Tentarix subs for $80M per subsidiary"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-15"", ""headline"": ""Gilead and Tentarix in pact to find therapies for cancer, inflamation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-16"", ""headline"": ""Gilead Sciences Inc. stock falls Thursday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-16"", ""headline"": ""Gilead (GILD), Tentarix To Develop Cancer, Inflammation Therapies"", ""summary"": ""Gilead (GILD) enters into a deal with Tentarix Biotherapeutics to discover and develop novel therapies for cancer and inflammation.""}, {""date"": ""2023-08-16"", ""headline"": ""Gilead\u2019s Focus on Ending the HIV Epidemic for Children Everywhere"", ""summary"": ""NORTHAMPTON, MA / ACCESSWIRE / August 16, 2023 / Gilead Sciences \""I am tired, so tired. When will this end?\"" That's the refrain that Dr. Eva Natukunda, a pediatric HIV specialist at the Joint Clinical Research Center in Kampala, Uganda says she ...""}, {""date"": ""2023-08-17"", ""headline"": ""Gilead Sciences Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-17"", ""headline"": ""Biotech Stock Roundup: GLTO Plunges on Setback, BLUE Offers Updates & More"", ""summary"": ""Regulatory updates from Galecto (GLTO) and Sonnet BioTherapeutics Holdings (SONN) are in focus in the biotech sector.""}, {""date"": ""2023-08-17"", ""headline"": ""10 Health Care Stocks With Whale Alerts In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-17"", ""headline"": ""Autolus Therapeutics' Obe-Cel's Shows Compelling Safety Over Gilead's Drug For Acute Lymphoblastic Leukemia"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-17"", ""headline"": ""Undervalued Biotech Gems: 2 Stocks Combining Dividends With Healthy Returns"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-17"", ""headline"": ""Undervalued Biotech Gems: 2Stocks Combining Dividends With Healthy Returns"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-17"", ""headline"": ""Undervalued Biotech Gems: Two Stocks Combining Dividends with Healthy Returns"", ""summary"": ""Distinguishing genuine value from market noise is essential for successful investments""}, {""date"": ""2023-08-17"", ""headline"": ""Gilead Sciences (GILD) Gets a Buy from Jefferies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-17"", ""headline"": ""Analysts Have Conflicting Sentiments on These Healthcare Companies: Paycor HCM (PYCR), Legend Biotech (LEGN) and Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-17"", ""headline"": ""Morgan Dempsey Capital Management LLC Reduces Stake in Polished.com Inc"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-17"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and CVS Health (CVS)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-18"", ""headline"": ""Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative\u00ae on HIV in the Southern United States"", ""summary"": ""FOSTER CITY, Calif. & NASHVILLE, Tenn., August 18, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and Meharry Medical College, one of the nation\u2019s oldest and largest historically Black academic health science centers, today announced the publication of a new supplemental issue of Meharry Medical College\u2019s Journal of Health Care for the Poor and Underserved. It details the impact of the Gilead COMPASS Initiative\u00ae \u2013 the company\u2019s 10-year, more than $100 million collaborative initiative that seeks to e""}, {""date"": ""2023-08-20"", ""headline"": ""A Closer Look At Gilead Sciences, Inc.'s (NASDAQ:GILD) Impressive ROE"", ""summary"": ""While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...""}]",{}
32,2023-08-20,74.46559143066406,2023-08-27,75.42733001708984,0.012915207788569916,U2,"[{""date"": ""2023-08-20"", ""headline"": ""A Closer Look At Gilead Sciences, Inc.'s (NASDAQ:GILD) Impressive ROE"", ""summary"": ""While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...""}, {""date"": ""2023-08-21"", ""headline"": ""Legend Biotech: Working On Supply Issues"", ""summary"": ""Carvykti's successful manufacturing ramp-up and clinical de-risking in earlier lines of multiple myeloma put Legend Biotech in a strong position. Learn more on LEGN stock here.""}, {""date"": ""2023-08-21"", ""headline"": ""Gilead Sciences Inc. stock rises Monday, still underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.08% higher to $75.94 Monday, on what proved to be an all-around mixed trading session for the stock market, with the...""}, {""date"": ""2023-08-21"", ""headline"": ""Vaccine makers light up as COVID hospitalizations rise"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-21"", ""headline"": ""UPDATE 1-US FDA puts Gilead Sciences blood cancer drug studies on hold"", ""summary"": ""Gilead Sciences said on Monday the U.S. health regulator placed a clinical hold on studies of its blood cancer drug, just a month after the company scrapped a late-stage trial due to efficacy concerns.  The company gained access to the drug, magrolimab, with its $4.9 billion buyout of Forty Seven Inc in March 2020.  The company said the U.S. Food and Drug Administration (FDA) had paused screening and enrollment of new study participants, while the patients already under the studies may continue to receive treatment.""}, {""date"": ""2023-08-21"", ""headline"": ""Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML"", ""summary"": ""FOSTER CITY, Calif., August 21, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the initiation of new patients in U.S. studies evaluating magrolimab to treat acute myeloid leukemia (AML).""}, {""date"": ""2023-08-21"", ""headline"": ""Large Cap Biopharmaceuticals Performance 2023 YTD: Mixed Results But Lilly Is A Big Winner"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-21"", ""headline"": ""5 Safe Stocks Under $40 to Buy Immediately"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-21"", ""headline"": ""Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative on HIV in the Southern United States"", ""summary"": ""FOSTER CITY - Gilead Sciences, Inc. and Meharry Medical College, one of the nation's oldest and largest historically Black academic health science centers, today announced the publication of a new...""}, {""date"": ""2023-08-21"", ""headline"": ""Gilead Sciences announces another magrolimab setback via US FDA action"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-21"", ""headline"": ""Gilead Sciences Magrolimab Studies Enrollment Paused by FDA Request"", ""summary"": ""By Adriano Marchese Gilead Sciences will pause the enrollment of new participants for its investigational drug study in treating acute myeloid leukemia. The pharmaceutical company said...""}, {""date"": ""2023-08-21"", ""headline"": ""Gilead says FDA hits pause on study of leukemia treatment"", ""summary"": ""Gilead Sciences Inc. said Monday that the U.S. Food and Drug Administration has put a partial clinical hold on U.S. studies evaluating a treatment for acute...""}, {""date"": ""2023-08-21"", ""headline"": ""US FDA puts Gilead Sciences blood cancer drug studies on hold"", ""summary"": ""Gilead Sciences said onMonday the U.S. Food and Drug Administration had placed apartial clinical hold on initiating new patients in the U.S.studies for drug to treat a type of blood...""}, {""date"": ""2023-08-21"", ""headline"": ""Gilead announces FDA partial hold on leukemia trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-21"", ""headline"": ""Gilead announces partial clinical hold on magrolimab studies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-21"", ""headline"": ""IN BRIEF: Guild Esports to launch Counter-Strike men's team"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-22"", ""headline"": ""Gilead Sciences Inc. stock rises Tuesday, outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.54% higher to $76.35 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the...""}, {""date"": ""2023-08-22"", ""headline"": ""Gilead's (GILD) Leukemia Study Progress Put on Clinical Hold"", ""summary"": ""Gilead (GILD) faces a setback as the FDA puts a partial clinical hold on enrolling new patients in studies evaluating magrolimab for treating AML in the United States.""}, {""date"": ""2023-08-22"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Regeneron (REGN) and Syndax Pharmaceuticals (SNDX)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-23"", ""headline"": ""GILD Stock Alert: FDA Expands Indications for Gilead Sciences\u2019 Veklury Covid-19 Treatment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-23"", ""headline"": ""Bristol-Myers Squibb: Top Defensive Pick During Recessions With A Value Proposition"", ""summary"": ""Discover why Bristol-Myers is a strong investment, undervalued with a promising dividend yield. After a slow start, expect a bullish turnaround.""}, {""date"": ""2023-08-23"", ""headline"": ""Gilead Sciences to Present at Upcoming Investor Conferences"", ""summary"": ""FOSTER CITY, Calif., August 23, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:""}, {""date"": ""2023-08-23"", ""headline"": ""Gilead Sciences Inc. stock rises Wednesday, still underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.90% higher to $77.04 Wednesday, on what proved to be an all-around positive trading session for the stock market,...""}, {""date"": ""2023-08-23"", ""headline"": ""How Gilead\u2019s Pharmaceutical Development and Manufacturing Team Delivers Transformative Medicines"", ""summary"": ""NORTHAMPTON, MA / ACCESSWIRE / August 23, 2023 / Gilead Sciences When Stacey Ma was a little girl, her dream was to work with patients as a doctor. \""As it turns out, I became an engineer who makes medicine to help patients,\"" says Stacey, who joined ...""}, {""date"": ""2023-08-23"", ""headline"": ""Gilead, Arcus, iTeos, other biopharmas get boost from accidental disclosure of Roche lung cancer trial data"", ""summary"": ""Shares of biopharmaceutical companies developing anti-TIGIT cancer therapies, including Gilead Sciences Inc. Arcus Biosciences Inc. and iTeos Therapeutics...""}, {""date"": ""2023-08-23"", ""headline"": ""BMO Capital Remains a Buy on Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-23"", ""headline"": ""Arcus to 'trade with strength' after leaked Roche data looked 'good,' says BofA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-23"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Zimmer Biomet Holdings (ZBH) and Premier (PINC)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-24"", ""headline"": ""Gilead Sciences Inc. stock outperforms market despite losses on the day"", ""summary"": ""Shares of Gilead Sciences Inc. slipped 0.92% to $76.33 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P...""}, {""date"": ""2023-08-24"", ""headline"": ""FDA Approves Veklury\u00ae (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment"", ""summary"": ""FOSTER CITY, Calif., August 24, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) for the use of Veklury\u00ae (remdesivir) with no dose adjustments to treat COVID-19 in people with mild, moderate and severe hepatic impairment. This approval further supports the safety profile of Veklury as the first and only approved antiviral COVID-19 treatment that can be used across all stages of liver di""}, {""date"": ""2023-08-24"", ""headline"": ""GILD Stock Alert: FDA Approves Gilead Sciences\u2019 Veklury Covid-19 Treatment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-24"", ""headline"": ""Galapagos cut to Neutral at Citi on lack of catalysts"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-24"", ""headline"": ""Gilead Sciences' Veklury wins FDA approval as Covid treatment option"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-24"", ""headline"": ""Gilead Covid-19 Drug Cleared by FDA for Patients with Liver Disease"", ""summary"": ""By Dean Seal Gilead Sciences said regulators have approved its antiviral remdesivir, sold under the name brand Veklury, for Covid-19 patients with hepatic impairment, or liver failure. The...""}, {""date"": ""2023-08-24"", ""headline"": ""Drugs picked for Medicare price negotiations to be announced on Tuesday \u2013 Politico"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-24"", ""headline"": ""Gilead wins FDA nod to use Veklury for COVID-19 in liver disease"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-24"", ""headline"": ""FDA approves Gilead's Veklury for COVID-19 in people with hepatic impairment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-25"", ""headline"": ""Gilead Sciences Inc. stock rises Friday, outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.69% higher to $76.86 Friday, on what proved to be an all-around favorable trading session for the stock market, with...""}, {""date"": ""2023-08-25"", ""headline"": ""Gilead (GILD) Gets FDA Nod for Veklury for Hepatic Impairment"", ""summary"": ""Gilead's (GILD) anti-viral treatment Veklury gets FDA approval for the treatment of COVID-19 in patients with mild, moderate or severe hepatic impairment.""}, {""date"": ""2023-08-25"", ""headline"": ""The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics"", ""summary"": ""Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics are part of the Zacks top Analyst Blog.""}, {""date"": ""2023-08-25"", ""headline"": ""Gilead Sciences, Inc. - FDA Approves Veklury to Treat COVID-19 in People with Mild to Severe Hepatic Impairment with no Dose Adjustment"", ""summary"": ""FOSTER CITY - Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration approved a supplemental new drug application for the use of Veklury with no dose adjustments to...""}, {""date"": ""2023-08-25"", ""headline"": ""Galapagos: Good To Have An Approval, Bad To Have No Major Catalysts"", ""summary"": ""Galapagos has an approved drug, filgotinib, for rheumatoid arthritis and ulcerative colitis. Read more to see why I'm rating GLBG stock as a soft sell.""}, {""date"": ""2023-08-25"", ""headline"": ""Guild Esports shares jump on launch of new Street Fighter team"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-25"", ""headline"": ""Robert W. Baird Sticks to Their Hold Rating for Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-27"", ""headline"": ""Here's Why We Think Gilead Sciences (NASDAQ:GILD) Is Well Worth Watching"", ""summary"": ""It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...""}, {""date"": ""2023-08-27"", ""headline"": ""AlloVir: An Intriguing $3 Biotech Concern"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
33,2023-08-27,75.42733001708984,2023-09-03,75.22124481201172,-0.0027322351862572036,D1,"[{""date"": ""2023-08-27"", ""headline"": ""Here's Why We Think Gilead Sciences (NASDAQ:GILD) Is Well Worth Watching"", ""summary"": ""It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...""}, {""date"": ""2023-08-27"", ""headline"": ""AlloVir: An Intriguing $3 Biotech Concern"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-28"", ""headline"": ""Gilead Sciences Inc. stock rises Monday, still underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.23% higher to $77.04 Monday, on what proved to be an all-around positive trading session for the stock market, with...""}, {""date"": ""2023-08-28"", ""headline"": ""12 Undervalued Wide Moat Stocks To Invest In"", ""summary"": ""In this piece, we will take a look at 12 undervalued wide moat stocks to invest in. If you want to skip our primer on wide moat investing, then check out 5 Undervalued Wide Moat Stocks To Invest In. The strategy of wide moat investing has gained a lot of traction over the past few [\u2026]""}, {""date"": ""2023-08-28"", ""headline"": ""10 Health Care Stocks Whale Activity In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-28"", ""headline"": ""Gilead Sciences: Searching For A Catalyst"", ""summary"": ""Over the long run, Gilead Sciences' pipeline and its oncology segment could lead to higher sales. Click here to read why GILD stock is a Buy.""}, {""date"": ""2023-08-29"", ""headline"": ""Gilead Sciences Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. rallied 1.52% to $78.21 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P...""}, {""date"": ""2023-08-29"", ""headline"": ""Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data"", ""summary"": ""Arcus Biosciences, Inc. stock has dropped 40% since its high in 2022, making it an attractive investment opportunity. Click here for more on RCUS stock.""}, {""date"": ""2023-08-29"", ""headline"": ""Nearing Retirement? These Stocks Will Pay You For Life"", ""summary"": ""One place to look is the stock market.  Investing in reliable dividend stocks can be a great source of steady passive income, but only if the stocks in question have the tools to distribute growing payouts for a while.  Let's look at two companies that can do that: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD).""}, {""date"": ""2023-08-30"", ""headline"": ""Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. slid 0.70% to $77.66 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-08-30"", ""headline"": ""Gilead Sciences: Fifth Anniversary of COMPASS: Helping Address the HIV Epidemic in the U.S. South"", ""summary"": ""This year marks the fifth anniversary of the Gilead COMPASS Initiative\u00ae, a 10-year, more than $100 million commitment to addressing the HIV epidemic in the Southern United States.""}, {""date"": ""2023-08-30"", ""headline"": ""Upcoming Dividend Run For GILD?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-31"", ""headline"": ""Gilead Sciences Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. slid 1.52% to $76.48 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-08-31"", ""headline"": ""With 86% institutional ownership, Gilead Sciences, Inc. (NASDAQ:GILD) is a favorite amongst the big guns"", ""summary"": ""Key Insights Institutions' substantial holdings in Gilead Sciences implies that they have significant influence over...""}, {""date"": ""2023-08-31"", ""headline"": ""The Highest Quality Dividend Challenger Summary"", ""summary"": ""Discover the top 20 highest-quality Dividend Challengers, along with stocks offering favorable valuations and compelling metrics for various investor types.""}, {""date"": ""2023-09-01"", ""headline"": ""Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know"", ""summary"": ""In the latest trading session, Gilead Sciences (GILD) closed at $76.65, marking a +0.22% move from the previous day.""}, {""date"": ""2023-09-01"", ""headline"": ""Gilead Sciences Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.22% higher to $76.65 Friday, on what proved to be an all-around favorable trading session for the stock market, with...""}, {""date"": ""2023-09-02"", ""headline"": ""3 No-Brainer Dividend Stocks to Buy in September"", ""summary"": ""When's a good time to invest in dividend stocks?  Here's why they picked AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), and Gilead Sciences (NASDAQ: GILD).  Keith Speights (AbbVie): It's never easy for a drugmaker to lose patent exclusivity for its top-selling product.""}, {""date"": ""2023-09-03"", ""headline"": ""U.S. Wide-Moat Stocks On Sale - The September 2023 Heat Map"", ""summary"": ""Our 3-step process focuses on wide-moat stocks (as per Morningstar\u00e2\u0080\u0099s rating). Find out the heat map of the most investable candidates.""}]",{}
34,2023-09-03,75.22124481201172,2023-09-10,74.58335876464844,-0.008480131496859,D1,"[{""date"": ""2023-09-03"", ""headline"": ""U.S. Wide-Moat Stocks On Sale - The September 2023 Heat Map"", ""summary"": ""Our 3-step process focuses on wide-moat stocks (as per Morningstar\u00e2\u0080\u0099s rating). Find out the heat map of the most investable candidates.""}, {""date"": ""2023-09-05"", ""headline"": ""Gilead initiated with a Reduce at HSBC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-05"", ""headline"": ""Gilead aims for 2026 opening for new cancer research center"", ""summary"": ""Gilead Sciences Inc. is moving forward with plans for a 190,000-square-foot research-and-development building, anchored by the drug maker's growing cancer focus, on its Foster City campus.  Cancer research will anchor the multipurpose building, Ganguly said.  The Foster City Planning Commission on Thursday is scheduled to review plans for the new building, which will house 300-350 scientists.""}, {""date"": ""2023-09-05"", ""headline"": ""Gilead Sciences Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. slid 1.94% to $75.16 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-09-05"", ""headline"": ""(GILD) - Analyzing Gilead Sciences's Short Interest"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-05"", ""headline"": ""MacroGenics achieves $15M milestone related to Gilead nomination"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-06"", ""headline"": ""Truist Securities Reiterates Gilead Sciences (GILD) Buy Recommendation"", ""summary"": """"}, {""date"": ""2023-09-06"", ""headline"": ""HSBC Initiates Coverage of Gilead Sciences (GILD) with Reduce Recommendation"", ""summary"": """"}, {""date"": ""2023-09-06"", ""headline"": ""Gilead Sciences Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Gilead Sciences Inc. slipped 1.22% to $74.24 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P...""}, {""date"": ""2023-09-06"", ""headline"": ""Google's investment arm leads $210M raise for biotech partnered with Takeda, Lilly"", ""summary"": ""Nimbus Therapeutics LLC has new investment from none other than GV, the investment arm affiliated with Google.""}, {""date"": ""2023-09-06"", ""headline"": ""Gilead Sciences, Inc. (GILD) Wells Fargo Healthcare Conference - (Transcript)"", ""summary"": ""Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Wells Fargo Healthcare Conference September 6, 2023 11:00 AM ETCompany ParticipantsAndrew Dickinson - Chief Financial OfficerConference Call...""}, {""date"": ""2023-09-06"", ""headline"": ""12 Best Healthcare ETFs To Buy"", ""summary"": ""In this article, we discuss 12 best healthcare ETFs. If you want to skip our discussion on the healthcare market, head directly to 5 Best Healthcare ETFs To Buy. In December 2022, BlackRock highlighted concerns about the performance for the healthcare sector in 2023. The previous year was rather challenging for equity and fixed income [\u2026]""}, {""date"": ""2023-09-06"", ""headline"": ""Is Amgen A Worthy Investment Despite President Biden's Inflation Reduction Act?"", ""summary"": ""Amgen discovers, develops, manufactures, and delivers human therapeutics worldwide. Find out why we initiate our coverage of AMGN stock with a hold rating.""}, {""date"": ""2023-09-06"", ""headline"": ""Gilead Sciences: How One School Has Transformed Education for First-Generation Students"", ""summary"": ""As an elementary school student, Nohely Peraza took a bus from her home in East Palo Alto to a school several miles away in another city. The local commute program sought to address the lack of diversity in schools in high-income neighborhoods and create educational opportunities for those in lower-income areas.""}, {""date"": ""2023-09-06"", ""headline"": ""GLOBAL BROKER RATINGS: Shore Capital raises B&M; HSBC likes Amgen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-06"", ""headline"": ""Where Gilead Sciences Stands With Analysts"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-06"", ""headline"": ""Federal Circuit Imperils Term-adjusted Patents"", ""summary"": ""The Federal Circuit recently upheld the Patent Office's decision to reject claims in four separate reexamination cases due to obviousness-type double patenting . In re Cellect, LLC, Appeal Nos....""}, {""date"": ""2023-09-07"", ""headline"": ""Gilead Sciences prices $2B senior unsecured notes in a public offering"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-07"", ""headline"": ""What You Missed On Wall Street On Friday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-07"", ""headline"": ""Catalyst Watch: Arm IPO, Apple event, and Senate AI Forum with Musk, Zuckerberg, and Gates"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-07"", ""headline"": ""IN BRIEF: Gilead Sciences prices USD2 billion in 10 and 30-year notes"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-07"", ""headline"": ""How To Earn $500 A Month From Gilead Sciences Stock"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-07"", ""headline"": ""Gilead Prices $2 Billion of Senior Unsecured Notes"", ""summary"": ""FOSTER CITY, Calif., September 08, 2023--Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $2 billion, in an underwritten, registered public offering, consisting of $1 billion of 5.250% senior notes maturing in 2033 and $1 billion of 5.550% senior notes maturing in 2053. The offering is expected to close Sep""}, {""date"": ""2023-09-07"", ""headline"": ""Biopharma Bounce-Back: From Policy Pains To Profitable Plains"", ""summary"": ""The legal challenges by big pharma companies against the IRA may derail the implementation of the drug pricing reforms. Click here for a detailed analysis.""}, {""date"": ""2023-09-07"", ""headline"": ""Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know"", ""summary"": ""Gilead Sciences (GILD) closed at $73.94 in the latest trading session, marking a -0.4% move from the prior day.""}, {""date"": ""2023-09-07"", ""headline"": ""Gilead Sciences Inc. stock falls Thursday, underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. slumped 0.40% to $73.94 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...""}, {""date"": ""2023-09-07"", ""headline"": ""$1000 Invested In This Stock 20 Years Ago Would Be Worth $9,000 Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-08"", ""headline"": ""Pfizer Vs. Gilead Sciences: COVID-19 Battle Of Pharma Titans"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-08"", ""headline"": ""The Unexpected Reason Gilead Just Notched Its Biggest Single-Day Move In A Month"", ""summary"": ""Investors don't fully appreciate Gilead Sciences' leadership in HIV treatment, an analyst said Friday as he upgraded GILD stock.""}, {""date"": ""2023-09-08"", ""headline"": ""US STOCKS-S&P 500 closes up slightly ahead of US inflation data"", ""summary"": ""The S&P 500 closed slightly higher on Friday but well below its session high and all three of Wall Street's major averages posted weekly declines as investors worried about interest rates and waited anxiously for upcoming U.S. inflation readings.  Investors worried about rising oil prices and have been fretting ahead of the Consumer Price Index (CPI) for August, due out on Sept. 13, seeking signals about the Federal Reserve's likely moves on interest rates.""}, {""date"": ""2023-09-08"", ""headline"": ""US STOCKS-Wall St rises as megacaps gain, yields slip ahead of US inflation data"", ""summary"": ""Wall Street's main indexes rose on Friday with a rising technology sector helping Nasdaq regain ground after four straight declines, but gains were limited as investors waited tentatively for August U.S. inflation readings.  Microsoft rose more than 1%, and Apple was up 1% after a deep two-day selloff following news Beijing had ordered central government employees to stop using iPhones at work.  Wall Street analysts calculated just a small hit to Apple revenue this year from the curbs, with Morgan Stanley calling a 4% drop the worst case scenario.""}, {""date"": ""2023-09-08"", ""headline"": ""Gilead Sciences Inc. stock rises Friday, outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. rallied 2.79% to $76.00 Friday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-09-08"", ""headline"": ""NEW YORK MARKET CLOSE: US stocks end losing week with modest gains"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-08"", ""headline"": ""US STOCKS-Wall St rises as megacaps gain, yields slip ahead of key inflation data"", ""summary"": ""Wall Street's main indexes rose on Friday as megacaps including Apple and Microsoft gained ahead of a fresh inflation reading next week that will provide further clues on the U.S. interest rate trajectory.  U.S. Treasury yields edged lower on Friday, helping boost major growth stocks, with Microsoft leading gains, up 1.9%, and Meta Platforms advancing nearly 1%.""}, {""date"": ""2023-09-08"", ""headline"": ""Unveiling Gilead Sciences (GILD)'s Value: Is It Really Priced Right? A Comprehensive Guide"", ""summary"": ""A deep dive into the intrinsic value and financial health of Gilead Sciences Inc (GILD)""}, {""date"": ""2023-09-08"", ""headline"": ""Gilead Stock Looks Underappreciated and Oversold, Say BofA Analysts"", ""summary"": ""BofA upgraded shares of biotech Gilead to Buy from Neutral, and lifted the target price to $95 from $88.""}, {""date"": ""2023-09-08"", ""headline"": ""Adobe upgraded, DigitalOcean double downgraded: Wall Street's top analyst calls"", ""summary"": ""Adobe upgraded, DigitalOcean double downgraded: Wall Street's top analyst calls""}, {""date"": ""2023-09-08"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-08"", ""headline"": ""Gilead Sciences Shares Trade Higher After Bullish Analyst Upgrades Stock"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-08"", ""headline"": ""Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-08"", ""headline"": ""Early notable gainers among liquid option names on September 8th"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-08"", ""headline"": ""4 stocks to watch on Friday: Kroger, DocuSign and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-08"", ""headline"": ""Adobe To Rally Over 12%? Here Are 10 Other Analyst Forecasts For Friday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-08"", ""headline"": ""Gilead raised to Buy at Bank of America on untapped potential"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-08"", ""headline"": ""Gilead upgraded at Bank of America on untapped potential"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-08"", ""headline"": ""BofA upgrades 'underappreciated' Gilead to Buy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-08"", ""headline"": ""Gilead upgraded to Buy from Neutral at BofA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-09"", ""headline"": ""Gilead's Phase 2 EVOKE-02 Study of Trodelvy\u00ae (sacituzumab govitecan-hziy) in Combination With KEYTRUDA\u00ae (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer"", ""summary"": ""\u2013 Results Show Encouraging Activity of Trodelvy in Combination with KEYTRUDA in 1L Metastatic NSCLC Across all PD-L1 Subgroups and Histologies Studied \u2013\u2013 Results Support Further...""}, {""date"": ""2023-09-09"", ""headline"": ""HSBC bullish on IQVIA, Zoetis, bluebird, Actinium; bearish on Gilead"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-09"", ""headline"": ""Only Four Days Left To Cash In On Gilead Sciences' (NASDAQ:GILD) Dividend"", ""summary"": ""Gilead Sciences, Inc. ( NASDAQ:GILD ) is about to trade ex-dividend in the next four days. The ex-dividend date is one...""}, {""date"": ""2023-09-09"", ""headline"": ""B of A Securities Upgrades Gilead Sciences (GILD)"", ""summary"": """"}, {""date"": ""2023-09-10"", ""headline"": ""Wall Street Analysts Are Bullish on Top Healthcare Picks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-10"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of September 10"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Click here to read the September 10 weekly update.""}, {""date"": ""2023-09-10"", ""headline"": ""Gilead\u2019s Phase 2 EVOKE-02 Study of Trodelvy\u00ae (sacituzumab govitecan-hziy) in Combination With KEYTRUDA\u00ae (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer"", ""summary"": ""FOSTER CITY, Calif., September 10, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced promising early data from the global, open-label, Phase 2 EVOKE-02 study evaluating Trodelvy\u00ae (sacituzumab govitecan-hziy) in combination with Merck\u2019s anti-PD-1 therapy KEYTRUDA\u00ae (pembrolizumab) with or without platinum agents in patients with previously untreated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations. The results are being presented today at th""}, {""date"": ""2023-09-10"", ""headline"": ""Gilead presents early data from Phase 2 EVOKE-02 study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-10"", ""headline"": ""Gilead says Trodelvy with Merck\u2019s Keytruda controls lung cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
35,2023-09-10,74.58335876464844,2023-09-17,74.98697662353516,0.005411634251553998,U1,"[{""date"": ""2023-09-09"", ""headline"": ""Gilead's Phase 2 EVOKE-02 Study of Trodelvy\u00ae (sacituzumab govitecan-hziy) in Combination With KEYTRUDA\u00ae (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer"", ""summary"": ""\u2013 Results Show Encouraging Activity of Trodelvy in Combination with KEYTRUDA in 1L Metastatic NSCLC Across all PD-L1 Subgroups and Histologies Studied \u2013\u2013 Results Support Further...""}, {""date"": ""2023-09-09"", ""headline"": ""HSBC bullish on IQVIA, Zoetis, bluebird, Actinium; bearish on Gilead"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-10"", ""headline"": ""Gilead Sciences Inc. stock rises Monday, outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-10"", ""headline"": ""IN BRIEF: Gilead says Troldevy & Keytruda lung cancer trial promising"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-10"", ""headline"": ""September Self-Indexing Strategies For A Possible Blue October"", ""summary"": ""Magic Formula is still one of my favorite broad-based indexing strategies. Find out the top 30 dividend paying Magic Formula stocks scored for September 2023.""}, {""date"": ""2023-09-10"", ""headline"": ""Wall Street Analysts Are Bullish on Top Healthcare Picks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-10"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of September 10"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Click here to read the September 10 weekly update.""}, {""date"": ""2023-09-10"", ""headline"": ""Gilead\u2019s Phase 2 EVOKE-02 Study of Trodelvy\u00ae (sacituzumab govitecan-hziy) in Combination With KEYTRUDA\u00ae (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer"", ""summary"": ""FOSTER CITY, Calif., September 10, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced promising early data from the global, open-label, Phase 2 EVOKE-02 study evaluating Trodelvy\u00ae (sacituzumab govitecan-hziy) in combination with Merck\u2019s anti-PD-1 therapy KEYTRUDA\u00ae (pembrolizumab) with or without platinum agents in patients with previously untreated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations. The results are being presented today at th""}, {""date"": ""2023-09-10"", ""headline"": ""Gilead presents early data from Phase 2 EVOKE-02 study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-10"", ""headline"": ""Gilead says Trodelvy with Merck\u2019s Keytruda controls lung cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-11"", ""headline"": ""Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-11"", ""headline"": ""Gilead's (GILD) Trodelvy Combo Shows Promise in NSCLC Study"", ""summary"": ""Gilead's (GILD) breast cancer drug Trodelvy, in combination with Keytruda, shows positive data in a phase II lung cancer study.""}, {""date"": ""2023-09-11"", ""headline"": ""Gilead's Breast Cancer Drug Shows Promise When Combined With Merck's Treatment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-11"", ""headline"": ""Gilead's Phase 2 EVOKE-02 Study of Trodelvy in Combination With KEYTRUDA Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer"", ""summary"": ""FOSTER CITY - Gilead Sciences, Inc. today announced promising early data from the global, open-label, Phase 2 EVOKE-02 study evaluating Trodelvy in combination with Merck's anti-PD-1 therapy...""}, {""date"": ""2023-09-11"", ""headline"": ""Guild Esports strengthens bond with Sky as Glass becomes TV partner"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-11"", ""headline"": ""Monday\u2019s Top Analyst Upgrades and Downgrades: Adobe, Apple, CSX, First Solar, Gilead Sciences, Lucid, Shopify, Snowflake and More"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-11"", ""headline"": ""GLOBAL BROKER RATINGS: Bank of America raises Gilead Sciences to 'buy'"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-11"", ""headline"": ""Marker gains as lymphoma therapy leads to complete remission"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-11"", ""headline"": ""Big Institutions Grab \u2018Strong Buy\u2019 Dividend Stocks in a Sector Not Totally Driven by AI"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-12"", ""headline"": ""BBH: Our Favorite Biotech ETF Can Keep Outperforming"", ""summary"": ""VanEck Biotech ETF outperforms other industry ETFs due to its focus on large-cap leaders and the potential of AI in R&D programs. Read more on BBH ETF here.""}, {""date"": ""2023-09-12"", ""headline"": ""Gilead Sciences goes ex-dividend tomorrow"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-12"", ""headline"": ""Gilead Sciences (GILD) Stock Moves -0.31%: What You Should Know"", ""summary"": ""In the latest trading session, Gilead Sciences (GILD) closed at $76.80, marking a -0.31% move from the previous day.""}, {""date"": ""2023-09-12"", ""headline"": ""Time for Gilead Sciences-Heavy ETFs?"", ""summary"": ""Bank of America expects the Gilead Sciences to jump about 30%, as quoted on CNBC.""}, {""date"": ""2023-09-12"", ""headline"": ""Gilead Sciences, Inc. (GILD) Management Presents at Morgan Stanley 21st Annual Global Healthcare Brokers Conference 2023 (Transcript)"", ""summary"": ""Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Morgan Stanley 21st Annual Global Healthcare Conference 2023 September 12, 2023 11:30 AM ETCompany ParticipantsDan O\u00e2\u0080\u0099Day - Chairman, Chief...""}, {""date"": ""2023-09-12"", ""headline"": ""RBC Capital Keeps Their Hold Rating on Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-12"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR), Shockwave Medical (SWAV) and Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-12"", ""headline"": ""Gilead Sciences (GILD) Receives a Buy from BMO Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-13"", ""headline"": ""Gilead Sciences Inc. stock outperforms market on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-13"", ""headline"": ""Investor Concerns Dragged Gilead Sciences (GILD) in Q2"", ""summary"": ""Ariel Investments, an investment management company, released its \u201cAriel Global Fund\u201d second-quarter 2023 investor letter. A copy of the same can be downloaded here. In the second quarter, the Ariel Global fund traded +3.32% higher, trailing the +6.18% return of the MSCI ACWI Index and outperforming the MSCI ACWI Value Index\u2019s +2.98% gain. The fund\u2019s lack [\u2026]""}, {""date"": ""2023-09-14"", ""headline"": ""Gilead Sciences Inc. stock falls Friday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-14"", ""headline"": ""Unraveling Gilead Sciences Inc's Dividend Performance and Sustainability"", ""summary"": ""Gilead Sciences Inc(NASDAQ:GILD) recently announced a dividend of $0.75 per share, payable on 2023-09-28, with the ex-dividend date set for 2023-09-14.  As investors eagerly anticipate this upcoming payment, it is also crucial to examine the company's dividend history, yield, and growth rates.  Using the data from GuruFocus, let's delve into Gilead Sciences Inc's dividend performance and assess its sustainability.""}, {""date"": ""2023-09-14"", ""headline"": ""My Dividend Stock Portfolio: New August Dividend Record - 99 Holdings With 27 Buys"", ""summary"": ""The S&P 500 and Dow Jones Industrial Average both saw slim positive returns in August. Check out the latest dividend stock portfolio update.""}, {""date"": ""2023-09-16"", ""headline"": ""IXJ: Healthcare Dashboard For September"", ""summary"": ""Healthcare providers and pharmaceuticals/biotechnology look fairly valued, whereas healthcare equipment is the less attractive subsector. Read more here.""}]",{}
36,2023-09-17,74.98697662353516,2023-09-24,74.33293914794922,-0.008722014208806805,D1,"[{""date"": ""2023-09-17"", ""headline"": ""Gilead Sciences Inc. stock falls Monday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-17"", ""headline"": ""$100 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-18"", ""headline"": ""Gilead Sciences Inc. stock outperforms market on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-18"", ""headline"": ""With ex-Vertex leader out as CEO, biotech makes layoffs, leaves Watertown HQ"", ""summary"": ""A biotech once led by a longtime Vertex Pharmaceuticals executive is making layoffs and moving headquarters.""}, {""date"": ""2023-09-18"", ""headline"": ""These 4 Measures Indicate That Gilead Sciences (NASDAQ:GILD) Is Using Debt Reasonably Well"", ""summary"": ""David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...""}, {""date"": ""2023-09-18"", ""headline"": ""Gilead Sciences' Kite says Yescarta therapy meets primary endpoint"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-18"", ""headline"": ""Kite\u2019s Car T-cell Therapy Yescarta\u00ae Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma"", ""summary"": ""SANTA MONICA, Calif., September 18, 2023--Kite, a Gilead Company (Nasdaq: GILD), today announced results from the Phase 2 ALYCANTE study, led and sponsored by the French collaborative group LYSA/LYSARC, for use of its chimeric antigen receptor (CAR) T-cell therapy Yescarta\u00ae (axicabtagene ciloleucel) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after one prior line of therapy who were deemed ineligible for high-dose chemotherapy (HDCT) and autologous stem cell transplan""}, {""date"": ""2023-09-18"", ""headline"": ""GLOBAL BROKER RATINGS: Bank of America raises Gilead Sciences to 'buy'"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-18"", ""headline"": ""Kite announces Alycante study met primary endpoint"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-19"", ""headline"": ""Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors despite daily gains"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-19"", ""headline"": ""Gilead Sciences Unusual Options Activity"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-19"", ""headline"": ""Gilead's Covid drug Veklury gets positive EU opinion for extended use"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-19"", ""headline"": ""CHMP Adopts Positive Opinion to Extend the Use of Veklury\u00ae (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment"", ""summary"": ""FOSTER CITY, Calif., September 19, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted a positive opinion for the use of Veklury\u00ae (remdesivir) to treat people with COVID-19 with mild to severe hepatic impairment. The European Commission (EC) will review the CHMP recommendation and, if adopted, Veklury will become the first and only authorized antiviral COVID-19 treatment that can""}, {""date"": ""2023-09-19"", ""headline"": ""Gilead wins EU backing to use remdesivir for COVID-19 in liver disease"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-19"", ""headline"": ""Gilead announces CHMP recommendation for the use of Veklury"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-20"", ""headline"": ""Gilead Sciences Inc. stock falls Thursday, still outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-20"", ""headline"": ""How Is The Market Feeling About Gilead Sciences?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-20"", ""headline"": ""How Wegovy and Other Weight-Loss Drugs Could Break the Healthcare System"", ""summary"": ""Between cost and demand, Wegovy and other weight-loss medications could transform healthcare in the U.S.\u2014for good and ill.""}, {""date"": ""2023-09-20"", ""headline"": ""Gilead's (GILD) Veklury Gets CHMP Nod in Damaged Liver Patients"", ""summary"": ""Gilead's (GILD) Veklury gets a positive CHMP opinion, recommending the use of the drug to treat people with COVID-19 with mild to severe hepatic impairment.""}, {""date"": ""2023-09-21"", ""headline"": ""Gilead Sciences Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-21"", ""headline"": ""3 Bargain Stocks to Buy in a Market That's Priced for Perfection"", ""summary"": ""Stock valuations are at historically high levels.  Three Motley Fool contributors identified bargain stocks to buy in a market that's priced for perfection.  Here's why they picked AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE).""}, {""date"": ""2023-09-21"", ""headline"": ""Blockbuster Cancer Treatment Stymied by Supply Chain\u2014for Now"", ""summary"": ""A cell therapy for multiple myeloma promises to be a major blockbuster for J&J and partner Legend, if they can increase manufacturing.""}, {""date"": ""2023-09-23"", ""headline"": ""Why Gilead Sciences, Inc. (NASDAQ:GILD) Looks Like A Quality Company"", ""summary"": ""While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...""}, {""date"": ""2023-09-24"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of September 24"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Explore more details here.""}]",{}
37,2023-09-24,74.33293914794922,2023-10-01,74.26356506347656,-0.0009332885967898719,D1,"[{""date"": ""2023-09-24"", ""headline"": ""Gilead Sciences Inc. stock falls Monday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-24"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of September 24"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Explore more details here.""}, {""date"": ""2023-09-26"", ""headline"": ""Gilead Sciences Inc. stock outperforms market on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-26"", ""headline"": ""Gilead Sciences (GILD) Gains As Market Dips: What You Should Know"", ""summary"": ""Gilead Sciences (GILD) closed the most recent trading day at $75.53, moving +0.94% from the previous trading session.""}, {""date"": ""2023-09-26"", ""headline"": ""IN BRIEF: Gilead stops Enhance-2 study in acute myeloid leukemia"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-26"", ""headline"": ""Unveiling Gilead Sciences (GILD)'s Value: Is It Really Priced Right? A Comprehensive Guide"", ""summary"": ""An in-depth analysis of Gilead Sciences' intrinsic value, financial strength, profitability, and growth""}, {""date"": ""2023-09-26"", ""headline"": ""Big Pharma R&D Spending: The Secret Ingredient To Outperformance?"", ""summary"": ""High R&D spending by pharma companies does not necessarily lead to sales growth, let alone shareholder returns. See why bold M&A deals may be a different story.""}, {""date"": ""2023-09-26"", ""headline"": ""Early notable gainers among liquid option names on September 26th"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-27"", ""headline"": ""Gilead Sciences Inc. stock falls Thursday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-27"", ""headline"": ""Here's Why We Think Gilead Sciences (NASDAQ:GILD) Might Deserve Your Attention Today"", ""summary"": ""It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...""}, {""date"": ""2023-09-28"", ""headline"": ""Gilead Sciences Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-28"", ""headline"": ""GILD Dividend Yield Pushes Past 4%"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-28"", ""headline"": ""Two Trial Halts In A Row - Gilead Sciences Stops Late Stage COVID-19 Study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-28"", ""headline"": ""Gilead Sciences Adapts to Economic Shifts to Support Investor Confidence"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-29"", ""headline"": ""20 Countries with Lowest Teenage Pregnancy Rates in the World"", ""summary"": ""In this article, we will be taking a look at the 20 countries with the lowest teenage pregnancy rates in the world. To skip our detailed analysis, you can go directly to see the 5 countries with the lowest teenage pregnancy rates in the world. In the 1960s, the birth rate per 1,000 adolescents, aged 15 [\u2026]""}, {""date"": ""2023-09-29"", ""headline"": ""10 Health Care Stocks With Whale Alerts In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-29"", ""headline"": ""Gilead Sciences: A Buy Rating Driven by Dominance in HIV Market and Positive Long-Term Growth Prospects"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-30"", ""headline"": ""3 Magnificent Dividend Stocks to Buy in October"", ""summary"": ""There's no better time than October to invest in high-quality dividend stocks.  Three Motley Fool contributors believe they've identified magnificent dividend stocks to buy in October.  Here's why they chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ).""}]","{""assetTurnoverTTM"": 0.4387, ""bookValue"": 22314, ""cashRatio"": 0.47760569275847636, ""currentRatio"": 1.3378, ""ebitPerShare"": 2.0867, ""eps"": 1.7343, ""ev"": 111679.7, ""fcfMargin"": 0.2316, ""fcfPerShareTTM"": 6.2975, ""grossMargin"": 0.778, ""inventoryTurnoverTTM"": 3.7134, ""longtermDebtTotalAsset"": 0.3718, ""longtermDebtTotalCapital"": 0.4903, ""longtermDebtTotalEquity"": 1.0392, ""netDebtToTotalCapital"": 0.4076, ""netDebtToTotalEquity"": 0.8639, ""netMargin"": 0.3092, ""operatingMargin"": 0.372, ""payoutRatioTTM"": 0.6436, ""pb"": 4.141, ""peTTM"": 15.7281, ""pfcfTTM"": 11.7665, ""pretaxMargin"": 0.3287, ""psTTM"": 3.3735, ""quickRatio"": 0.9757, ""receivablesTurnoverTTM"": 5.991, ""roaTTM"": 0.0941, ""roeTTM"": 0.2742, ""roicTTM"": 0.1261, ""rotcTTM"": 0.1772, ""salesPerShare"": 5.6094, ""sgaToSale"": 0.222, ""totalDebtToEquity"": 1.1196, ""totalDebtToTotalAsset"": 0.4005, ""totalDebtToTotalCapital"": 0.5282, ""totalRatio"": 1.557, ""period"": ""2023-09-30""}"
38,2023-10-01,74.26356506347656,2023-10-08,74.06536865234375,-0.0026688243550306856,D1,"[{""date"": ""2023-10-01"", ""headline"": ""Gilead Sciences Inc. stock falls Monday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-02"", ""headline"": ""Gilead Sciences Inc. stock falls Tuesday, still outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-02"", ""headline"": ""Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs"", ""summary"": ""Autologous chimeric antigen receptor T cell therapy is 0ne of the most promising, relatively new types of cancer treatments. CAR T involves \u201creprogramming\u201d patients\u2019 T cells, which fight hostile cells within the body. Specifically, CAR T treatments work by reconfiguring T cells so that they attack proteins found on tumors. CAR T also attacks other cells altered by tumors. One reason this type of therapy is so promising is that it produces treatments that work well within each patients\u2019 body. Tha""}, {""date"": ""2023-10-02"", ""headline"": ""Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know"", ""summary"": ""In the latest trading session, Gilead Sciences (GILD) closed at $74.10, marking a -1.12% move from the previous day.""}, {""date"": ""2023-10-02"", ""headline"": ""Gilead Board Director Kevin E. Lofton Named to List of Influential Leaders"", ""summary"": ""FOSTER CITY, Calif., October 02, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Kevin E. Lofton, Lead Independent Director, has been named one of the most influential leaders in corporate governance by the National Association of Corporate Directors (NACD) as part of their 2023 NACD Directorship 100\u2122, an annual list of leading corporate directors and governance advocates.""}, {""date"": ""2023-10-02"", ""headline"": ""Gilead call volume above normal and directionally bullish"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-03"", ""headline"": ""Gilead Sciences Inc. stock outperforms market on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-03"", ""headline"": ""U.S. Wide-Moat Stocks On Sale - The October 2023 Heat Map"", ""summary"": ""Discover the 3-step process of selecting wide-moat stocks, with a focus on attractively valued candidates. See a heat map of investment candidates here.""}, {""date"": ""2023-10-03"", ""headline"": ""With 86% institutional ownership, Gilead Sciences, Inc. (NASDAQ:GILD) is a favorite amongst the big guns"", ""summary"": ""Key Insights Significantly high institutional ownership implies Gilead Sciences' stock price is sensitive to their...""}, {""date"": ""2023-10-03"", ""headline"": ""Gilead to Present Latest Innovative Virology Data on Current and Potentially Transformative Therapies Across HIV and COVID-19 at IDWeek 2023"", ""summary"": ""FOSTER CITY, Calif., October 03, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from its virology research and development programs that will be presented at IDWeek 2023, October 11-15 in Boston. These latest data demonstrate the company\u2019s ongoing efforts to address the unmet medical needs of people and communities affected by HIV and COVID-19. Gilead will be presenting 16 abstracts, including real-world evidence, as the company continues to pursue the next wave of scientifi""}, {""date"": ""2023-10-04"", ""headline"": ""Eli Lilly names new head of diabetes and obesity division in leadership shakeup"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-04"", ""headline"": ""Gilead Sciences: A Healthy Buy With Solid Dividend"", ""summary"": ""Gilead Sciences has outperformed the S&P 500 with a 19% total return since my last Buy rating in August last year. Learn why GILD stock is a buy.""}, {""date"": ""2023-10-04"", ""headline"": ""IN BRIEF: Eli Lilly executive vice-president Mike Mason set to retire"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-05"", ""headline"": ""Biotech Sector: On The Verge Of Triumph Or Turmoil?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-05"", ""headline"": ""Gilead Sciences Inc. stock falls Thursday, still outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. slipped 0.05% to $74.70 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P...""}, {""date"": ""2023-10-05"", ""headline"": ""Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-05"", ""headline"": ""November 24th Options Now Available For Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-05"", ""headline"": ""RBC Capital Keeps Their Hold Rating on Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-06"", ""headline"": ""Gilead Sciences Inc. stock rises Friday, still underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.05% higher to $74.74 Friday, on what proved to be an all-around great trading session for the stock market, with the...""}, {""date"": ""2023-10-06"", ""headline"": ""Gilead put volume heavy and directionally bearish"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]","{""assetTurnoverTTM"": 0.4387, ""bookValue"": 22314, ""cashRatio"": 0.47760569275847636, ""currentRatio"": 1.3378, ""ebitPerShare"": 2.0867, ""eps"": 1.7343, ""ev"": 111679.7, ""fcfMargin"": 0.2316, ""fcfPerShareTTM"": 6.2975, ""grossMargin"": 0.778, ""inventoryTurnoverTTM"": 3.7134, ""longtermDebtTotalAsset"": 0.3718, ""longtermDebtTotalCapital"": 0.4903, ""longtermDebtTotalEquity"": 1.0392, ""netDebtToTotalCapital"": 0.4076, ""netDebtToTotalEquity"": 0.8639, ""netMargin"": 0.3092, ""operatingMargin"": 0.372, ""payoutRatioTTM"": 0.6436, ""pb"": 4.141, ""peTTM"": 15.7281, ""pfcfTTM"": 11.7665, ""pretaxMargin"": 0.3287, ""psTTM"": 3.3735, ""quickRatio"": 0.9757, ""receivablesTurnoverTTM"": 5.991, ""roaTTM"": 0.0941, ""roeTTM"": 0.2742, ""roicTTM"": 0.1261, ""rotcTTM"": 0.1772, ""salesPerShare"": 5.6094, ""sgaToSale"": 0.222, ""totalDebtToEquity"": 1.1196, ""totalDebtToTotalAsset"": 0.4005, ""totalDebtToTotalCapital"": 0.5282, ""totalRatio"": 1.557, ""period"": ""2023-09-30""}"
39,2023-10-08,74.06536865234375,2023-10-15,76.94910430908203,0.03893500713233844,U4,"[{""date"": ""2023-10-09"", ""headline"": ""Gilead Sciences (GILD) Ascends But Remains Behind Market: Some Facts to Note"", ""summary"": ""In the closing of the recent trading day, Gilead Sciences (GILD) stood at $75.06, denoting a +0.43% change from the preceding trading day.""}, {""date"": ""2023-10-09"", ""headline"": ""Gilead Sciences Inc. stock rises Monday, still underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.43% higher to $75.06 Monday, on what proved to be an all-around favorable trading session for the stock market, with...""}, {""date"": ""2023-10-09"", ""headline"": ""Will more bidders emerge or CVR ever be paid in Mirati takeover deal?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-10"", ""headline"": ""Those who invested in Gilead Sciences (NASDAQ:GILD) a year ago are up 21%"", ""summary"": ""We believe investing is smart because history shows that stock markets go higher in the long term. But if you choose...""}, {""date"": ""2023-10-10"", ""headline"": ""Guild Esports teams up with Adidas and Stormzy for sports diversity"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-11"", ""headline"": ""Gilead Sciences Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. rose 1.30% to $76.96 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""2023-10-11"", ""headline"": ""AQR Capital Management: AUM, Performance, Stock Picks"", ""summary"": ""In this article, we looked at Cliff Asness\u2019 investment philosophy and outlook on the US stock market. We also reviewed Asness\u2019 AQR Capital Management\u2019s assets under management, performance and stock picks. You can skip our detailed discussion of AQR Capital Management and go straight to AQR Capital Management\u2019s Top 5 Stock Picks. Following record-breaking returns [\u2026]""}, {""date"": ""2023-10-11"", ""headline"": ""Should You Invest in Gilead Sciences (GILD)?"", ""summary"": ""ClearBridge Investments, an investment management company, released its \u201cClearBridge Dividend Strategy\u201d third quarter 2023 investor letter. A copy of the same can be downloaded here. The strategy underperformed its S&P 500 Index benchmark in the third quarter. The strategy gained from three of the eleven sectors it invested in during the quarter on an absolute basis. [\u2026]""}, {""date"": ""2023-10-12"", ""headline"": ""Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-12"", ""headline"": ""Gilead Sciences to Release Third Quarter 2023 Financial Results on Tuesday, November 7, 2023"", ""summary"": ""FOSTER CITY, Calif., October 12, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2023 financial results and guidance will be released on Tuesday, November 7, 2023 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead\u2019s management will host a webcast to discuss the company\u2019s third quarter 2023 financial results and provide a business update.""}, {""date"": ""2023-10-12"", ""headline"": ""Gilead Sciences Inc. stock falls Thursday, still outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. slipped 0.26% to $76.76 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...""}, {""date"": ""2023-10-12"", ""headline"": ""SDOG: 50 Dogs In Portfolio, Many Are Not The Best Of Breed"", ""summary"": ""ALPS Sector Dividend Dogs uses Dogs of the Dow Theory in the S&P 500, but has underperformed SPY and Schwab U.S. Dividend Equity ETF. Learn more on SDOG ETF here.""}, {""date"": ""2023-10-12"", ""headline"": ""Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032"", ""summary"": ""PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic""}, {""date"": ""2023-10-12"", ""headline"": ""IN BRIEF: Guild Esports signs three new Fortnite players"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-13"", ""headline"": ""Gilead Sciences Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. rose 1.16% to $77.65 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""2023-10-14"", ""headline"": ""Gilead Sciences: Does The Stocks Reward Outweigh The Risk"", ""summary"": ""Gilead Sciences dominates the HIV and HCV pharmaceutical market but faces growing competition from AbbVie and Merck. Read why GILD stock is a Hold.""}, {""date"": ""2023-10-15"", ""headline"": ""Gilead Sciences Stock Is Cheap, With Broad Pipeline"", ""summary"": ""Gilead Sciences' pipeline is active, with multiple therapies progressing through clinical trials. Click here to read why GILD stock is dirt cheap in my opinion.""}, {""date"": ""2023-10-15"", ""headline"": ""2 Dirt Cheap High-Yield Dividend Stocks to Buy Right Now"", ""summary"": ""Pfizer (NYSE: PFE) and Gilead Sciences (NASDAQ: GILD) are two of the world's largest and most prominent drugmakers, not that this has somehow prevented investors from selling off their shares this year.  Pfizer's stock is down by 35% since January.  This terrible performance has made Pfizer's shares almost too cheap.""}, {""date"": ""2023-10-15"", ""headline"": ""ClearBridge Dividend Strategy Q3 2023 Portfolio Manager Commentary"", ""summary"": ""We have deliberately worked to reduce our exposure to higher-multiple names and increase our exposure to lower-priced, high-quality dividend growers.""}]","{""assetTurnoverTTM"": 0.4387, ""bookValue"": 22314, ""cashRatio"": 0.47760569275847636, ""currentRatio"": 1.3378, ""ebitPerShare"": 2.0867, ""eps"": 1.7343, ""ev"": 111679.7, ""fcfMargin"": 0.2316, ""fcfPerShareTTM"": 6.2975, ""grossMargin"": 0.778, ""inventoryTurnoverTTM"": 3.7134, ""longtermDebtTotalAsset"": 0.3718, ""longtermDebtTotalCapital"": 0.4903, ""longtermDebtTotalEquity"": 1.0392, ""netDebtToTotalCapital"": 0.4076, ""netDebtToTotalEquity"": 0.8639, ""netMargin"": 0.3092, ""operatingMargin"": 0.372, ""payoutRatioTTM"": 0.6436, ""pb"": 4.141, ""peTTM"": 15.7281, ""pfcfTTM"": 11.7665, ""pretaxMargin"": 0.3287, ""psTTM"": 3.3735, ""quickRatio"": 0.9757, ""receivablesTurnoverTTM"": 5.991, ""roaTTM"": 0.0941, ""roeTTM"": 0.2742, ""roicTTM"": 0.1261, ""rotcTTM"": 0.1772, ""salesPerShare"": 5.6094, ""sgaToSale"": 0.222, ""totalDebtToEquity"": 1.1196, ""totalDebtToTotalAsset"": 0.4005, ""totalDebtToTotalCapital"": 0.5282, ""totalRatio"": 1.557, ""period"": ""2023-09-30""}"
40,2023-10-15,76.94910430908203,2023-10-22,77.0977554321289,0.0019318109597454836,U1,"[{""date"": ""2023-10-14"", ""headline"": ""Gilead Sciences: Does The Stocks Reward Outweigh The Risk"", ""summary"": ""Gilead Sciences dominates the HIV and HCV pharmaceutical market but faces growing competition from AbbVie and Merck. Read why GILD stock is a Hold.""}, {""date"": ""2023-10-15"", ""headline"": ""Gilead Sciences Stock Is Cheap, With Broad Pipeline"", ""summary"": ""Gilead Sciences' pipeline is active, with multiple therapies progressing through clinical trials. Click here to read why GILD stock is dirt cheap in my opinion.""}, {""date"": ""2023-10-15"", ""headline"": ""2 Dirt Cheap High-Yield Dividend Stocks to Buy Right Now"", ""summary"": ""Pfizer (NYSE: PFE) and Gilead Sciences (NASDAQ: GILD) are two of the world's largest and most prominent drugmakers, not that this has somehow prevented investors from selling off their shares this year.  Pfizer's stock is down by 35% since January.  This terrible performance has made Pfizer's shares almost too cheap.""}, {""date"": ""2023-10-15"", ""headline"": ""ClearBridge Dividend Strategy Q3 2023 Portfolio Manager Commentary"", ""summary"": ""We have deliberately worked to reduce our exposure to higher-multiple names and increase our exposure to lower-priced, high-quality dividend growers.""}, {""date"": ""2023-10-16"", ""headline"": ""AstraZeneca data removes 'slight overhang' on Gilead, says Jefferies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-16"", ""headline"": ""Assembly (NASDAQ:ASMB) Rockets over 80% after Gilead Partnership"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-16"", ""headline"": ""Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know"", ""summary"": ""Gilead Sciences (GILD) reachead $79.20 at the closing of the latest trading day, reflecting a +2% change compared to its last close.""}, {""date"": ""2023-10-16"", ""headline"": ""Jim Simons Stock Portfolio: Top 10 Stock Picks"", ""summary"": ""In this piece, we will take a look at Jim Simons\u2019 stock portfolio and the top ten stock picks. If you want to skip our introduction to some fundamentals of stock trading and the legendary investor, then take a look at Jim Simons Stock Portfolio: Top 5 Stock Picks. As should be clear after the [\u2026]""}, {""date"": ""2023-10-16"", ""headline"": ""Gilead Sciences Inc. stock rises Monday, outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. rose 2.00% to $79.20 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...""}, {""date"": ""2023-10-16"", ""headline"": ""Gilead and Kite Oncology Present Important New Data Across Multiple Difficult-to-Treat Cancers at ESMO Congress 2023"", ""summary"": ""FOSTER CITY, Calif. & SANTA MONICA, Calif., October 16, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present new data, including three oral presentations, at the European Society for Medical Oncology (ESMO) Congress 2023. New clinical data for Trodelvy\u00ae (sacituzumab govitecan-hziy) continue to support its use in metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastatic breast cancer (mBC) and demonstrate the expanding body of evidence fo""}, {""date"": ""2023-10-16"", ""headline"": ""IN BRIEF: Guild Esports professional Fortnite player wins USD200,000"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-16"", ""headline"": ""Gilead and Kite present data across multiple difficult-to-treat cancers at ESMO"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-16"", ""headline"": ""Gilead Demonstrates the Impact of Global Collaboration in Advancing HIV Research and Health Equity at EACS 2023"", ""summary"": ""FOSTER CITY, Calif., October 16, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the 19th European AIDS Conference (EACS) to be held in Warsaw, Poland from October 18-21, 2023. As a leader in HIV innovation, Gilead will provide an update on its signature initiatives, key collaborations and share new scientific data from its HIV research and development programs. The research that will be presented at EACS 2023, along with symposia led by Gilead, reflects""}, {""date"": ""2023-10-17"", ""headline"": ""Dividend Income Update September 2023"", ""summary"": ""With the start of the final quarter of 2023, it\u2019s time to take a look back at my previous month of dividend income.""}, {""date"": ""2023-10-17"", ""headline"": ""Gilead Sciences Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. rose 1.62% to $80.48 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...""}, {""date"": ""2023-10-17"", ""headline"": ""IHF: Healthcare Dashboard For October"", ""summary"": ""Management fees and risk metrics for iShares U.S. Healthcare Providers ETF are significantly higher than the broad healthcare sector. Read more about IHF here.""}, {""date"": ""2023-10-17"", ""headline"": ""Gilead Sciences: Leading With Passion and Purpose: Sandra\u2019s Story"", ""summary"": ""NORTHAMPTON, MA / ACCESSWIRE / October 17, 2023 / Gilead Sciences / Many teenagers have some idea of what they want to do for a career - but few are as crystal clear as Sandra Patterson was. From a young age in Guatemala, Sandra was naturally good ...""}, {""date"": ""2023-10-17"", ""headline"": ""Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases"", ""summary"": ""FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif., October 17, 2023--Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases""}, {""date"": ""2023-10-17"", ""headline"": ""Why Is Assembly Biosciences (ASMB) Stock Up 92% Today?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-17"", ""headline"": ""First Week of GILD January 2026 Options Trading"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-17"", ""headline"": ""Assembly Biosciences Shares Soar Premarket on Gilead Pact"", ""summary"": ""By Colin Kellaher Shares of Assembly Biosciences more than doubled in premarket trading Tuesday after the biotechnology company inked a collaboration deal...""}, {""date"": ""2023-10-17"", ""headline"": ""Gilead Taking Stake in Assembly Bio Under Antiviral Collaboration"", ""summary"": ""By Colin Kellaher Gilead Sciences is taking a significant stake in smaller biotechnology peer Assembly Biosciences as part of a 12-year partnership aimed at...""}, {""date"": ""2023-10-17"", ""headline"": ""Gilead to pay Assembly Bio an initial $100 million as part of 12-year partnership to develop antiviral drugs"", ""summary"": ""Gilead Sciences Inc. announced Tuesday a 12-year partnership Assembly Biosciences Inc. to develop antiviral therapies, with an initial focus in hepatitis B...""}, {""date"": ""2023-10-17"", ""headline"": ""Gilead and Assembly Bio ink deal for antiviral drugs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-17"", ""headline"": ""Gilead to pay Assembly an initial $100 million as part of 12-year partnership to develop antiviral drugs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-17"", ""headline"": ""Gilead to buy 29.9% of Assembly voting stock in $100M pact"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-18"", ""headline"": ""Why AstraZeneca's Disappointing Lung Cancer Update Also Tripped Gilead Stock"", ""summary"": ""AstraZeneca stock tumbled Wednesday after its experimental drug led to only a month's benefit over chemotherapy in lung cancer patients.""}, {""date"": ""2023-10-18"", ""headline"": ""Gilead Sciences Inc. stock falls Wednesday, still outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. slipped 1.01% to $79.67 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P...""}, {""date"": ""2023-10-18"", ""headline"": ""Incyte: One Of The Most Undervalued Pharmaceuticals"", ""summary"": ""Incyte stock declined nearly 60% from all-time highs in 2017 due to market volatility, regulatory challenges, and increased competition. Read more about INCY here.""}, {""date"": ""2023-10-18"", ""headline"": ""My Dividend Stock Portfolio: New September Dividend Record - 98 Holdings With 22 Buys"", ""summary"": ""The S&P 500 and Dow Jones Industrial Average saw sharp losses for the month and the quarter. Click here to read my analysis.""}, {""date"": ""2023-10-18"", ""headline"": ""Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program"", ""summary"": ""FOSTER CITY, Calif., October 18, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced PURPOSE 5, the first Phase 2 clinical trial to evaluate an investigational long-acting HIV prevention option in Europe. The study will assess the persistence\u2014defined as consistent and continuous use\u2014of lenacapavir compared with emtricitabine/tenofovir disoproxil fumarate (F/TDF) in people who may benefit from pre-exposure prophylaxis (PrEP) and who are not currently taking PrEP. The study has an intention""}, {""date"": ""2023-10-18"", ""headline"": ""Hookipa Pharma announces publication of preclinical data on HB-400"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-18"", ""headline"": ""Gilead announces new lenacapavir clinical trial in Europe"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-19"", ""headline"": ""Gilead Sciences Inc. stock falls Thursday, underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. shed 1.54% to $78.44 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-10-19"", ""headline"": ""GILD or VRTX: Which Is the Better Value Stock Right Now?"", ""summary"": ""GILD vs. VRTX: Which Stock Is the Better Value Option?""}, {""date"": ""2023-10-19"", ""headline"": ""Insider Sell: CFO Andrew Dickinson Sells 5,000 Shares of Gilead Sciences Inc"", ""summary"": ""On October 17, 2023, Andrew Dickinson, the Chief Financial Officer (CFO) of Gilead Sciences Inc (NASDAQ:GILD), sold 5,000 shares of the company.""}, {""date"": ""2023-10-19"", ""headline"": ""First Week of February 2024 Options Trading For Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-19"", ""headline"": ""Biotech Alert: Searches spiking for these stocks today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-19"", ""headline"": ""Pfizer Decides To Raise COVID-19 Treatment Pill Price, Defends Itself Amid Criticism for Cost Increase"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-19"", ""headline"": ""Real-World Evidence Reinforces Biktarvy\u00ae as a Long-Term Treatment Option With a High Barrier to Resistance for People With HIV and a Range of Comorbidities"", ""summary"": ""FOSTER CITY, Calif., October 19, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today new long-term real-world data from the BICSTaR study highlighting the safety and efficacy profile of Biktarvy\u00ae (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) as a treatment regimen for a broad range of people with HIV, including those with a prior treatment history or comorbidities. These findings were presented at the 19th European AIDS Conference (EACS 2023), takin""}, {""date"": ""2023-10-19"", ""headline"": ""Vertex Pharmaceuticals, Gilead Sciences And 2 Other Stocks Insiders Are Selling"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-19"", ""headline"": ""Gilead announces new long-term data from BICSTaR study of Biktarvy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-20"", ""headline"": ""Gilead Sciences Inc. stock falls Friday, still outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. slumped 0.82% to $77.80 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-10-20"", ""headline"": ""7 Healthcare Stocks to invest in for a Healthy Future"", ""summary"": ""One of my favorite sectors will always be the healthcare sector. It is practically a basic need for all human beings and is always in constant development and growth. Thanks to this sector, the healthcare area is more effective and efficient due to the application of various technologies and scientific breakthroughs. They benefit healthcare stocks in more ways than one. Here are several healthcare stocks you can keep an eye on to add to your portfolio soon. Let\u2019s take a look. Medtronic (MDT) Sou""}, {""date"": ""2023-10-20"", ""headline"": ""Comparative Study: Gilead Sciences And Industry Competitors In Biotechnology Industry"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-20"", ""headline"": ""New Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca\u00ae for Adults With Multi-Drug Resistant HIV"", ""summary"": ""FOSTER CITY, Calif., October 20, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) presented new data today supporting Sunlenca\u00ae (lenacapavir) as an important treatment option for adults with multi-drug resistant (MDR) HIV who have extensive treatment history. These findings highlight the significance of lenacapavir, the first long-acting injectable HIV treatment medication administered twice-yearly, as a person-centric therapy option and its potential to help transform the future of coordinated HIV cl""}, {""date"": ""2023-10-20"", ""headline"": ""Gilead announces new Sunlenca data from CAPELLA trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-21"", ""headline"": ""We Think Gilead Sciences (NASDAQ:GILD) Can Stay On Top Of Its Debt"", ""summary"": ""Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...""}, {""date"": ""2023-10-22"", ""headline"": ""Eli Lilly, Gilead favorites at BofA ahead of Q3 earnings"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-22"", ""headline"": ""Eli Lilly, Gilead favorites at BofA ahead of Q3 biopharma earnings"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
41,2023-10-22,77.0977554321289,2023-10-29,75.92840576171875,-0.015167103942987814,D2,"[{""date"": ""2023-10-22"", ""headline"": ""Eli Lilly, Gilead favorites at BofA ahead of Q3 earnings"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-22"", ""headline"": ""Eli Lilly, Gilead favorites at BofA ahead of Q3 biopharma earnings"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-23"", ""headline"": ""Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know"", ""summary"": ""Gilead Sciences (GILD) concluded the recent trading session at $77.56, signifying a -0.31% move from its prior day's close.""}, {""date"": ""2023-10-23"", ""headline"": ""Circling Bank On Tango Therapeutics"", ""summary"": ""We are circling back on clinical stage developmental concern Tango Therapeutics, Inc. for the first time since November 2022. Read more about TNGX stock here.""}, {""date"": ""2023-10-23"", ""headline"": ""Gilead Sciences Inc. stock falls Monday, underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. slumped 0.31% to $77.56 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...""}, {""date"": ""2023-10-23"", ""headline"": ""Daiichi Sankyo: Positive Long-Term Outlook With High Market Expectations"", ""summary"": ""Daiichi Sankyo is a Japanese pharmaceutical company known for its flagship products Lixiana and Enhertu. Click here to read my analysis of DSKYF stock.""}, {""date"": ""2023-10-24"", ""headline"": ""Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider"", ""summary"": ""Gilead Sciences (GILD) concluded the recent trading session at $78.15, signifying a +0.76% move from its prior day's close.""}, {""date"": ""2023-10-24"", ""headline"": ""Gilead Sciences Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.76% higher to $78.15 Tuesday, on what proved to be an all-around positive trading session for the stock market, with...""}, {""date"": ""2023-10-24"", ""headline"": ""Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS"", ""summary"": ""FOSTER CITY, Calif., October 24, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today was recognized as the number one philanthropic funder of HIV-related programs for the second year in a row, in a new report released by Funders Concerned About AIDS (FCAA). FCAA\u2019s annual Philanthropic Support to Address HIV and AIDS report is widely regarded as the most comprehensive study of its kind, and analyzed data from more than 5,000 grants, disbursed by 187 funders and awarded to 2,800 grantee organizations""}, {""date"": ""2023-10-24"", ""headline"": ""3 Biotech Stocks With Decent Dividend for a Steady Return"", ""summary"": ""Here we pick three medical device stocks, AbbVie (ABBV), Amgen (AMGN) and Gilead Sciences (GILD), which have a solid five-year dividend growth history.""}, {""date"": ""2023-10-24"", ""headline"": ""10 Health Care Stocks With Whale Alerts In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-24"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: ESSA Pharma (EPIX), Boston Scientific (BSX) and Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-24"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Gilead Sciences (GILD) and Alkermes (ALKS)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-24"", ""headline"": ""Analysts\u2019 Top Healthcare Picks: Boston Scientific (BSX), Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-24"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-24"", ""headline"": ""Buy Rating for Gilead Sciences: Anticipated Growth in HIV and Oncology Sectors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-24"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Alkermes (ALKS) and Can-Fite BioPharma (CANF)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-25"", ""headline"": ""Should We Be Delighted With Gilead Sciences, Inc.'s (NASDAQ:GILD) ROE Of 26%?"", ""summary"": ""Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...""}, {""date"": ""2023-10-25"", ""headline"": ""USA Compression and Disney have been highlighted as Zacks Bull and Bear of the Day"", ""summary"": ""USA Compression and Disney have been highlighted as Zacks Bull and Bear of the Day.""}, {""date"": ""2023-10-26"", ""headline"": ""Gilead Sciences Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.14% higher to $78.50 Thursday, on what proved to be an all-around rough trading session for the stock market, with...""}, {""date"": ""2023-10-26"", ""headline"": ""3 Pharma Stocks That Are Screaming Buys in October"", ""summary"": ""It hasn't been the easiest of years for Johnson & Johnson (NYSE: JNJ), Amgen (NASDAQ: AMGN) and Gilead Sciences (NASDAQ: GILD).  Continued uncertainty regarding talc lawsuits is weighing on Johnson & Johnson.  Amgen's huge pipeline hasn't been fully appreciated by the market, and Gilead's settlement of an antitrust lawsuit resulted in lowering yearly earnings per share guidance.""}, {""date"": ""2023-10-27"", ""headline"": ""Gilead Sciences Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. slid 2.39% to $76.62 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-10-27"", ""headline"": ""BMO Capital Markets lists Chevron, Pfizer among oversold high dividend-yielding stocks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-29"", ""headline"": ""Pharma, PBMs spar over rising drug costs amid public scrutiny"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
42,2023-10-29,75.92840576171875,2023-11-05,80.8535385131836,0.064865483504567,U5+,"[{""date"": ""2023-10-29"", ""headline"": ""Pharma, PBMs spar over rising drug costs amid public scrutiny"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-30"", ""headline"": ""Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know"", ""summary"": ""Gilead Sciences (GILD) closed at $77.88 in the latest trading session, marking a +1.64% move from the prior day.""}, {""date"": ""2023-10-30"", ""headline"": ""Gilead (GILD) Gears Up to Report Q3 Earnings: What's in Store?"", ""summary"": ""Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its third-quarter 2023 results.""}, {""date"": ""2023-10-30"", ""headline"": ""11 Best Pharma Stocks To Buy Now"", ""summary"": ""In this article, we discuss the 12 best pharma stocks to buy now. You can skip our detailed analysis of the pharmaceutical sector and its outlook this year, and go directly to read the 5 Best Pharma Stocks To Buy Now. Shortly following the onset of the COVID-19 pandemic, it became evident that the world [\u2026]""}, {""date"": ""2023-10-30"", ""headline"": ""IN BRIEF: Guild Esports to raise GBP1.0 million from unnamed investor"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-31"", ""headline"": ""Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?"", ""summary"": ""Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.""}, {""date"": ""2023-10-31"", ""headline"": ""Gilead's Commitment to Advancing Health Equity for Black Women and Ending the HIV Epidemic"", ""summary"": ""NORTHAMPTON, MA / ACCESSWIRE / October 31, 2023 / Before I came to Gilead, I knew it as a company that produces innovative therapies across HIV, liver disease and cancer. Now I know it's so much more. Its focus goes well beyond medicine - and at its ...""}, {""date"": ""2023-10-31"", ""headline"": ""See Which Of The Latest 13F Filers Holds Gilead Sciences"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-31"", ""headline"": ""Kite and Epic Bio Announce Collaboration to Develop New Therapies for Cancer"", ""summary"": ""SANTA MONICA & SOUTH SAN FRANCISCO, Calif., October 31, 2023--Kite, a Gilead Company (Nasdaq: GILD) and Epicrispr Biotechnologies (\""Epic Bio\""), today announced the companies have entered into a research collaboration and license agreement using Epic Bio\u2019s proprietary gene regulation platform to develop next-generation cancer cell therapies. The agreement will allow Kite to leverage the licensed technology to modulate certain genes to potentially enhance CAR T-cell functionality.""}, {""date"": ""2023-10-31"", ""headline"": ""Leidos Sees Robust Demand In Digital Modernization, Raises Annual Outlook"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-01"", ""headline"": ""This Is What Whales Are Betting On Gilead Sciences"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-01"", ""headline"": ""Gilead Sciences Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. rose 2.10% to $80.19 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-11-01"", ""headline"": ""Is Now The Time To Put Gilead Sciences (NASDAQ:GILD) On Your Watchlist?"", ""summary"": ""It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...""}, {""date"": ""2023-11-02"", ""headline"": ""Fed Holds Rates Steady, Powell's Cautious Stance Soothes Investors, Labor Market Softens: The Week In The Markets"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-02"", ""headline"": ""Catalyst Watch: Disney earnings, Moderna AI event, Powell IMF speech and Las Vegas strike threat"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-02"", ""headline"": ""Gilead Sciences Inc. stock rises Thursday, still underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. rallied 1.30% to $81.23 Thursday, on what proved to be an all-around positive trading session for the stock market, with the...""}, {""date"": ""2023-11-02"", ""headline"": ""Earnings Preview: Illumina (ILMN) Q3 Earnings Expected to Decline"", ""summary"": ""Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.""}, {""date"": ""2023-11-02"", ""headline"": ""Gilead and Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023"", ""summary"": ""FOSTER CITY, Calif. & SANTA MONICA, Calif., November 02, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will share 29 presentations, including 10 oral presentations, during the 65th American Society of Hematology (ASH) Annual Meeting and Exposition (December 9-12).""}, {""date"": ""2023-11-02"", ""headline"": ""Arcellx jumps after data for Gilead-partnered multiple myeloma drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-03"", ""headline"": ""Gilead Sciences Inc. stock rises Friday, still underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.44% higher to $81.59 Friday, on what proved to be an all-around great trading session for the stock market, with the...""}, {""date"": ""2023-11-03"", ""headline"": ""Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting\u00ae 2023"", ""summary"": ""FOSTER CITY, Calif., November 03, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new viral hepatitis data at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting\u00ae, from November 10-14, 2023. Key findings from more than 80 presentations will include a late-breaker oral presentation of primary endpoint results from the Phase 2b MYR204 study evaluating Hepcludex\u00ae (bulevirtide), an investigational therapy in the U.S. and outside of the Eu""}, {""date"": ""2023-11-03"", ""headline"": ""Six bullish stocks to consider by the end of the year - BofA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-03"", ""headline"": ""Gilead to present late breaking data at The Liver Meeting 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-05"", ""headline"": ""Earnings week ahead: Disney, AMC, Plug Power, Lucid, Realty Income and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
43,2023-11-05,80.8535385131836,2023-11-12,75.2347183227539,-0.0694938068729486,D5+,"[{""date"": ""2023-11-05"", ""headline"": ""Gilead and Arcus Biosciences report results from EDGE-Gastric study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-05"", ""headline"": ""Earnings week ahead: Disney, AMC, Plug Power, Lucid, Realty Income and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-06"", ""headline"": ""S&P 500 futures dip after six-day winning streak"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-06"", ""headline"": ""Gilead Sciences: HIV revenue climbs 4% Y/Y; Oncology revenue up 33%"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-06"", ""headline"": ""Market Today: Rivian Rises on Q3 Beat, Upstart and Lucid Miss Revenue Estimates"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-06"", ""headline"": ""Gilead Sciences Non-GAAP EPS of $2.29 beats by $0.38, revenue of $7.05B beats by $260M"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-06"", ""headline"": ""Gilead stock rises on top-, bottom-line beats"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-06"", ""headline"": ""Gilead raises FY23 EPS view to $6.65-$6.85 from $6.45-$6.80, consensus $6.25"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-06"", ""headline"": ""Gilead reports Q3 adjusted EPS $2.29, consensus $1.81"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-06"", ""headline"": ""US Stocks Eye Longest Winning Streak In 2 Years, Oil Tumbles: What's Driving Markets Tuesday?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-06"", ""headline"": ""GLOBAL BRIEFING: China's imports return to growth as exports drop"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-06"", ""headline"": ""Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers"", ""summary"": ""FOSTER CITY, Calif. & HAYWARD, Calif., November 06, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate (ORR) and six-month progression-free survival (PFS) rate results in a preliminary analysis from Arm A1 of the EDGE-Gastric study. This ongoing Phase 2, multi-arm, global study is evaluating the safety and efficacy of various combinations of the Fc-silent""}, {""date"": ""2023-11-06"", ""headline"": ""Gilead Sciences Inc. stock falls Monday, underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. shed 0.55% to $81.14 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""2023-11-06"", ""headline"": ""Anticipated Performance and Potential Challenges: A Hold Rating for Gilead Sciences"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-06"", ""headline"": ""Gilead\u2019s HIV business in focus with Q3 results on deck"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-06"", ""headline"": ""Institutional investors must be pleased after a 4.9% gain last week that adds to Gilead Sciences, Inc.'s (NASDAQ:GILD) one-year returns"", ""summary"": ""Key Insights Significantly high institutional ownership implies Gilead Sciences' stock price is sensitive to their...""}, {""date"": ""2023-11-06"", ""headline"": ""Promising Growth and Strategic Outlook: An Analysis of Gilead Sciences\u2019s Stock Performance"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-06"", ""headline"": ""If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,200 Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-07"", ""headline"": ""Take-Two Interactive shares surge on report of new Grand Theft Auto game as Robinhood stock drops on earnings miss"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-07"", ""headline"": ""Challenges and Opportunities: An Analysis of Gilead Sciences\u2019 Hold Rating amid HIV Market Dominance, Oncology Expansion, and Legislative Impact"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-07"", ""headline"": ""Gilead initiated with a Hold at Deutsche Bank"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-07"", ""headline"": ""Noteworthy Wednesday Option Activity: GILD, MOS, PAYO"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-07"", ""headline"": ""Gilead Sciences (GILD) Q3 2023 Earnings Call Transcript"", ""summary"": ""The press release, slides, and supplementary data are available on the Investors section of our website at gilead.com.  The speakers on today's call will be our chairman and chief executive officer, Daniel O'Day; our chief commercial officer, Johanna Mercier; our chief medical officer, Merdad Parsey; and our chief financial officer, Andrew Dickinson.""}, {""date"": ""2023-11-07"", ""headline"": ""GLOBAL BRIEFING: Rivian raises guidance; eBay's outlook disappoints"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-07"", ""headline"": ""Compared to Estimates, Gilead (GILD) Q3 Earnings: A Look at Key Metrics"", ""summary"": ""The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.""}, {""date"": ""2023-11-07"", ""headline"": ""Gilead Sciences (GILD) Tops Q3 Earnings and Revenue Estimates"", ""summary"": ""Gilead (GILD) delivered earnings and revenue surprises of 19.90% and 4.08%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?""}, {""date"": ""2023-11-07"", ""headline"": ""UPDATE 1-Gilead quarterly results beat Street estimates as lower taxes boost profit"", ""summary"": ""Drugmaker Gilead Sciences on Tuesday said its third-quarter sales were little changed from a year earlier, but earnings rose 21% due mainly to lower taxes.  Wall Street analysts had expected an adjusted profit of $1.92 per share on revenue of $6.8 billion, according to LSEG data.  Sales of COVID drug Veklury fell 31% to $636 million, but still came in well above Wall Street expectations of $363 million.""}, {""date"": ""2023-11-07"", ""headline"": ""Gilead Squashes Expectations On The Back Of A Bullish Move For Its Cancer Drugs"", ""summary"": ""Gilead crushed forecasts Tuesday on the back of another quarter of double-digit growth for its cancer drugs. GILD stock was muted.""}, {""date"": ""2023-11-07"", ""headline"": ""Gilead quarterly results beat Street estimates as lower taxes boost profit"", ""summary"": ""(Reuters) -Drugmaker Gilead Sciences on Tuesday said its third-quarter sales were little changed from a year earlier, but earnings rose 21% due mainly to lower taxes.  Wall Street analysts had expected an adjusted profit of $1.92 per share on revenue of $6.8 billion, according to LSEG data.  Sales of COVID drug Veklury fell 31% to $636 million, but still came in well above Wall Street expectations of $363 million.""}, {""date"": ""2023-11-07"", ""headline"": ""Gilead Sciences Announces Third Quarter 2023 Financial Results"", ""summary"": ""FOSTER CITY, Calif., November 07, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter of 2023.""}, {""date"": ""2023-11-07"", ""headline"": ""Gilead quarterly results beat Street estimates as profit up on lower taxes"", ""summary"": ""Drugmaker Gilead Sciences on Tuesday said third-quarter sales were little changed from a year earlier, but earnings rose 21% due mainly to lower taxes.  The Foster City, California-based company reported a quarterly profit of $2.29 per share excluding items, on total revenue of $7.1 billion, up from $1.90 a share on revenue of just over $7 billion in the year-ago quarter.  Wall Street analysts had expected an adjusted profit of $1.92 per share on revenue of $6.8 billion, according to LSEG data.""}, {""date"": ""2023-11-07"", ""headline"": ""Gilead Sciences, Inc. (GILD) Q3 2023 Earnings Call Transcript"", ""summary"": ""Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ETCompany ParticipantsJacquie Ross - Vice President,...""}, {""date"": ""2023-11-07"", ""headline"": ""Dow futures remain steady, eBay, Bumble report earnings"", ""summary"": ""Investing.com - US stock futures were trading higher during Tuesday's evening deals, following a positive session for major benchmark averages as easing yields boosted sentiment, while investors digested a fresh slew of corporate earnings results.""}, {""date"": ""2023-11-07"", ""headline"": ""Gilead Sciences lifts outlook despite flat quarterly revenue"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-07"", ""headline"": ""Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. slid 0.65% to $80.61 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-11-07"", ""headline"": ""Gilead reports better-than-expected Q3 results amid stronger cancer drug sales"", ""summary"": ""Investing.com -- Gilead reported Tuesday third-quarter results that beat analyst estimates, driven by strong sales of its cancer drugs.""}, {""date"": ""2023-11-07"", ""headline"": ""Gilead Sciences 3Q Results Beat Estimates"", ""summary"": ""By Denny Jacob Gilead Sciences posted better-than-expected top- and bottom-line results in the latest quarter, which the company credited to its virology and...""}, {""date"": ""2023-11-07"", ""headline"": ""Gilead Sciences Raises 2023 Outlook"", ""summary"": ""By Denny Jacob Gilead Sciences raised its outlook for 2023. The biopharmaceutical company forecast total sales between $26.7 billion and $26.9 billion versus...""}, {""date"": ""2023-11-07"", ""headline"": ""Gilead: Q3 Earnings Snapshot"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-07"", ""headline"": ""Gilead Sciences, Inc. 2023 Q3 - Results - Earnings Call Presentation"", ""summary"": ""The following slide deck was published by Gilead Sciences, Inc.""}, {""date"": ""2023-11-07"", ""headline"": ""Gilead stock rises, then falls, on top-, bottom-line beats"", ""summary"": ""Gilead Sciences Inc.\u2019s stock initially climbed 2% before dipping 1% in extended trading Tuesday after the pharmaceutical company reported quarterly results...""}, {""date"": ""2023-11-07"", ""headline"": ""Gilead Sciences: Advancing Global Health Equity in Tropical Regions"", ""summary"": ""NORTHAMPTON, MA / ACCESSWIRE / November 7, 2023 / Gilead Sciences / In the late 1980s, people in Dr. Shyam Sundar's homeland in eastern India were dying by the hundreds of thousands of a debilitating parasitic disease known as visceral leishmaniasis ...""}, {""date"": ""2023-11-07"", ""headline"": ""The Better-Than-Expected Earnings Plus Cautious Commentary Trend Continues"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-07"", ""headline"": ""Notable companies reporting after market close"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-07"", ""headline"": ""Positive News For Gastric Cancers - Gilead/Arcus Biosciences' Combination Cancer Therapy Shows Encouraging Clinical Activity"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-07"", ""headline"": ""Analysts\u2019 Opinions Are Mixed on These Healthcare Stocks: Ascendis Pharma (ASND), Gilead Sciences (GILD) and SAGE Therapeutics (SAGE)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-07"", ""headline"": ""Gilead Sciences Tops Q3 Earnings And Revenue Estimates"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-07"", ""headline"": ""S&P 500, Nasdaq Set To Break 6-Day Rally Today? Traders Await Fed Cues, Analyst Says Seasonal Rally Has Started With Gusto"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-07"", ""headline"": ""Fly Intel: After-Hours Movers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-08"", ""headline"": ""Gilead Sciences to Present at Upcoming Investor Conferences"", ""summary"": ""FOSTER CITY, Calif., November 09, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:""}, {""date"": ""2023-11-08"", ""headline"": ""Gilead Tumbles After An Unpredictable Element Drove Its Third-Quarter Beat"", ""summary"": ""Investors hammered GILD stock on Wednesday after Gilead beat third-quarter expectations on the back of its Covid treatment, Veklury.""}, {""date"": ""2023-11-08"", ""headline"": ""Gilead Sciences, Inc. (NASDAQ:GILD) Q3 2023 Earnings Call Transcript"", ""summary"": ""Gilead Sciences, Inc. (NASDAQ:GILD) Q3 2023 Earnings Call Transcript November 7, 2023 Gilead Sciences, Inc. beats earnings expectations. Reported EPS is $2.29, expectations were $1.91. Operator: Hello everyone and welcome to the Third Quarter 2023 Gilead Sciences\u2019 Earnings Conference Call. My name is Nadia and I\u2019ll be coordinating the call today. [Operator Instructions] I will [\u2026]""}, {""date"": ""2023-11-08"", ""headline"": ""Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. shed 3.36% to $77.90 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P...""}, {""date"": ""2023-11-08"", ""headline"": ""Gilead (GILD) Q3 Earnings Beat, Trodelvy Fuels Oncology Sales"", ""summary"": ""Gilead (GILD) reports better-than-expected results for the third quarter as Trodelvy boosts oncology sales and Biktarvy maintains momentum in the HIV franchise.""}, {""date"": ""2023-11-08"", ""headline"": ""Warner Bros, Bumble, Robinhood fall premarket; Rivian, Upwork, Take-Two rise"", ""summary"": ""Investing.com -- U.S. futures stagnated Wednesday, as investors awaited a speech by Fed Chair Jerome Powell which could offer clues over future monetary policy.""}, {""date"": ""2023-11-08"", ""headline"": ""Q3 2023 Gilead Sciences Inc Earnings Call"", ""summary"": ""Q3 2023 Gilead Sciences Inc Earnings Call""}, {""date"": ""2023-11-08"", ""headline"": ""Toast, Upstart shares sink while Take-Two\u2019s stock rallies \u2014 and other stocks on the move"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-08"", ""headline"": ""Gilead Sciences slips despite Q3 beat and guidance raise"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-08"", ""headline"": ""GILD Crosses Below Key Moving Average Level"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-08"", ""headline"": ""Gilead Sciences declares $0.75 dividend"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-08"", ""headline"": ""Truist Financial Keeps Their Buy Rating on Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-08"", ""headline"": ""Analysts\u2019 Opinions Are Mixed on These Healthcare Stocks: Zimmer Biomet Holdings (ZBH), Stryker (SYK) and Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-08"", ""headline"": ""Gilead Sciences: A Promising Buy Recommendation Based on Expertise, Growth, and Strong Performance"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-08"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Masimo (MASI), Gilead Sciences (GILD) and Siemens Healthineers AG (OtherSEMHF)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-08"", ""headline"": ""Gilead price target raised to $82 from $80 at Barclays"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-08"", ""headline"": ""The Gilead Sciences Inc (GILD) Company: A Short SWOT Analysis"", ""summary"": ""Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight""}, {""date"": ""2023-11-08"", ""headline"": ""Analysts Conflicted on These Healthcare Names: Viatris (VTRS), Globus Medical (GMED) and Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-09"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Vertex (VERX)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-09"", ""headline"": ""Deutsche Bank Initiates Coverage of Gilead Sciences (GILD) with Hold Recommendation"", ""summary"": """"}, {""date"": ""2023-11-09"", ""headline"": ""Gilead Sciences Inc. stock falls Thursday, underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. slid 3.75% to $74.98 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...""}, {""date"": ""2023-11-09"", ""headline"": ""Gilead Sciences: Research Scholars Program Scientists Advancing HIV Research"", ""summary"": ""NORTHAMPTON, MA / ACCESSWIRE / November 9, 2023 / Gilead Sciences / Dr. Shringar Rao's inquisitive nature and dedication to addressing health inequities drive her eagerness to help advance innovative scientific breakthroughs. Even as an early-career ...""}, {""date"": ""2023-11-09"", ""headline"": ""A Closer Look at Gilead Sciences's Options Market Dynamics"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-09"", ""headline"": ""Eli Lilly declines a day after FDA nod for weight loss therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-09"", ""headline"": ""Video: Nasdaq 100 Movers: GILD, SIRI"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-09"", ""headline"": ""Top 20 Drug Companies in the US by Revenue"", ""summary"": ""In this article, we will be taking a look at the top 20 drug companies in the US by revenue. To skip our detailed analysis, you can go directly to see the Top 5 Drug Companies in the US by Revenue. Following the Covid-19 pandemic, which drastically altered the way of living, the top pharmaceutical [\u2026]""}, {""date"": ""2023-11-09"", ""headline"": ""Where Gilead Sciences Stands With Analysts"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-10"", ""headline"": ""Gilead Sciences Inc. stock rises Friday, still underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. rose 1.25% to $75.92 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-11-10"", ""headline"": ""U.S. Wide-Moat Stocks On Sale - The November 2023 Heat Map"", ""summary"": ""Discover our 3-step process for identifying attractive, undervalued stocks with wide economic moats - Morningstar approved. Click here to read more.""}, {""date"": ""2023-11-10"", ""headline"": ""Gilead Sciences (NASDAQ:GILD) shareholders YoY returns are lagging the company's 19% three-year earnings growth"", ""summary"": ""By buying an index fund, investors can approximate the average market return. But many of us dare to dream of bigger...""}, {""date"": ""2023-11-10"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Gilead Sciences (GILD) and Quanterix (QTRX)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-10"", ""headline"": ""WHO\u2019s new COVID guidelines see fewer patients requiring hospitalization"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-10"", ""headline"": ""Analysts Have Conflicting Sentiments on These Healthcare Companies: Vor Biopharma (VOR), Gilead Sciences (GILD) and Achieve Life Sciences (ACHV)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-10"", ""headline"": ""Positive Performance and Upward Guidance Revision Drive Buy Rating for Gilead Sciences"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-10"", ""headline"": ""Hold Rating for Gilead Sciences: Evaluating Q3 Performance, COVID-19 Impact, and Future Business Growth Predictions"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-11"", ""headline"": ""Stage Set For Moat Stocks Rebound?"", ""summary"": ""Despite a rough October for equities, there is optimism heading into year-end. Has the stage been set for moat stocks rebound? Find out.""}]",{}
44,2023-11-12,75.2347183227539,2023-11-19,74.76895904541016,-0.006190749267454665,D1,"[{""date"": ""2023-11-12"", ""headline"": ""Gilead Sciences: Slow Progress, But Progress Altogether"", ""summary"": ""Gilead Sciences has seen mixed signals in its earnings and sales growth. Click here to find out why I think GILD stock is appealing at lower levels.""}, {""date"": ""2023-11-13"", ""headline"": ""Jim Simons Stock Portfolio: 12 Biggest Healthcare Stocks"", ""summary"": ""In this piece, we will take a look at the 12 biggest healthcare stocks in Jim Simons\u2019 stock portfolio. If you want to skip our introduction to the billionaire former hedge fund boss and the healthcare industry, then read Jim Simons Stock Portfolio: 5 Biggest Healthcare Stocks. Owing to the sheer number of stocks that [\u2026]""}, {""date"": ""2023-11-13"", ""headline"": ""Gilead Sciences Inc. stock falls Monday, underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. slid 1.30% to $74.93 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""2023-11-14"", ""headline"": ""Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. sank 0.28% to $74.72 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...""}, {""date"": ""2023-11-14"", ""headline"": ""Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS"", ""summary"": ""- The New Report Also Recognized Gilead As the Number One Funder of Organizations Focused on Achieving Health Equity for Key Populations, Including U.S. BIPOC Communities, Transgender Communities and Gay Men -FOSTER CITY, CA / ACCESSWIRE / November ...""}, {""date"": ""2023-11-14"", ""headline"": ""Gilead price target lowered to $77 from $78 at RBC Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-15"", ""headline"": ""Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors despite daily gains"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.43% higher to $75.04 Wednesday, on what proved to be an all-around positive trading session for the stock market,...""}, {""date"": ""2023-11-15"", ""headline"": ""4%-Yielding Gilead Sciences' Potential Path To A $100 Stock Price"", ""summary"": ""Despite challenges, Gilead Sciences sees a path to sustained growth thanks to a promising pipeline and strong existing products. Find out why GILD stock is a Buy.""}, {""date"": ""2023-11-15"", ""headline"": ""Arcellx Stock Surges as Gilead Adds to Stake, Expands Collaboration"", ""summary"": ""Gilead Sciences  is devoting another $200 million to its existing partnership with  Arcellx  the biotechnology companies said Wednesday.  Kite, a Gilead (ticker: GILD) company, has exercised an option to negotiate a license for  Arcellx  \u2018s ARC-SparX program, ACLX-001, in multiple myeloma.  The companies said they also expanded the scope of their collaboration for Arcellx\u2019s CART-ddBCMA to include lymphomas.""}, {""date"": ""2023-11-15"", ""headline"": ""Arcellx: A Strong Contender In The CAR-T Multiple Myeloma Market"", ""summary"": ""Arcellx's CART-ddBCMA reported strong and competitive data in late-line multiple myeloma patients. Read more to see our analysis on ACLX stock.""}, {""date"": ""2023-11-15"", ""headline"": ""Gilead Sciences's Options: A Look at What the Big Money is Thinking"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-15"", ""headline"": ""Kite and Arcellx Announce Expansion in Strategic Partnership"", ""summary"": ""SANTA MONICA, Calif. & REDWOOD CITY, Calif., November 15, 2023--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced that the companies have expanded their existing collaboration, which was originally announced in December 2022.""}, {""date"": ""2023-11-15"", ""headline"": ""ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP"", ""summary"": ""Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced that the companies have expanded their existing collaboration, which was originally announced in December 2022.""}, {""date"": ""2023-11-15"", ""headline"": ""Gilead Sciences, Inc. (GILD) Jefferies London Healthcare Conference (Transcript)"", ""summary"": ""Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Jefferies London Healthcare Conference November 15, 2023 4:00 AM ETCompany ParticipantsAndrew Dickinson - Chief...""}, {""date"": ""2023-11-15"", ""headline"": ""My Dividend Stock Portfolio: New October Dividend Record - 98 Holdings With 23 Buys"", ""summary"": ""S&P 500 and Dow Jones dropped for the third straight month in October, just before staging a remarkable reversal in November. Click here to read more.""}, {""date"": ""2023-11-15"", ""headline"": ""Arcellx Shares Rise Premarket on Expanded Gilead Collaboration"", ""summary"": ""By Colin Kellaher Shares of Arcellx jumped more than 10% in premarket trading Wednesday after the clinical-stage biotechnology company inked an extension of...""}, {""date"": ""2023-11-15"", ""headline"": ""Global E Online, Zim Integrated Shipping, reAlpha Tech among premarket losers' pack"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-15"", ""headline"": ""Gilead Invests Further in Arcellx, Extends Collaboration"", ""summary"": ""By Colin Kellaher Gilead Sciences is investing another $200 million in clinical-stage biotechnology company Arcellx as part of an expansion of the duo's...""}, {""date"": ""2023-11-15"", ""headline"": ""Arcellx\u2019s stock set to surge after Gilead makes $200 million investment at a 30% premium"", ""summary"": ""Shares of Arcellx Inc. were set to surge Wednesday, after biotechnology company announced a $200 million equity investment by Gilead Sciences Inc.\u2019s Kite as...""}, {""date"": ""2023-11-15"", ""headline"": ""Gilead invests $200M in Arcellx as collaboration expands"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-15"", ""headline"": ""Arcellx to receive $200M investment from Gilead for ACLX-001"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-15"", ""headline"": ""Arcellx, Kite expand partnership"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-16"", ""headline"": ""Gilead Sciences Inc. stock falls Thursday, underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. dropped 0.69% to $74.52 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P...""}, {""date"": ""2023-11-16"", ""headline"": ""Arcellx (ACLX) Up 5% on Partnership Expansion With Gilead"", ""summary"": ""Arcellx (ACLX) and Gilead (GILD) expand their existing collaboration in cancer treatment. This deal is expected to close by year-end.""}, {""date"": ""2023-11-16"", ""headline"": ""Analysts Are Bullish on These Healthcare Stocks: Cytek Biosciences (CTKB), DENTSPLY SIRONA (XRAY)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-16"", ""headline"": ""Arcellx price target raised to $70 from $58 at Guggenheim"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-17"", ""headline"": ""Gilead Sciences Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. rallied 1.25% to $75.45 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""2023-11-17"", ""headline"": ""FDA Approves AstraZeneca's Truqap/Faslodex Combo Therapy For Breast Cancer, Competes With Gilead's Drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-19"", ""headline"": ""M&A, GLP-1s to dominate healthcare themes in 2024 as COVID fades: survey"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
45,2023-11-19,74.76895904541016,2023-11-26,74.69959259033203,-0.0009277440259131131,D1,"[{""date"": ""2023-11-19"", ""headline"": ""M&A, GLP-1s to dominate healthcare themes in 2024 as COVID fades: survey"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-20"", ""headline"": ""Gilead management to meet with Oppenheimer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-20"", ""headline"": ""Gilead Sciences Inc. stock rises Monday, still underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.73% higher to $76.00 Monday, on what proved to be an all-around great trading session for the stock market, with the...""}, {""date"": ""2023-11-20"", ""headline"": ""Analysts Have Conflicting Sentiments on These Healthcare Companies: Airsculpt Technologies, Inc. (AIRS), Vir Biotechnology (VIR) and Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-20"", ""headline"": ""20 Most Valuable Healthcare Companies in the World"", ""summary"": ""In this article, we will look into the 20 most valuable healthcare companies in the world. If you want to skip our detailed analysis, you can go directly to the 5 Most Valuable Healthcare Companies in the World. Healthcare Services Industry: A Market Analysis According to a report by Verified Market Research, the global healthcare [\u2026]""}, {""date"": ""2023-11-20"", ""headline"": ""Hookipa Pharma announces FDA clearance of IND application for HB-500"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-21"", ""headline"": ""Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. slipped 1.72% to $74.69 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P...""}, {""date"": ""2023-11-21"", ""headline"": ""The Zacks Analyst Blog Highlights Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics"", ""summary"": ""Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics are part of the Zacks top Analyst Blog.""}, {""date"": ""2023-11-21"", ""headline"": ""Gilead Sciences: Breaking Barriers to Breast Cancer Care in Rural Areas"", ""summary"": ""NORTHAMPTON, MA / ACCESSWIRE / November 21, 2023 / Gilead SciencesClaudia Hardy says she's found her life's mission. As director of Community Health Access and Relations for the O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham ...""}, {""date"": ""2023-11-21"", ""headline"": ""$100 Invested In This Stock 20 Years Ago Would Be Worth $1,000 Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-21"", ""headline"": ""Gilead Sciences (NASDAQ:GILD) Seems To Use Debt Quite Sensibly"", ""summary"": ""David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...""}, {""date"": ""2023-11-21"", ""headline"": ""Aurinia Pharma jumps amid takeover speculation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-21"", ""headline"": ""Aurinia strength may be related to Gilead suspicion, says Gordon Haskett"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-21"", ""headline"": ""Stocks Stall On November 21, 2023, As Systematic Flows Abate"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-22"", ""headline"": ""Gilead Sciences Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. rallied 1.35% to $75.70 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-11-22"", ""headline"": ""5 Biotech Stocks Likely to Thrive as Industry Prospects Look Bright"", ""summary"": ""New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, CRSP, ACAD, DVAX and LGND well amid volatility.""}, {""date"": ""2023-11-22"", ""headline"": ""Looking Into Gilead Sciences's Recent Short Interest"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-22"", ""headline"": ""GSK: Undervalued At Peak Pessimism"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-22"", ""headline"": ""Under Armour: Undervalued And Finally Turning Around"", ""summary"": ""Under Armour's struggles are possibly ending, as a better technical and fundamental outlook suggest a compelling buy opportunity. Click here to read.""}, {""date"": ""2023-11-22"", ""headline"": ""Jefferies U.S. quant portfolio - ROIC stars and high yield"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-24"", ""headline"": ""Gilead Sciences Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. dropped 0.42% to $75.38 Friday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-11-24"", ""headline"": ""Zacks Industry Outlook Highlights Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals"", ""summary"": ""Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals are part of the Zacks Industry Outlook article.""}, {""date"": ""2023-11-26"", ""headline"": ""3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later"", ""summary"": ""Three Motley Fool contributors think they've found fantastic dividend stocks to buy sooner rather than later.  Here's why they chose AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), and Gilead Sciences (NASDAQ: GILD).  Keith Speights (AbbVie): You could look at where things stand right now for AbbVie and decide to avoid this stock.""}, {""date"": ""2023-11-26"", ""headline"": ""15 Best Drug Stocks To Invest In"", ""summary"": ""In this article, we discuss the 15 best drug stocks to invest in. You can skip our detailed analysis of the drug and pharmaceutical sector and its outlook this year, and go directly to read the 5 Best Drug Stocks To Invest In. Healthcare expands on the defensive concept, encompassing a myriad of companies. This [\u2026]""}]",{}
46,2023-11-26,74.69959259033203,2023-12-03,76.94910430908203,0.030114109605480444,U4,"[{""date"": ""2023-11-26"", ""headline"": ""3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later"", ""summary"": ""Three Motley Fool contributors think they've found fantastic dividend stocks to buy sooner rather than later.  Here's why they chose AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), and Gilead Sciences (NASDAQ: GILD).  Keith Speights (AbbVie): You could look at where things stand right now for AbbVie and decide to avoid this stock.""}, {""date"": ""2023-11-26"", ""headline"": ""15 Best Drug Stocks To Invest In"", ""summary"": ""In this article, we discuss the 15 best drug stocks to invest in. You can skip our detailed analysis of the drug and pharmaceutical sector and its outlook this year, and go directly to read the 5 Best Drug Stocks To Invest In. Healthcare expands on the defensive concept, encompassing a myriad of companies. This [\u2026]""}, {""date"": ""2023-11-27"", ""headline"": ""Gilead Sciences Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Gilead Sciences Inc. slumped 0.61% to $74.92 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-11-28"", ""headline"": ""AWS expands big pharma partnerships in manufacturing, AI, and R&D"", ""summary"": ""Pfizer and Amazon Web Services are just another example of how artificial intelligence is working in the background in healthcare.""}, {""date"": ""2023-11-28"", ""headline"": ""Gilead Sciences Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. slipped 0.55% to $74.51 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P...""}, {""date"": ""2023-11-28"", ""headline"": ""Gilead Sciences, Inc. (GILD) Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript)"", ""summary"": ""Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) 6th Annual Evercore ISI HealthCONx Conference November 28, 2023 1:20 PM ETCompany ParticipantsAndrew Dickinson -...""}, {""date"": ""2023-11-28"", ""headline"": ""Cabaletta Bio\u2019s and Gracell\u2019s stock falls sharply as FDA investigates risks of CAR-T therapy"", ""summary"": ""Shares of small biotech companies involved in CAR-T therapies plunged Tuesday as the FDA said it was investigating potential cancer risks.""}, {""date"": ""2023-11-28"", ""headline"": ""Gilead's Ambition: To Help End the HIV Epidemic"", ""summary"": ""NORTHAMPTON, MA / ACCESSWIRE / November 28, 2023 / \""At Gilead, we have a bold ambition: We'd like to help end the HIV epidemic for everyone, everywhere and we know you cannot do that alone,\"" shared Janet Dorling, Senior Vice President, Intercontinental ...""}, {""date"": ""2023-11-28"", ""headline"": ""Gilead After Q3 2023 Earnings: Grading Its Top Cancer Acquisition"", ""summary"": ""Gilead's acquisition of Immunomedics has generated growing revenues from Trodelvy. Read more to see our analysis on GILD stock.""}, {""date"": ""2023-11-28"", ""headline"": ""FDA probing serious risk of T-cell malignancies in CAR-T cell therapy patients (update)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-28"", ""headline"": ""Cabaletta Bio, Gracell slide as FDA probes risk of CAR T cell immunotherapies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-28"", ""headline"": ""FDA investigating serious risk of T-cell malignancies in CAR-T cell therapy patients"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-28"", ""headline"": ""FDA probing risk of T-cell malignancy following CAR T cell immunotherapies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-29"", ""headline"": ""Gilead management to meet with Oppenheimer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-29"", ""headline"": ""Gilead Sciences Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.97% higher to $75.23 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with...""}, {""date"": ""2023-11-29"", ""headline"": ""Biogen: LAQEMBI's $10 Billion Potential"", ""summary"": ""Biogen's latest Alzheimer's drug, Aduhelm, faced challenges after FDA approval. Click here to read why we still rate the BIIB stock as a 'Strong Buy'.""}, {""date"": ""2023-11-29"", ""headline"": ""Gilead to lay off staff at cell therapy unit Kite"", ""summary"": ""The cuts will impact 7% of the cancer drug division\u2019s employees, although about 90 new roles will be created around \u201careas of growth.\u201d""}, {""date"": ""2023-11-29"", ""headline"": ""Gilead Sciences, Inc. (GILD) Presents at Piper Sandler 35th Annual Healthcare Conference (Transcript)"", ""summary"": ""Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Piper Sandler 35th Annual Healthcare Conference November 29, 2023 9:00 AM ETCompany ParticipantsAndrew Dickinson...""}, {""date"": ""2023-11-29"", ""headline"": ""Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-30"", ""headline"": ""17 Ideal Pre-Crash Recovery December Divi-Dogs"", ""summary"": ""Discover the top pre-crash-recovery stocks of 2023 in financial services, healthcare, and real estate sectors. Click for our top dividend picks in several sectors.""}, {""date"": ""2023-11-30"", ""headline"": ""Gilead Sciences Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. advanced 1.82% to $76.60 Thursday, on what proved to be an all-around positive trading session for the stock market, with the...""}, {""date"": ""2023-11-30"", ""headline"": ""2 Biotech Stocks You Can Buy and Hold for the Next Decade"", ""summary"": ""These stocks aren't popular on the market right now, but investors shouldn't let that scare them off.""}, {""date"": ""2023-11-30"", ""headline"": ""Gilead\u2019s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023"", ""summary"": ""FOSTER CITY, Calif., November 30, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it will present new data at San Antonio Breast Cancer Symposium (SABCS) 2023, supporting the use of Trodelvy\u00ae (sacituzumab govitecan-hziy) in certain metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastatic breast cancer (mBC) patients.""}, {""date"": ""2023-11-30"", ""headline"": ""3 Biotech Stocks That Could Be Multibaggers in the Making"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-30"", ""headline"": ""Piper Sandler Reaffirms Their Buy Rating on Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-01"", ""headline"": ""Gilead Employees Stitch Together To Create a Special Panel of the AIDS Quilt"", ""summary"": ""NORTHAMPTON, MA / ACCESSWIRE / December 1, 2023 / Nearly 36 years ago the AIDS Memorial Quilt was displayed for the first time to memorialize and physically represent lives lost to HIV. Gilead has always actively supported the Quilt, and creating ...""}, {""date"": ""2023-12-01"", ""headline"": ""Gilead Sciences Inc. stock rises Friday, outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. advanced 1.37% to $77.65 Friday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-12-01"", ""headline"": ""Gilead Sciences (GILD) Receives a Buy from Oppenheimer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-02"", ""headline"": ""Is Gilead Sciences, Inc.'s (NASDAQ:GILD) ROE Of 26% Impressive?"", ""summary"": ""While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...""}, {""date"": ""2023-12-03"", ""headline"": ""Biotechs post record gains in November amid improving outlook"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
47,2023-12-03,76.94910430908203,2023-12-10,78.30673217773438,0.01764319261208236,U2,"[{""date"": ""2023-12-03"", ""headline"": ""Gilead Sciences Breaks Above 200-Day Moving Average - Bullish for GILD"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-03"", ""headline"": ""Biotechs post record gains in November amid improving outlook"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-04"", ""headline"": ""Gilead Sciences Inc. stock rises Monday, outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.89% higher to $78.34 Monday, on what proved to be an all-around rough trading session for the stock market, with the...""}, {""date"": ""2023-12-04"", ""headline"": ""Ideaya Biosciences enters clinical study pact, supply agreement with Gilead"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-05"", ""headline"": ""Gilead Sciences a Top Socially Responsible Dividend Stock With 3.8% Yield (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-06"", ""headline"": ""Gilead's Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023"", ""summary"": ""FOSTER CITY, Calif. - Gilead Sciences, Inc. announced it will present new data at San Antonio Breast Cancer Symposium 2023, supporting the use of Trodelvy\u00ae in certain metastatic triple-negative...""}, {""date"": ""2023-12-06"", ""headline"": ""U.S. Wide-Moat Stocks On Sale - The December 2023 Heat Map"", ""summary"": ""We share the heat map of the most investable candidates that may be worth your time for further analysis. Explore more details here.""}, {""date"": ""2023-12-06"", ""headline"": ""Great week for Gilead Sciences, Inc. (NASDAQ:GILD) institutional investors after losing 6.8% over the previous year"", ""summary"": ""Key Insights Given the large stake in the stock by institutions, Gilead Sciences' stock price might be vulnerable to...""}, {""date"": ""2023-12-06"", ""headline"": ""If You Invested $1000 In This Stock 20 Years Ago, You Would Have $11,000 Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-07"", ""headline"": ""Gilead Sciences Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. slid 1.65% to $78.05 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""2023-12-07"", ""headline"": ""Why Is Gilead (GILD) Up 1.9% Since Last Earnings Report?"", ""summary"": ""Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.""}, {""date"": ""2023-12-07"", ""headline"": ""Gilead Sciences: The Bull Case Is More Powerful Than You Think"", ""summary"": ""The pharmaceutical company is a leader in the global HIV drugs market""}, {""date"": ""2023-12-07"", ""headline"": ""5 Dividend Growth Stocks To Consider Buying"", ""summary"": ""5 companies with high dividend yields and promising growth potential: Korn Ferry, Gilead Sciences, Qualcomm, Ralph Lauren, and Manpower. Click here to read more.""}, {""date"": ""2023-12-07"", ""headline"": ""Gilead Sciences on track to snap six-day winning streak"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-07"", ""headline"": ""Gilead Sciences on track to snap its six-day winning streak"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-07"", ""headline"": ""Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy"", ""summary"": ""Using gene therapy, companies can change patients\u2019 DNA. One type of gene therapy, called CRISPR, largely mimics a method used by bacteria to fend off viruses. As a result, they can reverse defects in cells that cause diseases. Companies are constantly improving CRISPR and other gene editing techniques, and one firm is already reportedly close to using the tech to cure a very prevalent disease. With that said, here are three leading gene therapy stocks for investors to consider. CRISPR Therapeuti""}, {""date"": ""2023-12-07"", ""headline"": ""A Look Into Gilead Sciences Inc's Price Over Earnings"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-07"", ""headline"": ""Guild Esports says Studios arm hits revenue milestone on Sky deal"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-08"", ""headline"": ""Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know"", ""summary"": ""In the latest trading session, Gilead Sciences (GILD) closed at $79.02, marking a +1.24% move from the previous day.""}, {""date"": ""2023-12-08"", ""headline"": ""Gilead Sciences Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. rose 1.24% to $79.02 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...""}, {""date"": ""2023-12-08"", ""headline"": ""IN BRIEF: Guild Esports gears up for World Cup with new 'Eagles' team"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-09"", ""headline"": ""Four Days Left To Buy Gilead Sciences, Inc. (NASDAQ:GILD) Before The Ex-Dividend Date"", ""summary"": ""Readers hoping to buy Gilead Sciences, Inc. ( NASDAQ:GILD ) for its dividend will need to make their move shortly, as...""}, {""date"": ""2023-12-10"", ""headline"": ""This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks"", ""summary"": ""On Nov. 28, the Food and Drug Administration (FDA) announced that it was opening an investigation into the possibility of previously unknown serious safety risks associated with the hottest and most technological group of cancer medicines produced to date.  Now, drugmakers including Novartis (NYSE: NVS), Gilead Sciences (NASDAQ: GILD), and Bristol Myers Squibb (NYSE: BMY) are on the hot seat, with their patients' well-being and billions of dollars in revenue on the line.  The FDA is concerned about chimeric antigen receptor T-cell (CAR T-cell) therapies.""}, {""date"": ""2023-12-10"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of December 10"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the December 10 weekly update.""}]",{}
48,2023-12-10,78.30673217773438,2023-12-17,80.33000183105469,0.02583774851858278,U3,"[{""date"": ""2023-12-10"", ""headline"": ""Kite announces results from three-year analysis of ZUMA-12"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-10"", ""headline"": ""This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks"", ""summary"": ""On Nov. 28, the Food and Drug Administration (FDA) announced that it was opening an investigation into the possibility of previously unknown serious safety risks associated with the hottest and most technological group of cancer medicines produced to date.  Now, drugmakers including Novartis (NYSE: NVS), Gilead Sciences (NASDAQ: GILD), and Bristol Myers Squibb (NYSE: BMY) are on the hot seat, with their patients' well-being and billions of dollars in revenue on the line.  The FDA is concerned about chimeric antigen receptor T-cell (CAR T-cell) therapies.""}, {""date"": ""2023-12-10"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of December 10"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the December 10 weekly update.""}, {""date"": ""2023-12-11"", ""headline"": ""Moat Stocks Show Grit In November Rally"", ""summary"": ""The S&P 500 registered its best month in nearly a year and a half, but still could not keep pace with the Moat Index in November.""}, {""date"": ""2023-12-11"", ""headline"": ""Analyses of Kite\u2019s Yescarta\u00ae CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas"", ""summary"": ""SANTA MONICA, Calif., December 12, 2023--Kite, a Gilead Company (Nasdaq: GILD), today announced data from follow-up analyses of three studies of Yescarta\u00ae (axicabtagene ciloleucel) that demonstrate the long-term survival potential for patients living with several sub-types of relapsed or refractory (R/R) non-Hodgkin lymphoma, which were presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition. This included ZUMA-1 (Abstract #4864) showing that patients with refracto""}, {""date"": ""2023-12-11"", ""headline"": ""New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite\u2019s Tecartus\u00ae in Patients With Aggressive Blood Cancers"", ""summary"": ""SANTA MONICA, Calif., December 12, 2023--Kite, a Gilead Company (Nasdaq: GILD), today announced the results of four new analyses supporting the use of Tecartus\u00ae (brexucabtagene autoleucel) in relapsed/refractory mantle cell lymphoma (R/R MCL) and relapsed/refractory adult B-cell precursor acute lymphoblastic leukemia (R/R B-ALL). These results include four-year overall survival (OS) data from the pivotal ZUMA-2 study and primary results from ZUMA-18, an expanded access study, evaluating the CAR""}, {""date"": ""2023-12-11"", ""headline"": ""Long-Term Data for Kite\u2019s Yescarta\u00ae CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma"", ""summary"": ""SANTA MONICA, Calif., December 11, 2023--Kite, a Gilead Company (Nasdaq: GILD), today announced results from a three-year follow-up analysis of ZUMA-12, a Phase 2 study of Yescarta\u00ae (axicabtagene ciloleucel) as first-line treatment after two cycles of chemoimmunotherapy in patients with high-risk, large b-cell lymphoma (LBCL). The analysis, which demonstrated durability of clinical benefit \u2013 both high complete response (CR) and objective response rates (ORR), including in patients with MYC and B""}, {""date"": ""2023-12-11"", ""headline"": ""Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year"", ""summary"": ""FOSTER CITY, Calif., December 11, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company has once again been recognized as one of the most sustainable pharmaceutical companies according to the Dow Jones Sustainability World Index (DJSI World) for the third consecutive year. The company was also included on the Dow Jones Sustainability North America Index (DJSI North America). These rankings are based on an in-depth analysis of Gilead\u2019s sustainability performance and highlight the""}, {""date"": ""2023-12-11"", ""headline"": ""Gilead Sciences Inc. stock rises Monday, outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. rallied 1.35% to $80.09 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P...""}, {""date"": ""2023-12-11"", ""headline"": ""10 Health Care Stocks With Whale Alerts In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-11"", ""headline"": ""Gilead Sciences Battles Rising Threat of Drug Counterfeiting, Initiates Legal Actions"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-11"", ""headline"": ""Gilead announces data from follow-up analyses of three studies of Yescarta"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-11"", ""headline"": ""Gilead announces results supporting use of Tecartus"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-12"", ""headline"": ""30 Largest Pharmaceutical Companies in the World"", ""summary"": ""In this article, we will be taking a look at the 30 largest pharmaceutical companies in the world. To skip our detailed analysis, you can go directly to see the 10 Largest Pharmaceutical Companies in the World. The world\u2019s leading pharmaceutical companies became the center of attention for people all over the world as a [\u2026]""}, {""date"": ""2023-12-12"", ""headline"": ""Gilead Sciences Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.91% higher to $80.82 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with...""}, {""date"": ""2023-12-12"", ""headline"": ""Gilead Sciences Is Building A Diversified Portfolio"", ""summary"": ""Gilead Sciences has several milestones, including the success of Trodelvy with over $1B in annualized sales. Read why I rate GILD stock a buy.""}, {""date"": ""2023-12-12"", ""headline"": ""Gilead's Legal Team Achieves Rigorous Diversity Certification"", ""summary"": ""NORTHAMPTON, MA / ACCESSWIRE / December 12, 2023 / Gilead SciencesOriginally published by Gilead SciencesWhen Shirley Cantin was a law student, about half of her classmates were women. Yet when she joined a corporate law firm, Shirley noticed that ...""}, {""date"": ""2023-12-12"", ""headline"": ""Ex-Dividend Reminder: Gilead Sciences, CRH and Merck"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-12"", ""headline"": ""Gilead price target lowered by $4 at Morgan Stanley, here's why"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-12"", ""headline"": ""Gilead Company - Long-Term Data for Kite s Yescarta CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients with High-Risk Large B-Cell Lymphoma"", ""summary"": ""was presented during an oral presentation at the 65th American Society of Hematology Annual Meeting & Exposition.Patients with high-risk, large B-cell lymphoma, have a poor prognosis with currently...""}, {""date"": ""2023-12-13"", ""headline"": ""Gilead Sciences Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. rose 2.81% to $83.09 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-12-13"", ""headline"": ""Gilead Sciences Inc's Dividend Analysis"", ""summary"": ""Gilead Sciences Inc (NASDAQ:GILD) recently announced a dividend of $0.75 per share, payable on 2023-12-28, with the ex-dividend date set for 2023-12-14.  As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates.  Using the data from GuruFocus, let's look into Gilead Sciences Inc's dividend performance and assess its sustainability.""}, {""date"": ""2023-12-14"", ""headline"": ""Pharma\u2019s Frontline: 3 Stocks Driving Revolutionary Drug Development"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-14"", ""headline"": ""Arcus Biosciences: Showing There Might Be Something To TIGIT After All"", ""summary"": ""Arcus Biosciences is developing a combination therapy of PD-1 and TIGIT inhibitors for esophagogastric cancer, showing promising efficacy in a phase 2 study. Read more here.""}, {""date"": ""2023-12-14"", ""headline"": ""Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why"", ""summary"": ""In the closing of the recent trading day, Gilead Sciences (GILD) stood at $81.78, denoting a -1.58% change from the preceding trading day.""}, {""date"": ""2023-12-14"", ""headline"": ""Gilead Sciences Inc. stock falls Thursday, underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. slipped 0.68% to $81.78 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-12-14"", ""headline"": ""Oppenheimer, Wedbush say buy these biotech stocks for 2024"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-14"", ""headline"": ""Biopharmaceutical Stocks: The Rally Has Just Begun"", ""summary"": ""With the recent rise in the XBI ETF, investors may begin to wonder if they 'missed the rally'. Read more to see my analysis.""}, {""date"": ""2023-12-14"", ""headline"": ""Gilead Sciences' (NASDAQ:GILD) 19% YoY earnings expansion surpassed the shareholder returns over the past three years"", ""summary"": ""By buying an index fund, you can roughly match the market return with ease. But if you choose individual stocks with...""}, {""date"": ""2023-12-15"", ""headline"": ""Gilead (GILD) Outperforms Industry in 6 Months: What Lies Ahead?"", ""summary"": ""Gilead (GILD) gains 3.7% in six months as its oncology portfolio gains traction and its HIV business maintains momentum.""}, {""date"": ""2023-12-15"", ""headline"": ""Gilead Sciences Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. shed 1.77% to $80.33 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""2023-12-16"", ""headline"": ""Patients Regain Weight After They Quit Using Ozempic Rival Zepbound. Here's Why That Makes Eli Lilly Stock an Even Better Buy."", ""summary"": ""Lilly's weight loss drug appears to be on the way to becoming a megablockbuster.""}]",{}
49,2023-12-17,80.33000183105469,2023-12-24,79.66000366210938,-0.008340572061163565,D1,"[{""date"": ""2023-12-17"", ""headline"": ""(GILD) - Analyzing Gilead Sciences's Short Interest"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-18"", ""headline"": ""Compugen spikes after deal with Gilead for anti-tumor drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-18"", ""headline"": ""Compugen spikes 180% on $848M deal with Gilead for anti-tumor drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-18"", ""headline"": ""Gilead Sciences\u2019 Hold Rating: Balancing Kite Pharma\u2019s Opportunities with Industry Challenges"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-18"", ""headline"": ""Gilead Sciences Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. slipped 1.03% to $79.50 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P...""}, {""date"": ""2023-12-18"", ""headline"": ""Gilead Sciences, Inc.'s (NASDAQ:GILD) Popularity With Investors Is Under Threat From Overpricing"", ""summary"": ""There wouldn't be many who think Gilead Sciences, Inc.'s ( NASDAQ:GILD ) price-to-earnings (or \""P/E\"") ratio of 17x is...""}, {""date"": ""2023-12-18"", ""headline"": ""XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector"", ""summary"": ""XLV comprises major healthcare industry players and offers a convenient and cost-effective way to invest in the sector. Find out my analysis of XLV ETF.""}, {""date"": ""2023-12-18"", ""headline"": ""13 Most Profitable Pharmaceutical Stocks Now"", ""summary"": ""In this article, we discuss the 13 most profitable pharmaceutical stocks to buy. You can skip our detailed analysis of the pharmaceutical sector and its outlook this year, and go directly to read the 5 Most Profitable Pharmaceutical Stocks Now. The healthcare sector encompasses a diverse range of companies, spanning pharmaceuticals, medical equipment and device [\u2026]""}, {""date"": ""2023-12-19"", ""headline"": ""Biggest stock movers today: Compugen, FedEx, Steelcase and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-19"", ""headline"": ""QQQ And QQQM ETFs Top Gainers And Laggards Of 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-19"", ""headline"": ""Gilead Sciences Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. slid 0.01% to $79.49 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-12-19"", ""headline"": ""Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program"", ""summary"": ""FOSTER CITY, Calif. & HOLON, Israel, December 19, 2023--Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program""}, {""date"": ""2023-12-19"", ""headline"": ""Compugen stock rockets 160% on Gilead development deal"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-19"", ""headline"": ""Compugen\u2019s stock rockets on deal with Gilead for anti-tumor drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-19"", ""headline"": ""Gilead Sciences signs deal to license Compugen antibody programme"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-19"", ""headline"": ""Why Is Compugen (CGEN) Stock Up 189% Today?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-19"", ""headline"": ""Gilead Supports World Health Organization To Bolster Public Health in Bangladesh"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-19"", ""headline"": ""Compugen's stock rockets on deal with Gilead for anti-tumor drug"", ""summary"": ""Shares are halted for volatility but rise to highest levels since mid-2022 on resumed trading.""}, {""date"": ""2023-12-19"", ""headline"": ""Arcellx initiated with an Outperform at Scotiabank"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-19"", ""headline"": ""Compugen stock rockets on anti-tumor drug deal with Gilead"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-19"", ""headline"": ""Gilead and Compugen in license deal for novel pre-clinical immunotherapy program"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-20"", ""headline"": ""FDA approves label update for Gilead's Kite for Yescarta to include OS analysis"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-20"", ""headline"": ""Gilead Sciences (GILD) Stock Moves -1.13%: What You Should Know"", ""summary"": ""In the closing of the recent trading day, Gilead Sciences (GILD) stood at $78.59, denoting a -1.13% change from the preceding trading day.""}, {""date"": ""2023-12-20"", ""headline"": ""Gilead Sciences Inc. stock falls Wednesday, still outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. shed 1.13% to $78.59 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...""}, {""date"": ""2023-12-20"", ""headline"": ""Gilead (GILD), Compugen Collaborate for Immunotherapy Program"", ""summary"": ""Gilead (GILD) enters into a license agreement with Compugen for its pre-clinical immunotherapy program.""}, {""date"": ""2023-12-20"", ""headline"": ""RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola"", ""summary"": ""RedHill Biopharma Ltd. (Nasdaq: RDHL) (\""RedHill\"" or the \""Company\""), a specialty biopharmaceutical company, today announced that its two novel, oral host-directed investigational drugs, opaganib[1] and RHB-107 (upamostat)[2], demonstrated robust synergistic effect when combined individually with remdesivir (Veklury\u00ae)[3], significantly improving viral inhibition while maintaining cell viability, in a new U.S. Army-funded and conducted Ebola virus in vitro study.""}, {""date"": ""2023-12-20"", ""headline"": ""RedHill Biopharma shares jump as Ebola treatment shows promise"", ""summary"": ""RedHill Biopharma Ltd. American depositary receipts climbed 10% premarket on Wednesday after the company said two of its experimental drugs, when...""}, {""date"": ""2023-12-21"", ""headline"": ""Gilead Sciences to Present at Upcoming Investor Conference"", ""summary"": ""FOSTER CITY, Calif., December 21, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference:""}, {""date"": ""2023-12-21"", ""headline"": ""U.S. FDA Approves Label Update for Kite\u2019s Yescarta\u00ae CAR T-Cell Therapy to Include Overall Survival Data"", ""summary"": ""SANTA MONICA, Calif., December 21, 2023--Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a label update for Yescarta\u00ae (axicabtagene ciloleucel) to include the overall survival (OS) primary analysis from the landmark Phase 3 ZUMA-7 study showing a statistically significant improvement for Yescarta in OS versus standard of care (SOC) as second-line treatment with curative intent for patients with relapsed or refractory large B-ce""}, {""date"": ""2023-12-21"", ""headline"": ""Gilead says US FDA approves label update for Kite's Yescarta"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-21"", ""headline"": ""Gilead Sciences Inc. stock rises Thursday, still underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.43% higher to $78.93 Thursday, on what proved to be an all-around great trading session for the stock market, with...""}, {""date"": ""2023-12-21"", ""headline"": ""Biotech Stock Roundup: CGEN Up on GILD Deal, MRNA Gains on Study Data & More"", ""summary"": ""Compugen (CGEN) and Moderna (MRNA) are in the news on collaboration and study updates, respectively.""}, {""date"": ""2023-12-21"", ""headline"": ""3 Biotech Stocks to Buy in the TradeSmith \u2018Green Zone\u2019"", ""summary"": ""Investors in search of high-risk, high-reward investments can often find them among the top biotech stocks to buy. Identifying worthwhile opportunities can be easier said than done when investing in biotech. Extensive due diligence is required. Therefore you may want to consider taking into account whether a particular biotech stock is in the \u201cGreen Zone.\u201d TradeSmith offers investors valuable tools for determining which stocks to watch. A good example is its Health Indicator feature. This compre""}, {""date"": ""2023-12-21"", ""headline"": ""HOOKIPA Pharma Shares Soar After Gilead Sciences Investment"", ""summary"": ""By Dean Seal Shares of HOOKIPA Pharma surged after the company said Gilead Sciences bought 15 million of its shares at about $1.42 apiece. The stock was up...""}, {""date"": ""2023-12-21"", ""headline"": ""Why Is Hookipa Pharma (HOOK) Stock Up 81% Today?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-21"", ""headline"": ""Gilead Stock Could Finally Have a Breakout Year. Here\u2019s Why."", ""summary"": ""Investors have been waiting years for  Gilead Sciences  to finally recover from its blowup in 2016.  It\u2019s hard to remember now, but Gilead was once the hottest of biotech stocks.  Investors failed to foresee the competition from other companies, as well as the pushback on cost, and Gilead fell from $101.19 at the end of 2015 to $62.55 by year end 2018.""}, {""date"": ""2023-12-21"", ""headline"": ""Hookipa Pharma announces $21.25M equity investment from Gilead"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-22"", ""headline"": ""Gilead Sciences Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.92% higher to $79.66 Friday, on what proved to be an all-around mixed trading session for the stock market, with the...""}, {""date"": ""2023-12-22"", ""headline"": ""Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-22"", ""headline"": ""Biotech Alert: Searches spiking for these stocks today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-22"", ""headline"": ""A Look Into Gilead Sciences Inc's Price Over Earnings"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-22"", ""headline"": ""U.S. FDA Approves Label Update for Kite's Yescarta CAR T-Cell Therapy to Include Overall Survival Data"", ""summary"": ""SANTA MONICA - Kite, a Gilead Company , today announced that the U.S. Food and Drug Administration has approved a label update for Yescarta to include the overall survival primary analysis from...""}, {""date"": ""2023-12-22"", ""headline"": ""IN BRIEF: Guild Esports inks further one-year contract with Subway"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-23"", ""headline"": ""Should You Be Adding Gilead Sciences (NASDAQ:GILD) To Your Watchlist Today?"", ""summary"": ""Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...""}, {""date"": ""2023-12-24"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of December 24"", ""summary"": ""Stay updated on dividend activity with a weekly summary.""}, {""date"": ""2023-12-24"", ""headline"": ""Gilead stock could finally have breakout year, Barron's says"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
50,2023-12-24,79.66000366210938,2023-12-31,81.01000213623047,0.01694700492165846,U2,"[{""date"": ""2023-12-24"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of December 24"", ""summary"": ""Stay updated on dividend activity with a weekly summary.""}, {""date"": ""2023-12-24"", ""headline"": ""Gilead stock could finally have breakout year, Barron's says"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-25"", ""headline"": ""$100 Invested In This Stock 20 Years Ago Would Be Worth $1,100 Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-26"", ""headline"": ""Gilead Sciences Inc. stock rises Tuesday, still underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.36% higher to $79.95 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with...""}, {""date"": ""2023-12-26"", ""headline"": ""JN.1 Omicron strain becomes dominant COVID variant in U.S."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-27"", ""headline"": ""The\u00a030 Happiest Cities in America in 2023"", ""summary"": ""In this article, we will take a look at the 30 happiest cities in America in 2023. If you want to skip our discussion on the impact of residence on well-being, you can go directly to The 5 Happiest Cities in America in 2023. Despite the common belief that money can\u2019t buy happiness, one cannot deny [\u2026]""}, {""date"": ""2023-12-27"", ""headline"": ""12 Best Stocks to Buy for an 18 Year Old"", ""summary"": ""In this article, we discuss the 12 best stocks to buy for an 18 year old. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Stocks to Buy for an 18 Year Old. It is an exciting time to be involved in trading stocks. The Federal Reserve in [\u2026]""}, {""date"": ""2023-12-27"", ""headline"": ""Gilead Sciences Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.53% higher to $80.37 Wednesday, on what proved to be an all-around great trading session for the stock market, with...""}, {""date"": ""2023-12-27"", ""headline"": ""A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?"", ""summary"": ""In pharma, a company can take a larger slice of the healthcare pie than peers, but it is still constrained by the size of the pie.""}, {""date"": ""2023-12-28"", ""headline"": ""The 500 Top Stocks to Buy for 2024, Ranked by AI"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-28"", ""headline"": ""Gilead Sciences Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.96% higher to $81.14 Thursday, on what proved to be an all-around positive trading session for the stock market, with...""}, {""date"": ""2023-12-28"", ""headline"": ""Gilead in 2024: What to expect?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-28"", ""headline"": ""Here's Why Gilead Sciences (NASDAQ:GILD) Can Manage Its Debt Responsibly"", ""summary"": ""David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...""}, {""date"": ""2023-12-29"", ""headline"": ""Gilead Sciences (GILD) Stock Moves -0.16%: What You Should Know"", ""summary"": ""In the latest trading session, Gilead Sciences (GILD) closed at $81.01, marking a -0.16% move from the previous day.""}, {""date"": ""2023-12-29"", ""headline"": ""Gilead Sciences Inc. stock outperforms market despite losses on the day"", ""summary"": ""Shares of Gilead Sciences Inc. slumped 0.16% to $81.01 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-12-31"", ""headline"": ""Without A Clear Growth Path, Gilead Sciences Is A Hold"", ""summary"": ""Gilead Sciences has seen stagnant sales growth over the past decade, but has potential for future growth in its oncology and virology programs. Read more here.""}]",{}
51,2023-12-31,81.01000213623047,2024-01-07,83.30999755859375,0.028391499342210746,U3,"[{""date"": ""2023-12-31"", ""headline"": ""Without A Clear Growth Path, Gilead Sciences Is A Hold"", ""summary"": ""Gilead Sciences has seen stagnant sales growth over the past decade, but has potential for future growth in its oncology and virology programs. Read more here.""}, {""date"": ""2024-01-02"", ""headline"": ""10 Health Care Stocks Whale Activity In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-03"", ""headline"": ""Gilead Sciences Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.29% higher to $83.48 Wednesday, on what proved to be an all-around poor trading session for the stock market, with...""}, {""date"": ""2024-01-03"", ""headline"": ""Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year"", ""summary"": ""- Gilead Also Included on the Dow Jones Sustainability North America Index; Rankings Reflect Gilead's Ongoing Commitment to Corporate Responsibility - -DJSI World Highlights the Most Sustainable Companies Around the World Based on Corporate Sustainability ...""}, {""date"": ""2024-01-03"", ""headline"": ""Nasdaq 100 Alert: 7 Undervalued Tech Stocks Ready to Rocket in 2024"", ""summary"": ""The Nasdaq 100 had a banner year. After a disastrous 2022 that saw the tech-laden index lose one-third of its value, it rebounded sharply in 2023 soaring 55% to hit a new all-time high. Of course, most of those gains were because of the performance of the Magnificent 7 stocks. Since the index is market cap-weighted the relative size of the companies skewed the results. Apple (NASDAQ:AAPL) alone accounts for 9% of the Nasdaq 100 while Microsoft (NASDAQ:MSFT) represents another 8.6%. Together, the""}, {""date"": ""2024-01-03"", ""headline"": ""This Analyst Downgrades Bristol-Myers Squibb, Cautions Amid Product Launch And Revenue Concerns"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-03"", ""headline"": ""The biopharmaceuticals stocks to own in 2024, according to BofA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-03"", ""headline"": ""(GILD) - Analyzing Gilead Sciences's Short Interest"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""Nasdaq 100 Snaps Longest Negative Streak In 14 Months As Tech Stocks Find Relief On Mixed Data"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""Gilead Sciences Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. rose 1.20% to $84.48 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...""}, {""date"": ""2024-01-04"", ""headline"": ""Masking returns to some U.S. hospitals amid rising COVID, flu cases"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""Gilead's Dividend Growth Potential Looks Phenomenal"", ""summary"": ""Learn about Gilead's recovery amid pandemic challenges, growth prospects in HIV and oncology, and attractive dividends and valuation. Click here to read.""}, {""date"": ""2024-01-05"", ""headline"": ""Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know"", ""summary"": ""In the most recent trading session, Gilead Sciences (GILD) closed at $83.31, indicating a -1.38% shift from the previous trading day.""}, {""date"": ""2024-01-05"", ""headline"": ""Gilead Sciences Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. slid 1.38% to $83.31 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""2024-01-05"", ""headline"": ""What Makes Gilead Sciences (GILD) an Attractive Investment?"", ""summary"": ""ClearBridge Investments, an investment management company, released its \u201cClearBridge Dividend Strategy\u201d fourth quarter 2023 investor letter. A copy of the same can be downloaded here. The market recovered in 2023 following a sharp decline in 2022, driven by excitement about artificial intelligence and an improving forecast for interest rates. The strategy underperformed the benchmark S&P 500 [\u2026]""}, {""date"": ""2024-01-05"", ""headline"": ""Florida wins FDA nod for mass drug imports from Canada (update)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-05"", ""headline"": ""Florida to become first state to win FDA nod for mass drug imports from Canada: NYT"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-05"", ""headline"": ""RBC Capital Sticks to Its Hold Rating for Gilead Sciences (GILD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-06"", ""headline"": ""7 Rock-Solid Healthcare Dividend Stocks to Buy in January"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-07"", ""headline"": ""ClearBridge Dividend Strategy Q4 2023 Portfolio Manager Commentary"", ""summary"": ""The ClearBridge Dividend Strategy underperformed its S&P 500 Index benchmark during Q2 2023. Click here to read the full fund letter.""}]",{}
52,2024-01-07,83.30999755859375,2024-01-14,86.37999725341797,0.03685031550583129,U4,"[{""date"": ""2024-01-07"", ""headline"": ""ClearBridge Dividend Strategy Q4 2023 Portfolio Manager Commentary"", ""summary"": ""The ClearBridge Dividend Strategy underperformed its S&P 500 Index benchmark during Q2 2023. Click here to read the full fund letter.""}, {""date"": ""2024-01-08"", ""headline"": ""Gilead Sciences, Inc. (GILD) J.P. Morgan 42nd Annual Healthcare Conference (Transcript)"", ""summary"": ""Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) J.P.""}, {""date"": ""2024-01-08"", ""headline"": ""Gilead Sciences Inc. stock rises Monday, still underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.82% higher to $83.99 Monday, on what proved to be an all-around great trading session for the stock market, with the...""}, {""date"": ""2024-01-08"", ""headline"": ""Healthcare Outlook 2024"", ""summary"": ""The healthcare sector was flat in 2023 year as a result of some unique issues. Check out the healthcare outlook for 2024.""}, {""date"": ""2024-01-09"", ""headline"": ""Gilead must face negligence claims over HIV drug development, court says"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-10"", ""headline"": ""JPM's annual healthcare conference: Here's what's next for GLP-1s and the weight loss market"", ""summary"": ""Several big pharma companies are rushing into the GLP-1 obesity space, which currently has two market leaders. How they plan to take some of that market share will be the story of the drug class for 2024.""}, {""date"": ""2024-01-10"", ""headline"": ""Gilead\u2019s Quiet Revolution: Is GILD the Next Big Stock to Soar?"", ""summary"": ""Biotechnology company Gilead Sciences (NASDAQ:GILD) wasn\u2019t a \u201cMagnificent Seven\u201d company or a darling of the financial markets in 2023. Yet, GILD stock deserves a long-overdue rally in 2024. Gilead Sciences is doing important scientific work, and the company\u2019s financials are fairly solid. Sure, weight-loss products deserve attention, but analysts and investors seem to be obsessing over them lately. Meanwhile, Gilead Sciences is making headway with critical, potentially lifesaving treatments. So,""}, {""date"": ""2024-01-10"", ""headline"": ""Gilead Sciences Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. slipped 1.81% to $84.50 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2024-01-10"", ""headline"": ""Gilead Pays Tribute to Patient Advocacy Work: Cara\u2019s Story"", ""summary"": ""NORTHAMPTON, MA / ACCESSWIRE / January 10, 2024 / Gilead Sciences: When employees at Gilead's recently opened New Jersey office need a place to meet, the \""Cara\"" conference room is one such place they gather. Given the room's namesake, it's especially ...""}, {""date"": ""2024-01-10"", ""headline"": ""U.S. Wide-Moat Stocks On Sale - The January 2024 Heat Map"", ""summary"": ""Our 3-step process focuses on wide-moat stocks. We are only interested in those targets that are attractively valued in historical comparison. Read more here.""}, {""date"": ""2024-01-10"", ""headline"": ""10 Health Care Stocks With Whale Alerts In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-10"", ""headline"": ""My Top 3 YARP Stocks Right Now (Yield At A Reasonable Price)"", ""summary"": ""I provide three stocks that meet the YARP criteria: Entergy, International Paper, and Gilead Sciences. Click here to read more.""}, {""date"": ""2024-01-10"", ""headline"": ""My Dividend Stock Portfolio: New December Dividend Record - 98 Holdings With 18 Buys"", ""summary"": """"}, {""date"": ""2024-01-11"", ""headline"": ""Gilead Sciences Inc's Chief Commercial Officer Johanna Mercier Sells 8,242 Shares"", ""summary"": ""Gilead Sciences Inc (NASDAQ:GILD), a biopharmaceutical company that researches, develops, and commercializes drugs in areas such as HIV/AIDS, liver diseases, hematology and oncology, inflammatory and respiratory diseases, and cardiovascular conditions, has reported an insider sell according to a recent SEC filing.""}, {""date"": ""2024-01-11"", ""headline"": ""Q2 2023 Gilead Sciences Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q1 2023 Gilead Sciences Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q4 2022 Gilead Sciences Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q3 2022 Gilead Sciences Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q2 2022 Gilead Sciences Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q1 2022 Gilead Sciences Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q4 2021 Gilead Sciences Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q3 2021 Gilead Sciences Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q2 2021 Gilead Sciences Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q1 2021 Gilead Sciences Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q4 2020 Gilead Sciences Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q3 2020 Gilead Sciences Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q2 2020 Gilead Sciences Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q1 2020 Gilead Sciences Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q4 2019 Gilead Sciences Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q3 2019 Gilead Sciences Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q2 2019 Gilead Sciences Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q1 2019 Gilead Sciences Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q4 2018 Gilead Sciences Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q3 2023 Gilead Sciences Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know"", ""summary"": ""In the closing of the recent trading day, Gilead Sciences (GILD) stood at $85.39, denoting a +1.05% change from the preceding trading day.""}, {""date"": ""2024-01-11"", ""headline"": ""Gilead Sciences Inc. stock rises Thursday, outperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. rallied 1.05% to $85.39 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...""}, {""date"": ""2024-01-11"", ""headline"": ""Sana Biotechnology: Finally Rewarding Investors, But Not Sufficiently Derisked"", ""summary"": ""If I were an investor, I'd be prepared to hold my Sana Biotechnology shares and wait for more data. Read more to see our analysis on SANA stock.""}, {""date"": ""2024-01-11"", ""headline"": ""Health stocks to watch this earnings season as sector poised for resurgence"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Health stocks to watch this earning season as sector poised for resurgence"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""AbbVie's Strategic Move: ImmunoGen Acquisition Triggers Golden Cross, Yet Valuation Caution Remains"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Wall Street Analysts Are Bullish on Top Healthcare Picks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-12"", ""headline"": ""Gilead Sciences Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. rallied 1.16% to $86.38 Friday, on what proved to be an all-around mixed trading session for the stock market, with the S&P...""}, {""date"": ""2024-01-12"", ""headline"": ""$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-14"", ""headline"": ""First RSV shots, groundbreaking gene therapy among 2024 drugs to watch"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
53,2024-01-14,86.37999725341797,2024-01-21,86.4800033569336,0.0011577460835316966,U1,"[{""date"": ""2024-01-14"", ""headline"": ""First RSV shots, groundbreaking gene therapy among 2024 drugs to watch"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-15"", ""headline"": ""Arcus Biosciences announces 'promising' ARC-8 Phase 1b study data"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-16"", ""headline"": ""Dividend Income Update December 2023"", ""summary"": ""The beginning of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated.""}, {""date"": ""2024-01-16"", ""headline"": ""Agree To Buy Gilead Sciences At $85, Earn 11.2% Annualized Using Options"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-16"", ""headline"": ""Gilead Sciences Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. slumped 0.45% to $85.99 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P...""}, {""date"": ""2024-01-16"", ""headline"": ""Gilead Sciences with Emma's Story: Self-Advocacy in Breast Cancer"", ""summary"": ""NORTHAMPTON, MA / ACCESSWIRE / January 16, 2024 / \""It's an experience that I hope no one goes through, but it's an empowering experience.\"" When Emma was diagnosed with breast cancer, she felt \""pushed aside\"" due to her age. Hear more about how she ...""}, {""date"": ""2024-01-16"", ""headline"": ""Top And Bottom S&P 500 Stocks To Consider In 2024"", ""summary"": ""Investors keep a close eye on the S&P 500 as it retreats at the start of the year. Check out the top and bottom S&P 500 stocks to consider in 2024.""}, {""date"": ""2024-01-17"", ""headline"": ""EXCLUSIVE: The 'Buy Everything' Market Is Over: Synopsys-Ansys Merger Provides Fertile Ground For This Stock Picker"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-17"", ""headline"": ""Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts"", ""summary"": ""In the closing of the recent trading day, Gilead Sciences (GILD) stood at $86.48, denoting a +0.57% change from the preceding trading day.""}, {""date"": ""2024-01-17"", ""headline"": ""Gilead Sciences Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Gilead Sciences Inc. inched 0.57% higher to $86.48 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with...""}, {""date"": ""2024-01-17"", ""headline"": ""Day One Biopharmaceuticals announces two new appointments to board"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-17"", ""headline"": ""Arcus posts early-stage data for Gilead-partnered cancer therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-18"", ""headline"": ""Gilead Sciences Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Gilead Sciences Inc. sank 0.09% to $86.40 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""2024-01-18"", ""headline"": ""Eli Lilly\u2019s Jaypirca to lead BTK inhibitor market for leukemia"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-18"", ""headline"": ""Gilead Sciences Inc CFO Andrew Dickinson Sells 5,000 Shares"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-18"", ""headline"": ""Drugmakers Raise Prices of Ozempic, Mounjaro and Hundreds of Other Drugs"", ""summary"": ""Drugmakers kicked off 2024 by raising the list prices for Ozempic, Mounjaro and dozens of other widely used medicines.  Companies including  Novo Nordisk  the maker of Ozempic, and  Eli Lilly  which sells Mounjaro, raised list prices on 775 brand-name drugs\u00a0during the first half of January, according to an analysis for The Wall Street Journal by 46brooklyn Research, a nonprofit drug-pricing analytics group.  The drugmakers raised prices of their medicines by a median of 4.5%, though the prices of some drugs rose by around 10% or higher, according to the research group.""}, {""date"": ""2024-01-18"", ""headline"": ""Medicare drug price negotiations hit critical phase"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-18"", ""headline"": ""AbbVie, Arch Capital, Gilead Sciences And A Telecom Giant On CNBC's 'Final Trades'"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-19"", ""headline"": ""Gilead Sciences Inc. stock rises Friday, still underperforms market"", ""summary"": ""Shares of Gilead Sciences Inc. rose 1.03% to $87.29 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}]",{}
